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ABSTRACT  
Cardiovascular diseases (CVDs) have remained the main cause of death in Finland. CVDs, 
especially coronary heart disease (CHD), have traditionally been considered to be diseases 
predominantly  affecting men.  However,  each year  more  women than men die  from CVD 
both in Finland and globally. In western countries women also surpass men in the absolute 
numbers of hospitalisations due to stroke and heart failure. While average cholesterol and 
blood  pressure  levels  have  declined  in  Finland,  some  CVD  risk  factors  that  are  more  
detrimental to women, such as type 2 diabetes and obesity, have become more prevalent. 
Technical developments in diagnostics, such as the adoption of troponin measurement and 
improvements in treatments, may also have an impact on CHD occurrence and prognosis. 
Therefore, it was decided to examine, whether these changes in risk factors and technical 
development have affected CVD occurrence in women.   
The  aim  of  this  study  was  to  examine  gender  differences  in  CVD  occurrence  and  
preventive treatments in Finland. It was studied 1) whether the incidence, mortality and 
attack rate of acute coronary events have declined differently in women than in men in 
Finland from the mid-1990s to the beginning of 2000s; 2) whether  the prognosis of acute 
coronary events has improved similarly in both genders in this time period; 3) are there 
gender  differences  in  the  prevalence  of  high  CVD  risk  and  in  risk  factor  management  
among high-risk subjects and 4) whether the genders differ in incidence and in proportions 
of different clinical presentations of CVD. Data was utilized from two national CVD 
registers, FINAMI and CVDR to identify acute coronary events. The events were compared 
between two time periods: 1992-1994 and 2000-2002. Risk factors and high-risk subjects 
were identified from the FINRISK Surveys using years 1992-2007. All analyses were also 
performed in different age groups: in subjects <55 years and 55 years old.  
 The incidence, attack rate and mortality of acute coronary events declined from the mid-
1990s to the 2000s and the prognosis improved. Nonetheless this improvement was slower 
among young, middle-aged (<55 years old) women. The slower pre-hospital case-fatality 
decline among younger women explained the slower overall case-fatality decline. 
Furthermore,  high CVD risk  was not  efficiently  recognised in  young women.  The overall  
risk factor treatment among high-risk individuals, especially among high-risk young 
women was not optimal, and the recommended target risk factor levels were poorly 
achieved.  The  incidence  of  CVD  events  was  higher  among  men,  as  expected;  only  the  
incidence of heart failure was equal in men and women. The most common incident CVD 
event was a non-fatal CHD event in men, and heart failure among women. 
National Library of Medicine Classification: WG 120, WG 210, WA 105, WA 309, QZ 53 
Medical Subject Headings: Cardiovascular Diseases; Coronary Disease; Myocardial Infarction; Acute 
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TIIVISTELMÄ  
Sydän- ja verisuonisairaudet ovat edelleen suomalaisten yleisin kuolinsyy. Perinteisesti 
etenkin sepelvaltimotautia on pidetty miesten sairautena. Suomessa, kuten 
maailmanlaajuisestikin, naisia kuolee kuitenkin vuosittain näihin sairauksiin suhteellisesti 
enemmän kuin miehiä. Naiset ovat myös enemmistönä aivohalvaukseen sairastuneista sekä 
käyttävät suurimman osan sydämen vajaatoiminnan hoitopäivistä. Keskimääräiset 
kolesteroliarvot ja verenpainetasot ovat parantuneet viime vuosikymmenien aikana. 
Samaan aikaan tyypin 2 diabetes ja lihavuus ovat kuitenkin yleistyneet suomalaisessa 
väestössä, ja näiden riskitekijöiden on todettu olevan haitallisempia naisille kuin miehille. 
Lisäksi sydäntautien diagnostiikassa ja hoidossa on viime vuosikymmenien aikana 
tapahtunut muutoksia, joilla on vaikutuksia sydän- ja verisuonisairauksien esiintymiseen ja 
ennusteeseen. 
Tutkimuksen tavoitteena oli selvittää sukupuolten välisiä eroja sydän- ja 
verisuonisairauksien esiintyvyydessä, ennusteessa sekä ehkäisevien hoitojen käytössä. 
Tutkimme 1) akuuttien sepelvaltimotautikohtauksen ilmaantuvuuden, kohtaustaajuuden ja 
kuolleisuuden laskun eroja 1990-luvun puolivälin ja 2000-luvun alun välillä 2) ennusteen 
muutoksia näiden aikajaksojen välillä molemmilla sukupuolilla 3) onko korkean sydän- ja 
verisuonitautiriskin esiintymisessä eroja sukupuolten välillä, ja 4) onko ensimmäisen 
sydäntautitapahtuman ilmaantuvuudessa eroja sekä eroaako tautitapahtumien kliininen 
kirjo naisilla ja miehillä. Akuutit sepelvaltimotautitapahtumat tunnistettiin käyttämällä 
kahta valtakunnallista sydän- ja verisuonitautirekisteriä, FINAMIa ja SYVEä. 
Tautitapahtumien muutoksia vertailtiin vuosijaksojen 1994-1996 ja 2000-2002 välillä. 
Riskitekijätasot ja korkean riskin henkilöt tunnistettiin FINRISKI-tutkimukseen vuosina 
1992-2007 osallistuneista.  Analyysit tehtiin erikseen myös ikäjaottelulla alle 55-vuotiaat ja  
 55-vuotiaat.  
 Tutkimuksessa todettiin akuuttien sepelvaltimotautitapahtumien ilmaantuvuuden, 
kohtaustaajuuden ja kuolleisuuden laskeneen tutkimusajanjaksolla. Nuorilla naisilla lasku 
oli hitaampaa kuin muilla ryhmillä. Lisäksi nuorten naisten ennuste oli parantunut tällä 
ajanjaksolla muita vähemmän, mikä johtui sairaalan ulkopuolisen kohtaustappavuuden 
hitaammasta laskusta. Kokonaisuudessaan korkean riskin potilaiden riskitekijöitä 
koskevien hoitotavoitteiden saavuttamisessa on edelleen parantamisen tarvetta. Etenkin 
nuorten naisten korkeaa riskiä ei myöskään tunnisteta riittävän hyvin. Ensimmäisen 
sydäntautitapahtuman ilmaantuminen on miehillä tunnetusti yleisempää, mutta sydämen 
vajaatoiminnan ilmaantuminen on molemmilla sukupuolilla yhtä suurta. Ensimmäinen 
sydäntapahtuma on naisilla useimmiten sydämen vajaatoiminta, ja miehillä ei-tappava 
sepelvaltimotautitapahtuma.  
Luokitus: WG 120, WG 210, WA 105, WA 309, QZ 53 
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“Medicine is a social science, and politics is nothing else but medicine on a large scale.” 
- Rudolf Virchow (1848) 
To women with cardiovascular disease  
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1 Introduction  
Cardiovascular diseases (CVDs) are the leading cause of mortality in both genders not 
only in Finland but throughout Europe. Previously, CVDs have typically been considered 
as “male diseases”. The lifetime risk of CVDs among women has often been 
underestimated, and a common belief has been that the effects of estrogen protect women 
against CVDs during their fertile years. However, since 1984 more women than men have 
died of CVDs in the United States, and currently 52% of women’s  deaths and only 42% of 
men’s deaths are due to CVDs in Europe (1, 2). Coronary heart disease (CHD) and stroke 
are the two main forms of CVD. CHD was considered as a disease of working-aged men in 
Finland 30-40 years ago, as was the case in the other western countries. Subsequently, the 
age-standardised CHD and CVD mortality rates have declined considerably, and general 
life-expectancy has increased among both genders in Europe, including Finland (3). On 
average women have 6 to 8 years longer life-expectancy than men. Because of the 
considerable decline in CVD occurrence among working-aged people, the burden of CVDs 
has shifted from working-aged to elderly subjects, of whom women constitute the 
majority. However, CHD, and CVD are not exclusively a problem of elderly women.  
Recently, the CHD and stroke mortality rates among young women have been failed to 
decline, plateauing and even started to increase among young middle-aged women in the 
United States (4, 5). In addition, the prognosis of CHD has been postulated to be worse 
among women than in men in this age group (6). The theory of “estrogen explaining it all, 
and the provision of (estrogen/progesterone) hormone replacement therapy for 
postmenopausal women have failed to provide any protection against CVD (7). The focus 
of attempts to explain gender differences in CVD has changed to research elucidating 
differences  in  major  CVD  risk  factors;  high  blood  cholesterol  and  blood  pressure  levels,  
diabetes and smoking and their prevalence in communities.   
Differences between men and women have proved a fascinating topic for speculation 
throughout the history of mankind. However, taking gender differences into account is a 
fairly new approach in the field of medical research. In cardiovascular medicine, gender 
differences have been examined since the mid-1980s (8). Nonetheless, women tend to be 
under-represented in clinical trials for heart disease treatments, which has in part 
hampered development of gender-specific treatment guidelines (9). The results both in 
clinical and epidemiological studies have usually combined genders, or have not given 
results on gender differences.   
CVD trends are known to reflect the trends in the major risk factors, and the differences in 
the risk factor burden between men and women have been claimed to explain differences 
in incidence among young populations (10, 11). In Finland, the average cholesterol- and 
blood pressure levels as well as the prevalence of smoking have declined (12). Women 
have  always  smoked  less  than  men  in  Finland.  However,  smoking  increased  among  
women during the latter half of the 1990s with this trend continuing until the beginning of 
the 2000s although it has recently started to decline again (12). At the same time, the 
prevalences of overweight, obesity and type 2 diabetes have increased (1). These risk 
factors have been postulated to have a stronger impact on CVD morbidity in women than 
in men (11). In addition to the changes in risk factors, the diagnostic and therapeutic 
2procedures for CVDs have improved during the past decades. More sensitive laboratory 
measurements, such as the analysis of cardiac troponins, were adopted during late 1990s 
in Finland to help in the diagnostics of acute coronary events. The adoption of troponin 
measurements has had an effect on CHD epidemiology (13). Also, more medicines, (i.e. 
statins and angiotensin-converting enzyme (ACE) inhibitors) have become available for 
prevention and treatment of CVD risk factors. 
In Finland, there is a long history of epidemiological research on CVD, and in fact the 
National Institute for Health and Welfare currently maintains two CVD registers. The 
CVD register (CVDR) is based on an administrative nationwide registers. The data are 
collected from the Hospital Discharge Register (HDR), the Causes of Death Register (CDR) 
and from the Finnish National Insurance Institute‘s Drug Reimbursement data. The 
FINAMI register is a descendant of the FINMONICA register, which was operational in 
Finland during 1983-1992 as part of the global World Health Organisation’s (WHO’s) 
Monitoring Trends and Determinants in Cardiovascular Disease (MONICA) project. The 
FINAMI register has collected data since 1993; it covers four geographical areas in Finland 
and it aims to collate data on every CHD event in the registration area. Events collected in 
FINAMI are evaluated by trained personnel. The FINRISK Surveys continue the work of 
the WHO MONICA Project and the North Karelia project started in 1972. The FINRISK 
survey is a cross-sectional study, which collects data from six geographical areas 
regarding cardiovascular risk factors at 5 year intervals. The FINRISK survey is also 
maintained by the National Institute for Health and Welfare. 
Due  to  the  changes  in  CVD  risk  factor  levels  in  Finland,  which  might  have  been  more  
detrimental to women, and changes in the diagnostic procedures of CVD, it seemed 
reasonable  (firstly)  to  evaluate  whether  the  acute  coronary event  incidence-,  attack-,  and 
mortality rates have declined equally in both genders from the mid-1990s to the early 
2000s. It was also decided to evaluate whether the adoption of troponin measurements 
had  affected  gender  differences  in  the  numbers  of  CHD  events.  Since  mortality  is  
associated both with changes in incidence and changes in case-fatality, it was further 
investigated, whether the case-fatality of acute coronary events had improved equally in 
men and women.  Gender differences were also evaluated in the prevalence of high CVD 
risk,   risk factor levels,  and in the use of preventive medications among subjects at high 
risk of CVD. Furthermore, gender differences were estimated in the incidence of first 
major adverse CVD events (i.e. non-fatal CHD, fatal CHD, stroke and heart failure), and in 
the  clinical  spectrum  of  incident  CVD  events.  Women  and  men  were  analysed  in  two  
different age groups, <55 years and 55 years.  
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2.1 Cardiovascular diseases 
Cardiovascular diseases (CVDs), defined as diseases of the heart and circulatory system, 
are the main cause of death among both genders. Globally, CVDs cause 30% of all 
mortality (14). In Europe, 42% of total deaths in men and 52% in women were attributable 
to CVDs in 2011 (15). In the Finnish population, CVDs have been the leading cause of 
death for many decades. In Finland in 2011, a total of 40% of all deaths were due to CVD, 
and one out of every five deaths (22%) was due to coronary heart disease (CHD). CVDs 
were the most common cause of death in both genders in 2011. Proportionally, more 
women than men died of CVD in Finland; of all deaths 41% among women but only 38.7% 
among men were due to CVDs (16). CVDs have remained an important cause of death in 
working-aged subjects. In 2011, alcohol-related diseases and accidental alcohol poisoning 
were most common causes of death in the working-aged (15-64 years old) men (1114 
deaths)  and  women  (346  deaths)  in  Finland.  However,  CHD  caused  an  almost  equal  
number of deaths in men (1111 deaths), and thus when the two most important causes of 
CVD mortality - CHD and stroke - are combined, CVDs were the main cause of death in 
working-aged men (1368 deaths vs. 1114 deaths due to alcohol-related diseases and 
accidental alcohol poisoning). In working-aged women, CHD and stroke combined 
contributed to an almost equal number of deaths (=287) as the second most common cause 
of death, breast cancer (=293 deaths).  Figure 1 shows total CVD mortality (excluding 
congenital heart defects) trends among both genders in the United States from 1979 to 
2009 (17).  
Figure  1. Total  CVD  mortality  trends  from  1979  to  2009  in  United  States  among  men  and  
women. Reproduced with permission from Go AS et al. Circulation 2013;127:e6-e245.
4CVD mortality is mainly due to CHD and stroke, which together account for two thirds of 
all cardiovascular deaths (14). In men, CHD evokes a larger proportion of CVD deaths 
than in women with CHD causing 46%, and cerebrovascular diseases 34% of all CVD-
related deaths in men, and in women CHD is responsible for 38% and cerebrovascular 
diseases 37% of all CVD deaths (14).  
The proportion of CVD mortality of all-cause mortality among working-aged men was the 
highest in Finland among all of the 21 countries participating in the World Health 
Organisation (WHO) MONItoring Trends and Determinants in Cardiovascular Disease 
(MONICA) Project during the 1980s. At the same time period (1985-1987), CVD mortality 
among Finnish women was the 5th highest among the MONICA populations (18). Age-
standardised mortality rates from CVD have declined during the past 40 years in high-
income countries including Finland. During the years 1969-71, the age-standardised CVD 
mortality rate in Finland was 680/100 000 among 35-64 year old men whereas in the year 
2006 it had fallen to 172/100 000. In women, CVD mortality was 217/100 000 in the 1969-71 
and 45/100 000 in 2006. Thus, among working-aged subjects, CVD mortality has declined 
by 75% in men and by 79% in women in the period from the beginning of the 1970s to 2006 
(19). Table 1 shows the main CVD events: age-standardised mortality rates of CHD and 
stroke per 100 000 inhabitants in some Organisation for Economic Cooperation and 
Development (OECD) countries in the latest available year.  
Table 1.  Age-standardised1 CVD death rates / 100 000 persons in the years 2007-2009 (2).
CHD2 Stroke2
Year Men Women Men Women 
Finland 2009 170 74 50 38
Sweden 2008 118 58 45 36
Estonia 2009 282 141 80 52
Netherlands 2009 62 27 35 32
Spain 2008 66 28 41 32
United States 2007 129 68 32 29
Japan  2009 38 17 53 30
1 Age-standardised to the 1980 OECD population  
2Source:OECD Health Data 2011; IS-GBE, 2011. For CHD http://dx.doi.org/10.1787/888932523348 and 
for stroke http://dx.doi.org/10.1787/88893252367.
Morbidity 
Morbidity can be described using different measurements such as incidence, prevalence 
and hospital discharge rates. These are affected by national methods of reporting diseases, 
and cannot be considered as truly comparable across different countries in the same way 
as mortality rates. WHO Global Burden of Disease-project sums up the lost years of life 
due to premature death and lost years of healthy life due to disability (Disability-Adjusted 
Life Years i.e. DALYs). Globally, WHO estimates that CVDs cause 10% of the total disease 
burden measured by DALYs. In Europe, CVDs are responsible for 17% of the total disease 
burden and in the EU countries it is slightly less but still 14%  (1, 20). In men, CHD is the 
second largest (6.8% of DALYs) and stroke (5.0% of DALYs) the third largest cause of 
disease  burden globally  after  HIV and AIDS (7.4% of  DALYs).  In  women,  CHD account  
5for the third largest and stroke the fourth largest proportion of lost healthy life years (CHD 
5.3% of women’s DALYs and stroke 5.2% of DALYs), after HIV and AIDS (7.2%) and 
unipolar depressive disorders (8.4%) (20). Table 2 illustrates cardiovascular morbidity data 
and case-fatalities in some selected countries.  
Table 2. Cardiovascular disease morbidity and case-fatality in selected countries in the years of 
2007 - 2009.
Year 30-day in-
hospital 
CF MI 1
(%) 
30-day in-
hospital 
CF Stroke 
1 (%) 
CHD 
DALYs2
/100
000
in 2004 
Stroke 
 DALYs2
/100 000
in 2004 
Hospital 
Discharges/  
1000 population 
 from CVD in 
20073
Finland 2009 4.8 2.8 730 394 27
Sweden 2007 2.9 3.9 543 281 25
Estonia - N/A N/A 1538 719 32
Netherlands 2007 5.3 5.7 417 291 17
Denmark 2009 2.3* 2.6* 551 358 20
U.K 2009 5.2 6.7 674 348 13
Spain 2009 5.6 6.1 401 276 13
USA 2008 4.3 3.0 715 327 20
Japan 2008 9.7 1.8 274 425 14
1  Age- and gender standardised to the 2005 OECD population +45 years old 
2 Age-standardised  Disability adjusted life years (DALYs) rate /100 000 population in 2004. According to 
the World Health Organisation Global Health Observatory Data Reposity. 
3 Source OECD Health Data 2011 http://www.oecd.org/els/health-systems/49105858.pdf 
* The lowest in Europe 
CF indicates case-fatality and N/A indicates not available 
In 2003, 7.4% of the working-aged (ages 16-64 years) population in Finland were on 
disability pension. CVDs were the third most common cause of disability, after mental 
health problems and musculoskeletal diseases. In 2003, 8.7% of disability pensions were 
granted in men and 3.4% in women due to CVDs. The number of disability pensions due 
to CVDs has decreased substantially: in 2003 the proportion of disabilities due to CVDs 
was a mere one third of the level existing in the 1970s (21). Among the elderly (65-74 years 
old) CVDs are responsible for large proportion of disability (22). 
CHD, stroke and heart failure are the main forms of CVD. More detailed information on 
those diseases and their gender differences are presented below. 
2.2 Coronary heart disease
CHD is a clinical syndrome characterized by angina pectoris, namely myocardial ischemia 
due to atherosclerotic coronary artery disease, caused by the accumulation of fatty 
deposits in the intima of epicardial coronary arteries leading to impairment of blood flow. 
CHD is clinically manifested either as stable (chronic) CHD or acute coronary syndrome 
(ACS)  which  includes  unstable  angina  (UAP),  myocardial  infarction  (MI),  or  sudden  
death. The proportions of these clinical manifestations are known to differ between the 
genders. Men have more clinical events (MIs) and a higher rate of sudden deaths whereas 
6women express more angina pectoris (23). According to Framingham data (23) the 
incidences of these clinical manifestations differs considerably between the genders. 
Expressed per 1000 inhabitants among aged 35 to 84 years the clinical manifestations were
in  men:  14.1  for  MI,  12.3  for  angina  and  3.1  for  sudden  death.  In  women,  the  
corresponding rates were: 4.4, 8.3 and 1.1 (23).    
CHD  mortality  is  either  due  to  sudden  death  or  ACS,  including  UAP  and  MIs  with  
different clinical presentations: non-ST-elevation and ST-elevation (STEMI) infarctions. 
CHD death does not necessary require that there is any objective evidence of a thrombus 
or myocardial necrosis as the actual lethal mechanism can be arrhythmic. Sudden death, 
most commonly defined as death occurring during the first hour after the onset of 
symptoms, accounts for approximately 30% – 50% of total CHD mortality, and can 
unfortunately be the first and only symptom of CHD (24, 25). Most of the CHD mortality 
(80%) occurs during the first day after the onset of symptoms, and over half of the CHD 
deaths occur in out of hospital circumstances (18). Gender differences are known to exist 
in the CHD mortality patterns. More men (74%) than women (61%) die in out of hospital 
circumstances (26). More women than men are unaware of the existence of CHD before 
sudden death: 50% of men, and 64% of women who die suddenly of CHD experience no 
previous symptoms of the disease (2).  
2.2.1 Mortality 
CHD  is  the  main  cause  of  CVD  mortality  and  it  is  the  most  common  cause  of  death.  
Globally, CHD is responsible for 12.8% of all deaths (14). In Europe CHD accounts for  
20% of deaths in men and 22% in women, and in working-aged subjects CHD is the reason 
for 16% of all deaths in men and 10% in women (1). In Finland, CHD accounted for 23% of 
all deaths among men and 21% among women in 2011, and it was the second most 
common cause of death in working-aged men (16% of total deaths) and the seventh most 
common cause of death among working-aged women (5.3% of total deaths) (16). Trends in 
age-specific CHD mortality rates are similar in men and women except for the fact that 
women’s mortality rates lag 10 years behind those of men (2). 
In the United States, CHD mortality started to increase in the 1920s and in Europe during 
the 1950s. The male excess in CHD mortality was most prominent in the late 1970s, when 
4-5 times more men died of CHD than women (19, 27). At the beginning of the 1970s, in 
the Seven Countries study, the age-standardised CHD mortality was the highest in 
working-aged men in North Karelia in Finland when they were compared to the other six 
participating countries. At that time, CHD mortality was 701/100 000 among working-
aged men and 126/100 000 among working-aged women (19).  
Since the early 1970s, age-standardised CHD mortality have shown a decline, and 
declining mortality rates have been seen both in national mortality statistics and in 
population-based cohort studies from different countries (2, 18, 28, 29). In the United 
States, CHD deaths have declined by 76% from 1963 to 2010 (2). Age-standardised CHD 
mortality declines according to the routine mortality statistics are shown for some selected 
countries in Table 3, and in some population-based register studies in Table 4. The decline 
in percentage terms may differ between the two different data sources due to different 
case definitions and lack of standardisation of the coding of causes of death in death 
certificates. Nevertheless, the CHD mortality declines have been faster among men than 
women in most studies and countries (Table 3, Table 4). In the study of Levi et al. (Table 3) 
7gender differences in the declines were not statistically tested (28). Gender differences in 
CHD event trends have been evaluated in only a few population-based studies. Gerber et 
al. found a total CVD mortality decline of 55% in men and 46% in women in the Olmsted 
County, Minnesota, between 1979 and 2003. These corresponded to an annual decline of 
3.3% in men and 2.5% in women (p for gender differences 0.007). Unfortunately, CHD 
mortality decline gender differences per se were not reported in that study (29). Slower 
CHD mortality declines among women than among men have been described from the 
Olmsted County, Minnesota, between 1979 and 1994, and from New England 
communities between 1980 and 1991 (30, 31).  In contrast, McGovern et al. reported similar 
CHD mortality declines in both genders in Minnesota from 1985 to 1997 (32). Among the 
MONICA populations, CHD mortality rate declined between 1983 and 1992 in working-
aged persons equally, on average by 2.7%/year in men and 2.1%/year in women (33).  
Table 3. Age-standardised1 CHD mortality rates per 100 000 persons per year according to the 
national mortality statistics and CHD mortality change between 1985-1989 and 2000-2004 
(28)
Men Women 
1985-
1989
1990-
1994
2000-
2004
Change2 1985-
1989
1990-
1994
2000-
2004
Change2
Finland 248 209 140 -43.7% 98 86 61 -37.7%
Sweden 194 153 98 -49.5% 80 65 44 -44.6%
Estonia 381 378 282 -26.1% 206 185 133 -35.5%
Netherlands 143 113 67 -52.8% 55 46 29 -47.0%
U.K 281 184 112 -48.7% 95 83 50 -47.4%
Spain 71 67 56 -20.6% 28 27 22 -21.2%
USA 166 140 111 -33.3% 83 71 58 -29.8%
Japan 33 29 29 -9.8% 18 15 13 -27.2%
1  Age-standardised to the World Standard Population 
2 Change from 1985-1989 to 2000-2004 
Table 4. Age-standardised CHD mortality declines (%) according to the population-based 
registers 
Years Age group in 
years 
Men  
(%) 
Women 
(%) 
Finland  CVDR database (34) 1 1991-2011 25-74 62 70
United States Ford et al.  (4) 1980-2002 35 52 49
Australia O´Flaherty et al.  (35) 1976-2006 25 73 70
U.K. O´Flaherty et al.  (36) 1984-2004 35 54.7 48.3
France Wagner et al.  (37) 2000-2007 35-74 24 38
USA Roger  et al. Olmsted County  
 (31) 
1979-1994 N/A 47 32
N/A indicates not available 
1 According to the cardiovascular disease register (CVDR) database, annual rates age-standardised to 
European population (34). Database accessed in June 2013. 
In Finland, CHD mortality has declined equally in both genders from the early 1980s to 
the beginning of the 2000s. A study combining all Finland’s MONICA areas for the time 
period  1983-1997 showed an average mortality decline of 6.4%/year (95%CI -5,4%, -7.4%) 
8in men aged 35-64 years  and 7.0%/year (95%CI -4.7%, -9,3%) in  women of the same age. 
According to the Cardiovascular Disease Register (CVDR), the CHD mortality decline 
between the years 1991 to 2001 was on average 5.2%/year in men (95 %CI -5.6%, - 4.8%) 
and 6.1%/year (95%CI -6.6%, -5.6%) in women aged 25 to 74 years (38). In the FINAMI 
register, during an almost similar time interval from 1993 to 2002, the CHD mortality 
decline  in persons aged 35-74 years  was similar between the genders, 5.3% in men 
(95%CI -6.6%, -3.9%) and 4.0% (95%CI -6.3%, -1.8%) in women (13).   
Age-standardised CHD mortality rates may conceal age-dependent differences seen in 
some of the countries. In the United States, England and Wales, Australia and France CHD 
mortality was proposed to have levelled off between the end of the 1990s and the 
beginning of the 2000s, or even increased among middle-aged (<55 years old) subjects (4, 
35-37). A recent study from France described an overall decline in women’s CHD 
mortality, which was apparent among older, 55 to 74 years old women, whereas no 
decline was seen  to occur in women aged 35-54 years (37). In the United States, CHD 
mortality even increased among 35-44 year old subjects during the period 1997 to 2002 (4). 
In contrast, no difference was detected between the genders in CHD mortality declines 
between 1980 and 2009 in the Netherlands (39). Bertuccio et al. used the WHO mortality 
database and reported that the average CHD mortality decline for young (35-44 years old) 
persons was -3.3% per year in men and -2.1% per year among women in the EU areas 
between 1980 and 2007. However, statistical differences between the genders were not 
estimated (40).  
With respect to the mortality decline in MONICA from 1982 – 1992, two thirds was 
considered to be explained by the decline of event rates, and one third by the decline in 
case- fatality (33). Correspondingly, the decline in CHD mortality during 1980 to 1997 in 
Finland 53-72% was estimated to be due to a reduction of the risk factor levels with about 
23% attributable to improved treatments (41). More recently, according to data from 
England in 2002-2010, it has been estimated that slightly over half of the mortality decline 
could be explained by the decline in event rates, and slightly less than half  by the decline 
in case-fatality occurring during the first month after the event (42). Adverse changes seen 
in CHD mortality among middle-aged subjects are difficult to explain; however, it has 
been speculated that unfavourable changes in risk factor prevalence, in particular obesity 
and diabetes, among young persons would explain the slower CHD mortality decline.     
According to the latest available year 2011 in the CVDR database, the age- standardised 
CHD mortality in Finland was 250/100 000 in men and 81/100 000 in women aged 35-84 
years. In subjects aged 35-64 years, the age-standardised CHD mortality was 87/100 000 in 
men and 15/100 000 in women.  
2.2.2 Case- fatality  
Case-fatality refers to the percentage of subjects who die of an acute CHD event of all the 
subjects diagnosed with an acute CHD event (incident or recurrent) within a defined time 
period (fatality =100- survival %), whereas mortality describes acute CHD event deaths 
per population within a defined time period. The declines in case-fatality have been 
estimated to have had an impact of 23 - 48% on total CHD mortality decline (41, 42). The 
American Heart Association (AHA) estimates that revascularization and secondary 
preventive therapies after MI would have been responsible for a 11% decline, initial 
treatments for ACS for a 10% decline, heart failure treatments for a 9% decline, 
9revascularisation for chronic angina for a 5% decline, and finally antihypertensive and 
lipid-lowering therapies in primary prevention are believed to have achieved a 12% 
reduction (2). Unfortunately, case-fatalities differ in acute coronary events, according to 
time definition, study setting, and patient-related characteristics such as clinical 
presentation, age, gender and co-morbidities.  The prognosis after an acute coronary event 
is  often considered to  be  poorer  in  women;  a  higher  proportion of  women than men die  
within one year after MI. Approximately 26% of women and 19% of men aged 45 years 
hospitalized due to MI will die during the first year after the MI (2). This gender difference 
is considered to be due to the higher age of women at the time of acute coronary event.  
However, among the young, i.e. working-aged subjects, a recurrent event is more likely to 
be fatal in men as compared to women, despite the fact that there were equal numbers of 
recurrent  events  in  both  genders  during  their  follow-up  of  almost  6  years  (43).  
Nevertheless, the AHA statistics reported the median survival after the first MI to be 
worse among women aged <75 years than among men:  in subjects aged 55 to 64 years, the 
median survival after the first MI was 17 years in men and 13.3 years in women. In the age 
group of 65 to 74 years, the remaining life expectancy after the first MI was estimated to be 
9.3 years in men and 8.8 years in women. After the age of 75 years the estimated remaining 
life expectancy was 3.2 years in both genders (2). However, it is not clear whether the 
female gender is an independent predictor of poorer prognosis, or whether the worse 
prognosis after MI is related to certain age-groups in women (young vs. older women).  
Short-term case-fatality 
Age- and gender-standardised 30-day case-fatalities after hospital admission are shown in 
Table 1 for some selected countries. According to the WHO MONICA study, the median 
28-day case-fatality for MI was 49% in men and 51% in women (44). The short-term case-
fatality has declined since the 1980s, and in CVDR, the latest available age-adjusted case-
fatalities for the year 2011 in persons aged 35-64 years were: 35% in men and 27% in 
women with the corresponding percentages for the age group of 35-84 years being 47% in 
men and 39% in women.  
Results on gender differences in short-term prognosis have appeared to be conflicting 
depending on the adjustments made and on the study setting. Studies including patients 
admitted to hospital have found higher case-fatality for women (6, 45-49). In some studies 
women’s higher age, higher number of co-morbidities, differences in clinical presentation, 
greater difficulties in reaching diagnosis, and lesser usage of reperfusion therapies have 
been shown to explain the higher case-fatality among women compared to men (47-49) 
whereas in other studies, these differences have remained after adjustments for these 
factors (6, 45, 46). Gender differences in studies recruiting only hospitalized patients may 
be distorted due to different proportion of pre-hospital deaths between the genders (50). 
Population-based studies from Scotland, Sweden and New Zealand, which evaluated 
overall case-fatality by taking the pre-hospital deaths into consideration, reported higher 
case-fatality among men in pre-hospital circumstances, higher case-fatality among women 
in in-hospital cases, and equal short-term case-fatality between the genders (51-54). In 
some studies, a gender difference in prognosis has been shown to exist, especially among 
young women (6, 53, 55). Vaccarino et al. described two times higher in-hospital case-
fatality among <50 year old women in the United States,  with this difference remaining 
also after adjustments for medical history, clinical severity and early management of 
coronary event (6).   
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In Finland, the overall 28-day case fatality was 38% in men and 25% in women in 1983-
1987, then until the year 1997, case-fatality declined equally among both genders in 
persons aged 35-64 years (Table 5). During this time period, 74% of all fatal events among 
men occurred in pre-hospital circumstances, and 61% of women’s fatal events were pre-
hospital. A gender difference was seen in the location of case-fatality decline in 1983 - 
1997: pre-hospital deaths declined significantly only among women, whereas in-hospital 
deaths declined only in men (26). More recently, between 1993 and 2002, the 28-day case-
fatality declined only in men (Table 5). During this time interval, case-fatality for 
hospitalised  acute  coronary  events  declined  in  both  genders,  which  may  point  to  an  
unfavourable pre-hospital case-fatality trend occurring in women. Pre-hospital case-
fatality data for the period 1993-2002 were not available (13).  
Table 5. Average annual  28-day, pre-hospital and in-hospital case-fatality (CF) change (%) 
with 95 % confidence intervals  in 1983- 2002 in Finland.
Average annual  
 change (%) in 
28-day CF  
Average annual 
change (%) in pre-
hospital CF 
Average annual 
change (%) in in-
hospital CF 
Salomaa et al. (26)  
1983-19971
Men -1.3 (-2.3 – -0.3) -1.0 (-2.1, +0.2) -2.7 (-4.7 – -0.8) 
Women -3.1 (-5.5 – -0.7) -4.0 (-7.1 – -0.8) -3.0 (-6.7 – +0.7) 
Salomaa et al. (13) 
1993-20022
Men -2.4 (-3.8 – -0.7) N/A -3.3 (-5.9 – - 0.5) 
Women 1.2 (-3.5 – +1.1) N/A -4.9 (-8.5 – -1.2) 
1 Age-group of 35-64 years old 
2 Age-group of 35-74 years old 
 N/A for not available 
There has been a 56% improvement in the one month case-fatality in the United States 
between 1987 and 2006 (56). The temporal trends in 30-day case-fatality during this time 
period did not differ between the genders or age groups in the Olmsted, Minnesota, cohort 
(56). In 2002-2006, 30-day case-fatality for incident MI was higher among women, 
approximately 11%, as compared to 5% in men (56). Vaccarino et al. have detected an 
improvement especially in case-fatalities of young (<55 years old) women in the period 
from the 1990s to 2006 (57).   
Long-term case-fatality 
Overall 1- and 5-year case-fatality has declined by 55-69% from the 1960s to 1999 in the 
United States (58). According to the CVD register, in the year 2009 in Finland the 1-year 
age-standardised case-fatality among 28-day survivors aged 35-84 years old was 8% in 
men and 6% in women. Among 45-54 years old subjects, the case-fatality was 1% among 
men and 2% among women (34). Studies on long-term prognosis have revealed no gender 
differences in case-fatality after discharge from hospital (59), although some have 
described a better prognosis among women (60). Vaccarino et al. reported higher overall 2-
year case-fatality among survivors of acute myocardial infarction in women (28.9%) 
compared to men (19.6%). This gender difference was shown to be age-dependent: only 
women <60 years old had higher 2-year case-fatality compared to men of a similar age (HR 
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1.40). This difference diminished with age, so that among 70 years old subjects, the HR 
was 0.95 between women and men. These differences still remained after adjustments for 
medical history, hospital treatments and procedures, co-morbidities (diabetes) and 
discharge treatments (61).   
2.2.3 Incidence  
CHD incidence, as well as CHD mortality increase with age. Among males, the incidence 
increases until the age of 45-55 years, and after that the increase levels off and then the rate 
is maintained throughout the remaining age bands. In women, the incidence remains low 
until the age of 65-74 years after which it rapidly increases, the gender gap in the incidence 
narrows with the rates becoming almost equal after the age of 75 years (23). Comparable 
rates  of  men  and  women  are  in  general  achieved  10  years  later  in  women  compared  to  
men (62). Men have 2 to 6.5 times more CHD before the age of 64 (23). Among women, 
CHD incidence increases by a factor of 4 after menopause when compared to the situation 
in premenopausal women (23).  
Age-standardised incident CHD event rates were ranked highest for men in North Karelia 
in Finland in the 1985-1989 period from all MONICA regions (18). At that time, the CHD 
incidence rate was 586/100 000/year in 35-64 year old men in North Karelia, and the rate 
for all CHD events (fatal, nonfatal, incident and recurrent) was 915/100 000/year. Women 
of a similar age in North Karelia had the fourth highest event rate of the MONICA regions. 
In women, the incident CHD event rate was 115/100 000/year, and the total CHD event 
rate was 165/100 000/year in North Karelia. Other  MONICA registration areas in Finland, 
Kuopio and Turku-Loimaa, also ranked in the “top 10” regions in the CHD event rates 
(18).
In the United States, the age-and gender adjusted CHD incidence increased from 
274/100000 in 1999 to 287/100 000 in 2000, but after that, the rate has declined to 208/100000 
in 2008 (63). Gender differences in incident acute CHD events have also been reported. 
Hospitalisations in the Olmsted County, Minnesota, increased among women, especially 
among older women between the years of 1979 to 1994 while the numbers of  
hospitalisations remained the same in men (64). More recent incidence rates are affected 
by adoption of troponins. Between 1986 and 2006, the incidence of hospitalized MIs did 
not  change  significantly  in  the  Olmsted  County,  Minnesota,  cohort  (56).  However  when  
the effect of the troponins in incidence was taken into account, the incidence was found to 
decline by 1.1% per year.  It was stated that the incidence trends did not differ by age and 
gender (56). In the Atherosclerosis Risk in Communities cohort in the United States, age-
adjusted MI incidence was reported to decrease by 4.3% annually among white men and 
by 3.8% in white women between the years of 1987 to 2008, when biomarker adjustments 
were taken into account. Gender differences in decline rates were not tested statistically 
and no age-dependent differences in incidence were  reported (65).  
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2.2.4 Prevalence 
The CHD prevalence is estimated to be 8.3% in men and 6.1% in women in the adult 
population of the United States  and the corresponding prevalence of MI  is  4.3% in men 
and 2.2% in women (2). In contrast to those figures, angina pectoris is more prevalent 
among women than men (4.0% vs. 3.8%), and furthermore, this excess prevalence of 
angina symptoms is known to exist in both pre-and postmenopausal women (2, 66). The 
prevalence of CHD increases with age in the United States; 6.0% of the population (both 
genders) aged 40-59 years has CHD, and among the population aged 60-79 years 23%, of 
men and, 14% of women have CHD. In the age group of >80 years, 36% of men and 21% of 
women have CHD (2).  
Data from the National Health and Nutrition Examination Surveys (NHANES) have 
shown that over the past two decades, the prevalence of MI has increased among young 
and middle-aged women, while  it has declined among  men of a similar age (67). In the 
NHANES 1999-2004, MI prevalence was 2.2% in men and 1.0% in women aged 35-54 
years.  In the United States it has been estimated that by 2030 the overall CHD prevalence 
will increase by 16% from the level in 2010 (2).  
In Finland, according to the Health 2000 Survey, the prevalence of persons with a history 
of  MI  was  2.2%  in  working-aged  men,  and  0.3%  in  working-aged  women.  In  the  
population aged >65 years, the prevalence of MI was 15.4% in men and 6.8% in women. 
Angina symptoms were also more common among men; 3.1% of working-aged men and 
1.1% of working-aged women suffered from angina. The corresponding numbers in the 
population aged >65 years  were 27.9%  and 20.3% (68).  
The  overall  CHD  prevalence  has  increased  by  18%  in  Finland  from  the  1980s  to  the  
beginning of the 2000s (69). The most predominant patient group was 45-64 years old men 
in the 1980s, whereas in the year 2000 this first place position had been taken by over 75 
year old women (69). The number of hospitalisations due to CHD among 75 year old 
subjects  was  higher  among  women  than  in  men  in  2011  (the  total  number  of  
hospitalizations was 20190 in women, and 17600 in men) (34). Women have a longer life-
expectancy than men in Finland. According to Statistics of Finland, the life-expectancy at 
birth in the 2011 was 84 years in women and 77 years in men. In 2011, 65-year old men 
were estimated to have a life-expectancy of 17 years i.e. five years less than the 22 years in 
women (70). The general life-expectancy has increased since the 1950s throughout Europe 
(3). In 2010 the gender gap in the western countries was 5.6 years. The life-expectancy 
difference between the genders has narrowed during the past 30 years. Men have gained 
higher  increases  in  life-expectancy  in  most  OECD  countries  and,  a  part  of  this  
improvement in life expectancy is due to the decrease in CVD occurrence among men  
(71).   
2.2.5 Effects of troponins 
ACS and the detection of MI have changed over time. Sensitive troponins became 
available for MI diagnostics in the 1990s and were adopted into clinical use in Finland in 
the late 1990s. Cardiac troponins are known to have higher sensitivity and better 
specificity  to  detect  MIs  than  the  older  enzymatic  biomarkers  (creatine  kinase  (CK),  its  
isoenzyme CK-MB, and CK-MBm). Troponin adoption has increased the estimates of the 
MI incidence compared to old biomarkers but has had no effect on acute coronary event 
mortality rates or case-fatalities (13, 56, 58, 65). Roger et al. reported similar effects of 
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troponin adoption on MI incidence rates in different age-groups and in both genders (56). 
However, in that study, the age- or gender differences were not analysed in detail.  
Salomaa et  al.  studied the  effects  of  troponins  in  FINAMI study subjects  for  whom both 
old enzymatic biomarkers and cardiac troponins were available (13). Troponins were 
found to have exerted effect on the incidence in both genders and all ages, but the greatest 
effect  of  troponin  adoption  on  MI  event  numbers  was  observed  among  the  elderly  (75  
years of age) women (13). Troponins had no significant effect on case-fatality in either 
gender  or  in  any  special  age  group.   Investigators  of  the  Framingham  Heart  Study  also  
reported  similar trends in case-fatality of MI events detected by electrocardiogram (ECG) 
or by biomarkers (58). Troponins have only a small effect on acute coronary event 
mortality due to the large proportion of deaths occurring before any diagnostic testing 
(13).    
The clinical presentation of MI has changed after the adoption of troponins. The number of 
non-ST-elevation MIs has increased whereas those of STEMIs have decreased (56).  
However, this change seems to be independent of the adoption of troponins (56). The 
prognosis  of  MIs  has  not  changed  due  to  the  adoption  of  troponins,  because  the  MIs  
detected by troponins only seem to have a poor prognosis (72) .  
2.3 Stroke 
The WHO defines stroke as: “rapidly developing clinical signs of focal or global 
disturbance of cerebral function, with symptoms lasting 24 hours or longer or leading to 
death,  with  no  apparent  cause  other  than  vascular  origin”  (73).  Most  strokes  are  due  to  
blockade in the arteries supplying the cerebrum (ischemic stroke), accounting for 87% of 
all stroke events, or due to a rupture of blood vessel in brain (hemorrhagic stroke), which 
makes up 10% of all stroke events. The third stroke type is subarachnoid haemorrhage, 
which constitutes approximately 3% of all stroke events (2). In Finland, the proportions of 
stroke types among hospitalised subjects have been 79% for ischemic strokes, 14% for 
intracerebral hemorrhages and 7% for subarachnoid haemorrhages (74).  Ischemic strokes 
can be further divided on the basis of their cause to cardioembolic, large artery, and small 
artery infarcts, or as those of unidentified origin. Each of these subcategories is responsible 
for approximately one quarter of the total ischemic strokes. 
Studies on gender differences of stroke are being published in increasing numbers.  Most 
of the population-based studies have found controversial results on gender differences. 
However, most of the researchers are unanimous that women are older at the time of the 
first  stroke  as  compared  to  men,  and  therefore  have  more  co-morbidities  and  poorer  
functionality prior to the stroke (75, 76). Stroke aetiology, important when considering the 
preventive  actions,  has  been shown to  differ  between the  genders.  In  a  systematic  meta-
analysis, Appelros et al. evaluated 17 community-based studies with 7783 strokes in men 
and 8371 strokes in women. Men had more incident ischemic and hemorrhagic strokes 
compared to  women.  Male/  female  incidence ratios  (stroke incidence in  men divided by 
stroke incidence in women) adjusted for WHO world population was 1.55 for ischemic 
stroke and 1.60 for intracerebral hemorrhage. The male/female ratio for subarachnoid 
haemorrhage was 0.84, with 95% CI 0.69- 1.04. More men than women suffered large-
vessel and small vessel strokes, i.e. mainly strokes caused by atherosclerosis, whereas 
women had more cardioembolic strokes (75). However, Petrea et al. published 
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controversial  results  from the  Framingham cohort  which found no differences  in  clinical  
stroke subtypes between the genders (76). Stroke occurrence is reviewed in detail below. 
Studies on age- dependent differences in stroke occurrence are still few in number.  
2.3.1 Mortality 
In Europe, stroke is responsible for 15% of all deaths among women and 10% of all deaths 
in men, and it is  the leading cause of disability (15). Globally, stroke accounts for 10% of 
all deaths (77). Due to the higher proportion of women in the older population, and due to 
the increasing stroke risk with ageing, proportionally more women than men die of stroke: 
women account for 60.1% of all stroke deaths (2). In the United States, the age-adjusted  to 
year 2000 standard, stroke mortality among adults was 82.4/100 000 in women and 
84.8/100 000 among men between 1994 and 2004 in the white population (78). Age affects 
stroke mortality; before 45 years of age the mortality is similar  in both genders, whereas in 
the age group 45-74 years, women have 20% lower stroke mortality compared to men (78). 
A population-based study from Scotland detected a lower stroke mortality among women 
until 84 years of age, but after that, women displayed a 15% excess in mortality as 
compared to men of a similar age (79).  The authors concluded that even though the sex-
by-year interaction was statistically significant for the study period of 1986-2002 i.e. 
revealing a slower decline in stroke mortality rate in women, the minor differences in  
percentages were of no practical importance  due to the similar  female-male relative risk 
(RR) over the whole study interval (79). Table 6 shows stroke mortality rates obtained 
from routine mortality statistics per 100 000/year in selected countries during the 1980s 
and 1990s and at the beginning of the 2000s (28).  
Table 6. Age-standardised1 stroke  mortality  per  100  000  inhabitants  from  routine  mortality  
statistics  in 1985 – 2004 in  selected countries and the change (%) in mortality (28) 
Men Women 
1985
-
1989
1990
-
1994
2000
-
2004
Change* 
(%) 
1985
-
1989
1990
-
1994
2000
-
2004
Change* 
(%) 
Finland 69 63 41 -40.8 55 49 32 -42.5
Sweden 44 43 34 -22.5 37 34 28 -24.0
Estonia 149 154 110 -26.0 119 117 76 -36.1
Netherlands 45 43 33 -26.8 36 34 28 -22.5
United 
Kingdom 
61 52 39 -37.1 54 45 34 -36.2
Spain 65 52 34 -48.3 42 33 26 -51.3
United States 35 31 26 -25.5 30 27 23 -22.7
Japan 75 58 45 -39.7 53 40 27 -48.9
1  Age-standardised to the World Standard Population 
* Change from the 1985-1989 time interval to 2000-2004 
Similarly  to  the  situation  with  CHD,  Bertuccio  et  al.  described  a  decline  in  stroke  death  
rates based on  routine mortality statistics among young subjects aged 35-44 years and 
found a similar -2.5% decline for both genders in the EU area (40).  
In Finland, the stroke mortality trend has followed the overall decline in CHD event rates.  
The population-based FINSTROKE study reported an average decline of 3.7% per year  in 
men and 4.1% per year  in women aged 25-74 years in the 15 year period of 1983-1997 (80). 
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Pajunen et al. reported declines in all three stroke subtypes using CVDR data for the 
period 1991-2002. Ischemic stroke mortality had declined by 4.8% per year in men, and by 
6.2% per year in women aged 35-74 years, and the mortality of intracerebral haemorrhage 
had declined by 2.8% per year in men and by 4.2% per year in women. The corresponding 
values for subarachnoid haemorrhage had declined by 5.0% per year in men, and by 1.9% 
per year in women (81). According to the latest available CVDR data (year 2011), stroke 
mortality was 55/100 000 persons among 35-74 year old men and 30/100 000 persons 
among women of a similar age. The stroke mortality rate was substantially higher among 
both genders in persons aged 75 years than among younger persons. However, in 
subjects 85 years old, the mortality rates were higher among women (34).   
2.3.2 Case-fatality 
Depending on the population the overall 1-month case-fatality in western countries for all 
stroke subtypes combined was 17-30% during 2000-2008 (82). Stroke subtype exerts a great 
impact on case-fatality, since haemorrhagic strokes have a higher case-fatality when 
compared to ischemic strokes. The 1-month case-fatality of ischemic stroke in western 
countries was in the range 13-23%. Similarly, case-fatality of intracerebral haemorrhage 
was 25-35%, and 25-35% for subarachnoid haemorrhage (82). Stroke case-fatality has 
declined in most western countries from the 1970s to 2008, and the latest 1-month case-
fatalities for this time period were 14.3% for ischemic stroke, 41.0% for intracerebral 
haemorrhage and 30.0% for subarachnoid haemorrhage (82).  
In Finland, the 28-day case-fatality did not decline significantly in either gender during 
1983-1997 (80). However, more recently the 28-day case-fatality for all stroke subtypes has 
been reduced substantially in persons aged 35-74 years  from 1991 to 2002: ischemic stroke  
3.0% per year in men and  2.9% per year  in women, and intracerebral haemorrhage   2.3% 
in men and 2.0% in women.  The case-fatality of subarachnoid haemorrhage also declined 
significantly,  3.5%  per  year  in  men  and  1.8%  per  year  in  women  (81).  According  to  the  
CVDR database, the 28-day case-fatality for all stroke subtypes combined in subjects aged 
35-74 years was 10% in men and 8% in women in 2011. Case-fatality increased with age, 
and for subjects aged 85 years, the case-fatality was 37% in women and 27% in men (34). 
There is a controversy about whether there are gender differences in stroke case-fatality. 
The WHO MONICA study found, on average, higher average 28-day case-fatality for 
women than men (31.8% vs. 28.7%). However, stroke case-fatality has varied between the 
populations, revealing either similar or higher case-fatality for women, depending on the 
population. In Finland, 28-day case-fatality was lower in women than men in all three 
MONICA areas (83). In the Framingham cohort including all age groups,  case-fatality did 
not differ significantly between the genders, despite the large differences in the 
percentages between men and women: 30-day case-fatality was 21% in women and 15% in 
men, and 180-day case-fatality was 30% in women and 23% in men (76). A significant 
difference was found in the pooled results of 31 population-based analyses, which  
revealed a 1-month case-fatality  that was 1.25 times higher in women than in men (95% CI 
1.17- 1.34). The pooled 1-month case-fatality was 24.7% in women and 19.7% in men (75). 
The poorer prognosis for women was also reported in a Scottish study of hospitalised 
patients. Lewsey et al. reported a higher 30-day case-fatality in women over a 20-year 
study period. The gender difference was age-dependent, and the largest difference was 
seen in subjects 55-64 years old. In this age group, after adjustments for co-morbidities and 
socioeconomic differences, the 30-day case-fatality in women revealed an excess of 35%. 
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Moreover, this higher case-fatality was seen in all age groups, and the smallest difference, 
an excess of 9%, was seen among subjects 85 years old. Furthermore, the gender 
difference increased from 1980s to 2005, with the 30-day case-fatality being 20.6% for 
women and 14.7% for men aged 55-64 years in 2005 (79).  
A German population-based study did not detect any gender differences in 1-year 
survival (84). According to the AHA statistics, gender differences in long-term prognosis 
depended on age. During the first year after incident stroke, deaths occurred in 35% of 
women and 31% of men 65 years old, whereas 21% of women and 16% of men <65 years 
old died (2). 
Gender differences in stroke subtype may affect the case-fatality results, if indeed women 
have a higher rate of cardioembolic strokes, as is often – but not unanimously – reported 
(75, 78). This may distort the gender differences in case-fatality, since cardioembolic 
strokes are on average more severe than their atherosclerotic counterparts (75, 85). Some 
other reasons might also explain the possibly higher case-fatality among women; however, 
the  findings  are  conflicting.  Some researchers  have reported longer  waiting times  before  
seeking treatment and more atypical symptoms among women (for example pain and 
lightheadness) compared to men, gender disparities in acute phase treatment, lower rate 
of diagnostic procedures in women (echocardiography and carotid artery evaluation), and 
furthermore, a lower rate of secondary preventive medication usage among women as 
compared to men (78, 86, 87). 
Nevertheless, trends and gender differences in stroke case-fatality are important, because 
the MONICA study reported that in those countries where the stroke mortality had 
declined during the MONICA period, the decline was mostly (2/3) due to declines in 
stroke case-fatality (83).  Moreover, even should the stroke event not be fatal, women are 
known  to  have  poorer  functional  outcome.  Women  have  been  shown  to  have  higher  
institutionalization rates and higher rate of depression after stroke, to suffer from lower 
quality of life, and to need more assistance after stroke than men, even when controlling 
for age and the pre-stroke functional capacity (76, 78).  
2.3.3 Incidence 
Similarly to the situation with stroke mortality, stroke incidence increases with age. Men 
have a higher incidence during midlife. However, after the age of 75 years, gender 
differences diminish, and after  the age of 85 years women have a higher incidence (76). 
Due to the longer life-expectancy of women, the life-time stroke risk after the age of 55 
years is higher in women (1:5 among women and 1:6 among men) (76). The Framingham 
investigators reported age-standardised stroke incidence of 407/100 000 person years  in 
women and 496/100 000 person years in men (76). During the early mid-life (45-54 years), 
stroke incidence was 82/100 000 person years among women and 116/100 000 person years 
among men. Among individuals aged 75-84 years the incidence was 1209/100 000 person 
years  in women and 1340/100 000 person years in men (76). The stroke incidence has 
declined by 42% in high-income countries since the 1970s, when the overall stroke 
incidence was 163/100 000 person years, compared to the 94/100 000 person years in 2000-
2008 (82). In Finland, according to the CVDR database in the latest available year of 2011, 
the overall age-standardised stroke incidence was 197/100 000 among 25-74 years old men 
and 116/100 000 among women. In subjects 85 years old, the  incidences were 2538/100000 
in men and 2594/100 000 in women (34). 
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Studies  on gender differences in the decline of stroke incidence are more concordant than 
those examining mortality; in most studies the declines in incidence have been discordant 
between the genders (85, 88). A population-based study from the years 1988-2002 in 
Canada found a lower incidence decline in women and, a similarly, lower stroke incidence 
decline was observed in the Framingham cohort in 1950-2004 (85, 88). The Framingham 
study reported that the incidence had declined by 30.3% in men but by 17.7% in women 
(88). Recent population-based studies have even shown an increasing stroke incidence in 
mid-life  in  women  according  to  the  NHANES  data  in  the  United  States  and  Sweden  (5,  
89). A lower decline in stroke incidence was also seen in Scotland among middle-aged 
women (79). In the Framingham study, however, no increase in stroke incidence rate was 
seen among middle-aged women, but  the numbers in this age group were small (76). The 
increasing  stroke  incidence  has  been  postulated  to  be  caused  by  the  increases  in  the  
prevalence of obesity, adverse life-styles changes, metabolic syndrome and type 2 diabetes 
(89, 90).  
2.3.4 Prevalence 
In the United States, stroke prevalence has been reported to be 2.4% in adult white men 
and 3.3% in women (2). The prevalence increases with age among both genders: among 
subjects aged 65 years the prevalence was elevated to 8.3%, among the 45-64 years old 
2.9%, and among persons aged <44 years 0.7% (91). The prevalence of silent strokes is 
estimated to be 6-28%, depending on the age group (2). Pooled analysis by Appelros et al. 
showed an average 41% higher prevalence in men as compared to women. The 
male/female prevalence ratio was the highest (male per female ratio of 1.56) in the age 
group of 65-74 years, and diminished with aging (75). In contrast, Reeves et al. reported 
higher prevalence of stroke among females than men after the age of 65 years, and after 
the age of 85 years the prevalence in women was twice that of men (78). Recently Towfighi 
et al. described data for the period 2005-2006 indicating that young (aged 45- 54 years) 
women had suffered 3 times more prior strokes than  similarly aged men (92).  
2.4 Heart failure 
Heart failure can physiologically be defined as a state where defects in heart function or 
structure lead into failure of the heart to provide sufficient amount of oxygen to satisfy the 
needs of the metabolising tissues despite a normal filling pressure or only at the expense 
of increasing filling pressure. The European Society of Cardiology (ESC) defines heart 
failure more clinically: heart failure is a syndrome depicted with symptoms of shortness of 
breath, ankle swelling and fatigue and signs of elevated jugular venous pressure, 
pulmonary crackles and displaced apex beat, resulting from abnormality in heart structure 
and function (93). In epidemiological studies, heart failure has been defined mainly by 
using the Framingham Heart Study criteria (Table 7) or the ESC clinical criteria (93, 94). 
Previously in clinical settings, and also in many clinical trials, the definition of heart failure 
has been connected to decreased left ventricular ejection fraction. Heart failure can be 
divided, according to findings in functional cardiac imaging, to heart failure with reduced 
ejection fraction (EF) (HF- REF reduced ejection fraction, commonly considered EF  40%) 
and heart failure with preserved EF (HF-PEF), also referred to as ´diastolic´ heart failure.  
According to the updated ESC 2012 heart failure guidelines, a heart failure diagnosis 
requires  that  there  be  symptoms  and  signs  of  typical  heart  failure,  and  an  HF-REF-
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diagnosis requires evidence of reduced ejection fraction, whereas diagnosis for HF-PEF 
requires symptoms, signs and functional cardiac imaging to show specified alterations in 
detail: 1) normal / mildly reduced left ventricular EF, and no dilatation of  the left 
ventricle, 2) relevant structural heart disease (left ventricular hypertrophy/ left atrium 
enlargement) and / or diastolic dysfunction (reduced left ventricular passive filling i.e. 
reduced é or increased E/é ratio, i.e., active filling caused by left atrium systole divided by 
passive filling of the left ventricule during diastole) (93). Since heart failure is an end result 
of another underlying cause, this aetiological cause needs to be identified. 
Table 7.  Framingham Heart Study criteria for heart failure 
Framingham criteria for Heart Failure 
Major criteria 
Paroxysmal noctural dyspnea or orthopnea 
Neck vein distension 
Rales 
Cardiomegaly 
Acute pulmonary edema 
S3 gallop 
Increased venous pressure 16 cm H2O
Circulation time 25 seconds 
Hepatojugular reflux 
Minor criteria 
Ankle edema 
Night cough 
Dyspnea on exertion 
Hepatomegaly 
Pleural effusion 
Vital capacity decreased one third from maximum 
Tachycardia 120/min 
Major or minor criterion 
Weight loss 4.5 kg in 5 days in response to treatment 
Heart failure  is present if two major or 1 major criterion plus 2 minor criteria apply
Gender differences in heart failure are related to differences in the underlying aetiology, 
clinical characteristics and outcomes of heart failure. Women are more likely to have a 
non-ischaemic cause for heart failure than men, i.e. a higher prevalence of hypertension 
and valvular defects. Men have a higher rate of CHD before the heart failure diagnosis 
and men have more dilated cardiomyopathy than women (95-97). More women have a 
preserved ejection fraction,  i.e.  diastolic  heart  failure  than men,  whereas  more men have 
reduced  EF,  i.e.  systolic  heart  failure  (96).  As  with  other  CVDs,  women  are  older  at  the  
time of the heart failure diagnosis; on average 79 years vs. 73 years in men (95). Women 
have  more  diabetes  and  anemia  compared  to  men,  who  are  more  likely  to  have  chronic  
obstructive pulmonary disease, peripheral arterial disease and renal failure (96). During 
the 2000s, the age of onset of heart failure has increased, and the numbers of co-
morbidities among heart failure patients have increased (98). 
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2.4.1 Mortality and prognosis 
Heart failure has high a mortality, even though the prognosis has improved in parallel 
with introductions of modern drug therapy. Still, approximately 50% of people diagnosed 
with heart failure will die within five years after the diagnosis (95). The AHA statistics 
indicate overall age- and gender adjusted 30-day fatality of 10.4%, 1-year  fatality of 22% 
and 5-year fatality of 42.3% (2). In a large population-based study from the United 
Kingdom with over 600 000 heart failure patients mainly from a primary care setting, the 
3-year fatality after a definitive heart failure diagnosis was reported to be 54% in men and 
47%  in  women.  Mean  survival  was  on  average  22.9  months  in  men  and  24.5  months  in  
women (99).  In some population-based studies the prognosis of heart failure is reported 
to be worse among men than among women (95, 100). No gender differences were seen in 
the Rotterdam study  nor in the Framingham Heart Study in 1 to 5 year-prognosis of heart 
failure (94, 101). Van Jaarsveld et al. described an  age- and gender dependent difference in 
1 to 7 year-prognosis of heart failure: among <75 years old subjects the prognosis is worse 
among men, and after 76 years of age, no gender differences were seen in heart failure 
prognosis (102). Table 8 depicts the fatality proportions of heart failure in different 
population studies for both genders separately.  
Table 8.   Proportions of  fatal  outcome at 30-day, 1-year and 5-year time points,  in different 
population-based studies
Years  Age
group 
30-day % 1-year % 5-year % 
Men Women Men Women Men Women 
Levy et al. 
Framingham 
(94)
1990-
1999
65-74 11 10 28 24 59 45
Roger et al. 
Olmsted County 
(95)
1996-
2000
mean 
age 75 
6* 4 21* 17 50* 46
Jhund et al. 
Scotland1(103)
1999 N/A 19.6 18.9 27.8 27.8 65.8 63.6
2003 N/A 16.2 16.9 27.6 25.6 N/A N/A 
Vaartjes I et al. 
Netherlands 1
(100)
1997-
2000
mean 
age 76 
18** 27 38** 36 67** 66
1 Hospitalised with first episode of heart failure. N/A indicates not available. * Significant (p<0.001) age-
adjusted gender difference, towards higher fatal outcome in men. ** Significantly higher fatal outcome in 
men when adjusted for age and co-morbidities including diabetes mellitus
Population-based studies have detected an improvement in heart failure prognosis. The 
Framingham study reported an improvement in heart failure prognosis from 1950 to 1999 
in both genders. The risk of death declined approximately by 12% per decade in both 
genders (94).  Data from the Olmsted county, Minnesota, also revealed an improvement in 
prognosis between the two time periods of 1979-1984 and 1996-2000, although these 
improvements were greater in men and among younger subjects. Heart failure prognosis 
had improved by 52% in men and by 33% in women in the age group of 60-69 years, and 
by 41% in men and by 21% in women aged 70-79 years. For the eldest age group (80
years), no improvement was seen in women, whereas for men, the survival had improved 
by 28% (95).
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2.4.2  Incidence  
Heart failure incidence and its time trends depend on the definition of heart failure. Heart 
failure incidence increases with age, with men displaying a higher heart failure incidence 
in  all  age  groups.  According  to  the  AHA  statistics,  incidences  indicated  as  numbers  per  
1000 person years, are 9.2 in men vs. 4.7 in women in the age group of 65-74 years, 22.3 in 
men vs. 14.8 in women in the age group of 75-84 years, and 41.9 in men vs. 32.7 in women 
in subjects 85 years old (2). Population-based cohort studies using either the Framingham 
heart failure definition (Table 7) or clinical heart failure definition of the ESC have 
reported age-adjusted heart failure incidence of ~ 2-5 per 1000 person-years (94, 95, 101). In 
the Framingham study, the age-adjusted incidence was 564 per 100 000 person-years in 
men compared to 327 per 100 000 person-years in women (94). More similar incidences 
between the genders were reported by the Rotterdam study group: an age-adjusted 
incidence of 17.6 per 1000 person-years in men and 12.5 per 1000 person-years in women 
(101). In the Olmsted County study, the age-adjusted incidence was 378/100 000 in men 
and 289/100 000 in women (95). Most of the heart failure diagnoses (>70%) are, however, 
assigned in primary care by general practitioners (GPs) without applying the above 
mentioned strict criteria (99). A large population-based study from the United Kingdom 
reported an overall age-adjusted heart failure incidence of 9.3/1000 person-years, when 
most of the diagnoses were made by the GPs. Men had a higher incidence, but 
unfortunately that study did not report incidence rates separately for men and women 
(99).
The temporal changes in heart failure incidence rates have shown inconsistent results. The 
population-based  study  from  the  Olmsted  County,  Minnesota,  showed  no  difference  in  
heart failure incidence between the years 1979 and 2000 in either gender (95). A recently 
published population-based study from Spain, in which the Framingham case definition 
was used, reported a 32% increase in heart failure incidence from 2000 to 2007 (98). In this 
study, the incidence had increased in both genders. Data from the United States Medicare 
system  found  evidence  for  an  increasing  incidence  among  the  65-69  years  old,  but  a  
declining incidence among subjects >75 years old during the period 1994-2003 (104).   
2.4.3 Prevalence 
Heart failure prevalence in the adult population is estimated to be 2-3% (2, 105). The 
prevalence increases with age, to reach over 8.4% in the population aged >75 years, and 
then up to 17.4% in subjects aged 85 years (101, 105). Only half of the patients with 
moderate or severe ventricular dysfunction receive a heart failure diagnosis, suggesting 
that asymptomatic heart failure is as prevalent as symptomatic heart failure (105). In the 
Rotterdam study, the heart failure prevalence was 3.9% with no gender differences, with 
60%  of  the  persons  who  were  considered  to  have  left  ventricular  systolic  dysfunction  in  
echocardiography exhibiting no symptoms or signs of heart failure (106). Heart failure 
prevalence has increased over the past decades (101, 104). It has been claimed that the 
increasing prevalence is due to several factors i.e. improvements in CHD and heart failure 
treatments, increasing awareness, and the aging of the population. In Finland, the heart 
failure prevalence was higher among women than in men (9% of women and 5% of men) 
among subjects 65-years old according to data from the Health 2000 survey. The 
prevalence was similar in working-aged people, of whom 0.2% of women and 0.5% of men 
were assessed to have heart failure in a doctor’s examination. Compared to the values 
above obtained from the clinical evaluation, a higher proportion of subjects appeared to 
have heart failure according to the self-reporting: 1.4% of working-aged men and 1.1% of 
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working-aged women had heart failure (p for gender difference not significant (NS)). 
Similarly, 14.1% of men and 15.5% of women over 65 years old have reported that they 
have heart failure (p for gender difference NS) (68). 
2.5 Risk factors 
2.5.1 Cardiovascular disease risk factors 
Traditionally CVD risk factors have been divided into non-modifiable and modifiable 
factors. The non-modifiable risk factors are age, gender, family history and genetic 
contributions. The modifiable, behavioural, risk factors, namely tobacco use, physical 
inactivity, unhealthy diet and excess use of alcohol are associated with four independent, 
major risk factors for CVD: high total blood cholesterol level, elevated blood pressure, 
smoking and diabetes (107). These main risk factors are same for both genders, although 
some gender differences have been shown to exist in prevalences of the main risk factors 
and their significance (11). In addition, women have some unique gender-related risk 
factors: menopause, polycystic ovary syndrome (PCOS), usage of oral contraceptives 
(OCs), and pregnancy-related disorders such as pre-eclampsia, gestational hypertension 
and gestational diabetes (108). These risk factors, their effects and possible gender 
differences in CHD and stroke (Table 9 and Table 10) are presented in detail below.  
Age
Aging increases the risk for CVD; women develop CVD approximately 10 years later in 
life compared to men (11). The average age of the first MI is 64.5 years in men and 70.3 
years in women (2). Most of this difference is due to the higher prevalence of risk factors 
among men in the younger age groups (11). In Finland in 2002 the mean age of having the 
first MI was 70.2 years in men and 80.0 years among women (CVDR database accessed 
2005). The average age of an incident stroke in the Framingham cohort was 75 years in 
women and 71 years in men  (76).  
Family history 
Family history of CVD increases the risk for CVD independently of traditional risk factors. 
The greatest  risk,  doubling the  risk  for  offspring,  is  when a  first  degree  relative  (parent,  
offspring or sibling) has had an early-onset CVD (<55 years old in men and <65 years old 
in women) (109, 110). Some studies have indicated that family history is a stronger risk 
factor for women than for men (111). In particular in females a maternal history of CVD 
may predict CVD more strongly than a paternal history (112). However, the 
INTERHEART study reveal to show any difference in maternal vs. paternal family history 
of MI among the offspring with MI events (109).  
Socioecomic status
Socioeconomic status refers to a person´s social status relative to other members in their 
society. Socioeconomic status is often evaluated using education, income or employment 
status as indicators. High social standing is known to protect from CVD events: in the 
Whitehall  Study cohort,  subjects (i.e.  male civil  cervants) in the lowest social group were 
3.6 times more likely to die of a CHD event than those in the highest social group (113). 
Socioeconomic factors have been postulated to exert a higher impact on a woman’s CVD 
risk. However, in some studies there are  methodological issues, such as using the 
woman´s partner’s income or whole household income to evaluate woman´s 
socioeconomic status (114, 115). Results from NHANES, in a prospective follow-up setting, 
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indicated  that  education  had  a  gender  specific  role  as  a  risk  indicator  for  CHD;  women  
with a low level of education had a 61% increase in their risk for incident CHD as 
compared to women with  high  education, while men with a low level of education had 
only a 29% increase in risk compared to men with  high  education (116). These analyses 
were adjusted for smoking, diabetes, cholesterol and blood pressure, i.e. indicators which 
are known to be worse in persons with a low level of education.  Low socioeconomic 
status, measured as the subject´s own level of education,  pointed to a twofold increase in 
the risk for CHD mortality among 30-59 years old women, whereas in men of the same 
age, the increase in risk was only 55% when compared to those males with a high level of 
education (117). In the NHANES low income (adjusted  as above) displayed no significant  
gender differences with  low income status increasing the risk of CHD events for both men 
and women (116). Socioeconomic status has also been studied using FINMONICA data of 
25-64  years  old men and women.  In  that  study,  low levels  of  occupation,  education and 
income  were  associated  with  an  increased  risk  of  CVD  in  both  genders.  In  women,  the  
family income was also an important factor contributing to the  risk (114).  
Elevated blood cholesterol  
A strong association has been found for total blood cholesterol, especially low-density 
lipoprotein (LDL) cholesterol to increase the risk for CVD and this relationship exists in  
both genders (10, 118-120). CHD is known to be rare among the population with total 
cholesterol  less  than 3-4  mmol/l,  even in  the  presence  of  other  risk  factors  (121).  Most  of  
the cholesterol in plasma is carried in the form of LDL, and total and LDL cholesterol have 
been shown to display a graded, positive association to CVD risk (119). The adverse effect 
of high LDL cholesterol is clinically evident in patients with heterozygote familial 
hypercholesterolaemia;  in these individuals CHD has been found already in men at the 
age of 17 years and in women at the age of 25 years (122).  Apoprotein B is a major protein 
component of apolipoprotein B, which carries LDL, intermediate-density lipoprotein and 
very-low density lipoprotein, which in turn are the atherogenic components, whereas 
apoprotein A1 is the main protein in high-density lipoprotein (HDL) particles and is 
considered to be antiatherogenic (121). Tables 9 and 10 show odds ratios (ORs) of 
ApoB/Apo A1 for CHD and stroke for both genders according to the INTERHEART and 
INTERSTROKE studies. However, in the routine clinical work, total cholesterol, or the 
ratio of total cholesterol and HDL cholesterol are measured and used for risk prediction 
(121).
Gender  differences  due  to  aging  can  be  observed  in  cholesterol  values.  In  men,  total  
cholesterol values tend to be higher than in women until the age of 50 years, whereafter 
women tend to have higher values. HDL cholesterol levels decline in men at puberty, and 
in women after menopause. Thus, the gender difference in the total cholesterol per HDL 
cholesterol ratio diminishes with aging (62). Blood lipid analyses from the Framingham 
Offspring cohort have shown that premenopausal women have a less atherogenic lipid 
profile when compared to men of a similar age. Furthermore, premenopausal women had 
lower LDL cholesterol and triglyceride levels, and higher HDL-cholesterol values 
compared to men of a similar age. (123). Blood total cholesterol level might be a more 
important  risk  factor  in  men  compared  to  women.  In  a  Swedish  population  study  of  
middle-aged women, those with a total cholesterol level above 8 mmol/l, had a double risk 
of  future  CHD  death  compared  to  women  with  cholesterol  below  6  mmol/l  (120).  In  
middle-aged men, the risk of death is doubled, when the total cholesterol increases from 
5.0 mmol/l to 6.5 mmol/l, and is increased 4 fold when the total cholesterol concentration is 
above 8.0 mmol/l (124). Data from the Finnish MONICA cohorts showed that a total 
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cholesterol increase of 1 mmol/l was associated with increases in CHD mortality by 36% in 
men and by 21% in women (10). However, the Finnish MONICA study recruited 25-64 
year  old  women,  and  in  the  Swedish  study  the  follow-up  was  19  years  and  women  
recruited in this study were mostly under 55 years old. Thus, the subjects in both of these 
studies were mainly under 75 years old (10, 120). Since cholesterol levels increase later in 
life among women, and most of the CHD events occur after the 7th decade of life in 
women, the impact of hypercholesterolaemia on CHD mortality might be underestimated 
among elderly women (120). Total cholesterol levels have been shown to predict CHD 
events among young individuals, whereas hypertriglyceridemia (triglycerides 1.7
mmol/l) has been proposed to be a stronger predictor among old, postmenopausal women 
when compared to their premenopausal counterparts in whom the triglyceride 
concentration displayed no predictive value for MI or CHD death (125). In the 
Framingham  study,  a  low  HDL  cholesterol  level  was  a  stronger  predictor  of  CHD  in  
women than in men (23).  
The WHO estimates that globally 1/3 of CHD, and 4.5% of total deaths are due to high 
cholesterol levels. In 2008, the prevalence of hypercholesterolaemia, defined as total 
cholesterol 5.0 mmol/l or having medication  for high cholesterol, was globally found  in 
40% of adult women and in 37% of adult men (14). The prevalence of 
hypercholesterolaemia was highest in the European region, 54% of Europeans, of both 
genders, had either medication for hypercholesterolaemia or total cholesterol 5.0 mmol/l.  
Globally,  total cholesterol levels have not changed considerably; from 1980 to 2008 there 
was a 0.1 mmol/l decrease per decade (14). In Finland in 1972, the mean total cholesterol 
was 6.92 mmol/l in men and 6.81 mmol/l in women, but subsequently it has declined by 
21% in men and 23% in women (Figure 2). In 2007, the mean cholesterol was 5.39 mmol/l 
in men and 5.18 mmol/l in women when all FINRISK areas were pooled (12). In 2007 33-
41% of men and 42-49% of women had a total cholesterol level <5.0 mmol/l (12). More 
recently, FINRISK 2012 reported that the mean cholesterol levels had increased in the 
Finnish population. According to FINRISK 2012 the mean cholesterol level was 5.34 
mmol/l (+ 0.05 mmol/l from 2007 level) in men and 5.31mmol/l (+0.13 mmol/l from 2007 
level) in women. These increases were significant in both men (p for increase 0.0054)  and 
women (p for increase p<0.001) (126) .  
Figure 2. Total cholesterol levels between 1972-2007 in men (A) and in women (B) aged 30-
59 years in FINRISK areas (19).
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Elevated Blood Pressure  
Optimal blood pressure is considered to be <120/80 mmHg, whereas prehypertension is 
considered as the range of systolic blood pressure (SBP) 120-139 mmHg and diastolic 
blood pressure (DBP) 80-89 mmHg. Hypertension is defined as SBP 140 or DBP 90
mmHg. For subjects with diabetes and individuals with renal disease, lower values of SBP 
>130 or DBP >85 mmHg are considered as hypertensive (2). Elevated blood pressure is one 
of the main risk factors for CHD, heart failure, stroke and other CVDs, with up to 2-3 fold 
higher risk on average detected in both hypertensive men and women (127). The ORs of 
CHD event and stroke due to hypertension are shown in Table 9 and Table 10. The risk for 
both CHD and stroke increases linearly and progressively from SBP values as low as 115 
mmHg and DBP 75 mmHg (128). Blood pressure exhibits a continuous relationship, 
without any significant cutpoint, to CVDs.  Every 20 mmHg increase in SBP or  10 mmHg 
increase in DBP doubles the risk for a CVD event (128).  
There is known to be a gender difference in blood pressure from adolescence, men having 
6-7 mmHg higher SBP and 3-5 mmHg higher DBP than women throughout their adult life. 
In men, SBP rises throughout the adult life with DBP reaching its’ highest level at 60 years, 
whereas in women DBP peaks 10 years later at the age of 70 years, whereafter DBP starts 
to decline (121, 129). Women have more isolated systolic hypertension, and some 
differences in the pathophysiology of hypertension have been discovered: women have 
more labile blood pressure, a higher rate of white coat hypertension, and they are more 
likely to have salt-sensitive hypertension, and high volume hypertension in comparison to 
men (129). Women also are subject to unique hypertension-inducing conditions, i.e. 
pregnancy, menopausal hormonal changes and usage of OCs. OCs may cause mild blood 
pressure  elevation:  in  a  cross-sectional  survey  from  the  United  Kingdom  low-dose  
estrogen containing OCs users had significantly (p<0.001 for both SBP and DBP) higher 
blood pressure values when compared to non-users; the difference was 2.3 mmHg in SBP 
mmHg and 1.6  mmHg in  DBP between OCs users  and non-users  (130).  However,  blood 
pressure usually descends back to the normal range within 6 months after drug 
withdrawal. Pregnancy- and menopause-related changes in blood pressure will be 
described in more detail later in the chapter “Unique risk factors for women”. 
Globally,  as many as 40% of adults have high blood pressure (14). In the United States, 
one out of three adults has high blood pressure (2). The prevalence of high blood pressure 
is higher among men than women before the age of 45 years old. After that, the prevalence 
hypertension is similar in both genders, and later after the age of 64 years, the prevalence 
becomes higher in women (2). In 1972 in North Karelia, the mean SBP was 149 mmHg in 
30-59 year old men and 153 mmHg in similar aged women, and the mean DBP 92 mmHg 
in men and 92 mmHg in women. In FINRISK 2007 in subjects aged 30-59 years, the mean 
SBP was 138 mmHg in men and 130 mmHg in women, and the mean DBP 83 mmHg in 
men and 77 mmHg in women (12). Overall, blood pressure levels have declined in Finland 
since the 1970s (Figure 3). In the FINRISK 2012 survey, mean SBP among 25-64 years old 
participants was 134 mmHg in men and 127 mmHg in women; SBP has declined both in 
men and women from the year 2007 (131, 132). The mean DBP was 84mmHg in men aged 
24-64 years and  78 mmHg in women of a similar age (131).  In fact, DBP has increased in 
both genders since 2007 (132). The prevalence of hypertension (SBP 140mmHg or 
DBP90mmHg or medication to hypertension) has declined in both men and women from 
the 1980s, however that decline levelled off in the late 1990s. The prevalence of 
hypertension  did not change between 2007 and 2012 in men, and in women hypertension 
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prevalence has not declined in the past 10 years (132). In FINRISK 2012, the prevalence of 
hypertension was 47% in men and 27% in women (132).  
Figure 3. Mean  systolic  blood  pressure  levels  in  FINRISK  areas  between  1972-2007  among  
men and women aged 30-59 years old (19).
Smoking
Smoking is the second most important risk factor after dyslipidemia for MI, and one of the 
leading preventable causes of CHD in both genders (133). The INTERHEART Study 
estimated that 29% of all MIs in western Europe could be blamed on smoking (133). 
European Heart Network Statistics 2012 indicated that 20% of CVD deaths in men and 3% 
in women were due to smoking in Europe (1). ORs with 99% confidence interval (CI) for 
first MI and stroke due to smoking are shown in Table 9 and Table 10. In the Systematic 
Coronary Risk Evaluation System (SCORE) project, the 10-year risk of fatal CVD event is 
considered to be doubled in smokers in comparison to non-smokers (134).  
Smoking does not only speed up the development of atherosclerosis, but it also is a major 
risk factor for coronary thrombosis and sudden death and this is true in both genders (135, 
136). Smoking is known to display a dose dependent relationship with the MI risk: the OR 
for MI in individuals smoking 1-9 cigarettes per day was 1.63 (95% CI 1.45- 1.82) and those 
who smoked >20 cigarettes per day had a strikingly high OR of 4.59 (95% CI 4.21-5.00). A 
similar dose-dependence has also been reported in women. In the Nurses’ Health Study, 
the women who were the heaviest smokers (>20 per day) had a 6 times higher risk for 
CVD compared to non-smokers (137). In fact, smoking has been found to be more 
detrimental in women than men: in a systematic meta-analysis analysing 2.4 million 
participants and 75 cohorts, the currently smoking women had a 25% increased risk for 
CHD compared to the currently smoking men (138). The smoking-associated CHD risk is 
postulated to be more harmful to younger people, and smoking has been reported as the 
greatest risk factor for MI in young, <45 years old subjects (139). In younger 35-39 year old 
subjects with non-fatal MI, 81% of men were smokers whereas only 45% of 60-64 years old 
subjects with the same condition were smokers. The corresponding numbers for women 
were 77% and 36% (140).  
Regular exposure to secondhand smoke has also been shown to increase CVD risk by 15% 
in women (141). A population-based register study from the United States described a 
decline in MI incidence after the implementation of smoke free laws in workplaces (142). 
In addition to additive effects to other CVD risk factors, smoking has some gender specific 
26
adverse effects: smoking decreases endogenous levels of estrogen and increases the risk 
for premature menopause. 
In 1972 in North Karelia, 52% of men and 10% of women were smokers (12).  Figure 4 
shows the smoking prevalence in men and women in the period from 1972 to 2007 in the 
FINRISK  areas.  The  proportions  of  never  smokers  has  declined  and  ex-smokers  have  
increased since then (19). However, in 2011 20% of Finnish adults still smoked on a daily 
basis. Smoking has declined among men, in 1990 32% of men smoked daily, compared to 
22% in 2011. Historically, fewer women than men have smoked in Finland. However, the 
rate of decline rate has been slower for women: in 1990 20% of women were daily 
smokers, compared to 15% in 2011 (143). According to FINRISK 2012, the prevalence of 
smoking was 25% in men aged 25-64 years old and 20% in similar aged women (144).  
Figure 4. Smoking  prevalence  (%)  in  men  (A)  and  women  (B)  aged  30-59  years  between  
1972-2012 in the FINRISK areas (19).
Diabetes 
Diabetes is a major risk factor for CVD, and traditionally the risk for a CHD event or 
stroke is considered to be elevated by two to three fold in diabetic persons (14, 78, 145, 
146). In type I diabetes, the CVD risk is almost entirely confined to patients with renal 
disease, whereas in type 2 diabetes, all patients display an increased risk (121). Subjects 
with diabetes also have poorer prognosis after an acute CHD event compared to their non-
diabetic counterparts, and this prognosis is known to be worse among diabetic women 
than men with diabetes (14, 147). Diabetes is known to abolish the general gender-related 
difference in CVD risk and diabetes is considered to be more detrimental in women. In the 
Nurses’ Health Study, age-adjusted RR for CHD mortality in diabetic women was 8.7 
compared to healthy women and the RR for a fatal CHD event was 25.8 in women with 
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known  CHD  and  diabetes  in  comparison  to  healthy  women  (148).  In  the  INTERHEART  
study, which had a cross-sectional case control design, the OR for a CHD event was 4-fold 
among women and 3-fold among men with diabetes compared to subjects without 
diabetes (11). In the meta-analysis published by Huxley et al. the age-adjusted RR for CHD 
was 3.69 in women and 2.16 in men with diabetes. The RR was reduced to 3.12 in women 
and 1.99 in men after multiple adjustments for other risk factors: weight, hypertension and 
lipid abnormalities which often cluster in these diabetic persons (149). In the meta-analysis 
conducted by Huxley et al. the high RR for CHD morbidity among women was apparent 
even after these adjustments and women had a higher RR also for fatal CHD events (149). 
In the meta-analysis of Kanaya et al. the gender difference, not in favour of women, was 
related  to  the  increased  risk  factor  burden  in  diabetic  women  and  thus  the  gender  
difference  was not  statistically  significant  after  adjusting for  other  traditional  risk  factors  
(146). There has been a debate about, whether this difference is due to the higher 
prevalence of risk factors and co-morbidities among women with diabetes; the alternative 
is that gender has an independent effect on morbidity (146, 150). Some studies have also 
hinted at poorer risk factor treatment among women with diabetes in comparison to men 
(147, 150). Nevertheless, women with diabetes are known to suffer their first MI at the 
same age as men with diabetes, i.e. there is an evident risk for premature CHD (151).  
According to WHO statistics, the prevalence of diabetes was 10.9% among adult men and 
9.6% among adult women in Europe in 2008. It has been estimated that the prevalence of 
diabetes will increase by 20% until the 2030s (14).  In the FIN-D2D survey in Finland, the 
prevalence of type 2 diabetes (established diagnosis) was 7.4% in men and 4.3% among 
women aged 45–74 years, and previously undiagnosed type 2 diabetes was found in an 
additional 8.3% of men and 6.9% of women. The prevalence of abnormal glucose 
regulation (high fasting glucose, impairment in glucose tolerance or type 2 diabetes) was 
very high; 42% in men and 33% in women (152).   
Obesity, waist- hip ratio and the metabolic syndrome 
Obesity increases the risk for CHD, stroke, heart failure and total CVD mortality in both 
genders, this being mainly attributable to the effect on other traditional risk factors, i.e. 
hypertension, type 2 diabetes and alterations in blood lipid levels (153, 154). The 
association of weight with CVD mortality has been shown to be J-shaped (154). Total CVD 
mortality  is  known  to  increase  by  34%  in  men  and  by  29%  in  women  with  every  5  unit  
increase of body mass index (BMI) (154). The Nurses’ Health Study reported that obesity 
increased CVD risk in a dose response manner, with the risk in the heaviest category (BMI 
40 kg/m2) being 3-fold higher than that of women in the leanest category (BMI in a range 
of 18.5-22.9 kg/m2) (155). Waist-hip ratio, a marker of visceral fat amount, has been 
proposed to predict CVD risk better than BMI alone (156). Some cohort studies have 
suggested that an increase in waist-hip ratio increases CVD risk irrespective of overall 
body weight or BMI, and that there are gender differences depending on the evaluation 
method of obesity. (157, 158). In men, the waist-hip ratio was shown to be associated  with 
increased CVD incidence only in normal weight men, and no additive effect of waist-hip 
ratio was seen among overweight or obese men, whereas in women, the CVD risk 
increased in parallel with the increasing waist-hip ratio irrespective of BMI (157, 159).  In 
the  INTERHEART  study,  abdominal  obesity  i.e.  waist-hip  ratio,  was  related  to  MI  three  
times more strongly than when BMI was used as the variable (156). A large systematic 
meta-analysis of prospective studies, including 56% of women, revealed the equal 
importance of BMI, waist-hip ratio and waist circumference in prediction of CVD events 
(160).
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The prevalence of obesity (BMI 30 kg/m2)  has doubled during the past 20 years: in 1980  
only 5% of men and 8% of women were obese worldwide, but in 2008 10% of men and 
14% of women were obese (15). According to FINRISK 2012, the mean BMI was 27.1 kg/m2
among working-aged men and 26.0 kg/m2 among  similar  aged  women  in  Finland,  and  
thus 66.3% of adult men were overweight (BMI 25 kg/m2) and 20.4% were obese, 
similarly 46.4% of adult women were overweight and 19.0% were obese. Thirty-one 
percent of the working-aged men had a waist circumference > 100cm and 29.7% of women 
had a waist circumference >90 cm (161). Figure 5 shows the prevalence of obesity in 
FINRISK areas between 1972 and 2007. 
Figure 5. Prevalence  of  obesity  (BMI  30  kg/m2)  in  FINRISK  areas  1972-2007  in  men  and  
women aged 30-59 years (19). 
The metabolic syndrome is a cluster of risk factors for CVD and type 2 diabetes. The 
metabolic syndrome includes central obesity (waist 94-102 cm in men and 80-88 cm in 
women), impaired glucose regulation, elevated triglyceride levels, reduced HDL and 
hypertension. Different clinical definitions for metabolic syndrome exist; of these the 
definition  of  NCEP-AT  III  is  most  often  used  in  clinical  work  (121).  It  is  controversial,  
whether metabolic syndrome predicts CVD risk more efficiently and independently than 
the individual components of metabolic syndrome. In the European action on secondary 
prevention through intervention to reduce events (EUROASPIRE) - study the prevalence 
of metabolic syndrome was 56% in women and 40% in men (162). In Finland, the 
prevalence of metabolic syndrome has increased significantly (P=0.003) among women 
from the year 1992 to 2002, from 32.2% to 39.1%, and non-significantly in men from 48.8% 
to 52.6% (163).  It has been suggested that metabolic syndrome would be a stronger risk 
factor for CVD in women compared to men.  In a meta-analysis by Agassi et al., the overall 
RR for CVD risk was 1.61 (with 95% CI of 1.42-1.83), and gender-specific analyses showed 
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a higher RR for CVD in women; 2.10 (with 95% CI 1.79-2.45) vs. 1.57 (with 95% CI 1.41-
1.75) in men (164). Recently, metabolic syndrome has been suggested to associate with 
subclinical progression of atherosclerosis independently of hypertension, waist 
circumference, hyperlipidaemia, BMI and age, but  only among women (165). 
Physical activity 
Regular physical activity and aerobic exercise training is associated with beneficial effects 
on cardiovascular health in both genders and all ages by reducing CVD and CHD 
mortality (166, 167). CVD prevention guidelines of the WHO recommend at least 2.5 hours 
of moderate physical activity (3-5.9 times the intensity of rest measured as energy 
expenditure) or 75 minutes of vigorous activity (6 times of intensity of rest measured as 
energy expenditure) per week  for both genders (166, 168).  The 2008 Physical Activity 
Guidelines for Americans have concluded that the physically most active persons enjoy a 
30-35% risk reduction in developing CHD when compared to the least active individuals 
(14). The beneficial effect has been proposed to be somewhat stronger among women; 
Shiroma and Lee concluded in an evaluation of prospective cohort studies, that the 
median risk reduction was 40% among women and 30% among men when comparing 
those subjects with the least physical activity to those with the highest physical activity 
(169). Physical activity, especially good aerobic fitness, may reduce some of the increased 
risk of CVD events related to being overweight or obese (155, 170). The Women’s Health 
Initiative indicated that for postmenopausal women brisk walking was as beneficial in risk 
reduction as more vigorous exercise (171). A systematic review showed a dose-
dependency for the effects of physical activity: a 33% decline in CVD-related death for 
most active women and protective effects were seen for as little as walking 1 hour a week 
(172). Physical activity has been shown to have beneficial effects also among 
premenopausal women: it lowers the blood pressure, improves insulin sensitivity, 
increases HDL cholesterol and improves lipid profile by lowering total and LDL 
cholesterol (173). In addition to lowering the prevalence of obesity and type 2 diabetes, 
physical  activity  has  also  been  shown  to  improve  coronary  blood  flow  and  enhance  
endothelial function (174).  
When  asked:  “How  often  do  you  exercise  or  play  sports”,  39%  of  participants  in  an  EU  
survey answered never, and 21% responded that they exercised 3 times a week. At least 
once a week was reported by 43% of men and 37% of women. Regular non-sport activities 
(cycling, walking, gardening) were reported by 27% of men and women. When  sufficient 
physical activity was considered as 30 minutes of moderate exercise 5 times a week, or 20 
minutes of vigorous exercise 3 times a week, then it was found that 38% of Finnish adults 
could be considered to be  insufficiently physically active;  when divided by gender 41% of 
Finnish men and 35% of women exercised less than  the amounts mentioned above (1).  
Psychosocial stress 
Depression  has  been  the  most  commonly  studied  psychosocial  stress  factor,  and  
observational studies have shown that depression increases the risk for incident CHD. A 
large meta-analysis reported the hazard ratio (HR) of depression for fatal CHD or MI of 
1.81 (1.53-2.15) (175). This risk was greatly reduced, but still significant, after adjusting for 
traditional risk factors. The Women’s Health Initiative detected a higher CVD mortality 
and all-cause mortality among postmenopausal women with depressive symptoms (176).  
A study of a  Finnish cohort also pointed to a small increase in the RR of CVD events in 
women with depressive symptoms; the RR was 1.09 (CI 95% 1.06-1.11) when prevalent 
CVD was excluded and with adjustment  for  traditional  risk  factors,  but  no increase  was 
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seen in men (177). Moreover, the Nurses’ Health Study reported the strongest association 
of depressive symptoms with fatal CHD events, and this was mainly thought to be due to 
an increasing effect of antidepressant use and the risk of sudden cardiac death (178). The 
effect of psychosocial stress on CHD has also been studied. It has been believed commonly 
that  work-related  stress  predicts  CHD  events  in  men,  whereas  stress  at  home  and  in  
relationships increases the risk in women. However, in a recent meta-analysis of 13 
European cohort studies, work-related stress increased the risk of incident CHD events 
equally in both genders (age-and gender adjusted work-stress vs. no work-stress HR 1.23) 
(179).  A comparable risk increase was also reported from another  recent meta-analysis of 
6 prospective cohort studies of general perceived stress: The RR for CHD event  was 1.27 
(95% CI 1.12-1.45) after adjustment for traditional risk factors (180). Stress was evaluated 
by assessing the level of stress in life in general with no difference being found between 
the genders (180). In the INTERHEART Study, psychosocial stress had a stronger impact 
on women´s CHD risk (11).     
2.5.2 Coronary heart disease risk factors 
The INTERHEART study was a large cross-sectional case-control study of 27 098 
participants from 52 countries, 6787 of whom were women. Nine different risk factors 
explained >90% of acute MI events. The population attributable risk for these nine risk 
factors together was 96% in women and 93% in men (133). The ORs of these risk factors 
are shown in Table 9 for both genders separately and pooled.  Current smoking was more 
strongly  associated  with  MI  in  men  than  in  women,  but  there  was  no  statistically  
significant gender difference. When comparing the risk factor associations between 
younger (<60 years old) and older (60 years old) age groups in both genders, the 
INTERHEART study found a stronger association of traditional risk factors - ApoB/ApoA, 
hypertension, diabetes and current smoking - among younger women compared to older 
women. In men, ApoB/ApoA, current and former smoking, hypertension, and abdominal 
obesity, but not diabetes, were more strongly associated with acute MI among the younger 
age group than in the older age group (11). 
In the Framingham cohort among persons aged 30 – 74 years, the RRs for CHD with the 
following risk factors were: hypertension 1.93 (95% CI 1.28-2.92) among men and 1.24 
(95% CI 0.69-2.24) in women, diabetes 1.69 (95%CI 1.11- 2.57) in men and 2.38 (95% CI 
1.40-4.06) in women, current smoking 2.65 (95% CI 1.77-3.97) in men and 2.07 (95%CI 1.60-
2.68) in women, total cholesterol in the range of 5.0-6.1 mmol/l (when compared to subjects 
with cholesterol values in  the range of 4.1-5.0 mmol/l) 1.77 (95% CI 1.23-2.50) in men and 
1.55 (95% CI 0.81-2.96) in women (181). Moderate alcohol consumption was found to have 
a protective effect against CHD event (Table 9), but the effect of alcohol is known to be J-
shaped (166). Women are recommended to limit alcohol intake to a maximum of one 
glass/day (10 g of alcohol), in men the limit intake is double, 20 g alcohol/ day (166). 
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Table 9. Factors that influence the risk of acute myocardial infarction according to INTERHEART 
study (11, 133) 
Risk factor OR (99% CI) 1 OR (95% CI) 2
Both genders Men  Women p3
Increasing risk 
ApoB:ApoA1 ratio 4.73 (3.93-5.69) 2.87 (2.63-3.13) 3.30 (2.85-3.82) 0.20
Smoking (current vs. never) 2.87 (2.58-3.19) 3.04 (2.84-3.26) 2.86 (2.47-3.32) 0.06
Psychosocial factors 2.67 (2.21-3.22) 2.58 (2.11-3.15) 3.49 (2.40-5.09) 0.02
Diabetes 4 2.37 (2.07-2.71) 2.67 (2.43-2.94) 4.26 (3.68-4.94) <0.0001
Hypertension4 1.91 (1.74-2.10) 2.32 (2.16-2.48) 2.95 (2.66-3.28) 0.0001
Abdominal Obesity 1.62 (1.45-1.80) 2.24 (2.08-2.42) 2.26 (1.98-2.57) 0.03
Decreasing risk 
Alcohol consumption 3
times a week 4
0.91 (0.82-1.02) 0.88 (0.82-0.94) 0.41 (0.34-0.50) <0.0001
Regular physical exercise 4 0.86 (0.76-0.97) 0.77 (0.71-0.83) 0.48 (0.41-0.57) <0.0001
Daily fruit and vegetable 
consumption 
0.70 (0.62-0.79) N/A N/A N/A 
ApoB/ApoA1- ratio is  given as a comparison of  upper tertile  to the lowest tertile.  Abdominal  obesity is  
gender specific and the odds Ratios (ORs) are for the comparison of upper tertile to the lowest tertile of 
waist-hip  ratio.  Individuals  were  considered  to  have  psychosocial  stress,  if  at  least  one  of  the  stress  
components were present (i.e. depression, global stress, financial stress, locus of control or other 
stresses (separation, job loss, family conflict). Diabetes and hypertension were self-reported. Subjects 
were considered to be physically active if they did moderate (walking and cycling) / strenuous exercise 
4 hours / week.  
1 Yusuf et al. Lancet 2004 (133)
2 Anand et al. Eur Heart J 2008 (11)
3 p- value for gender interaction  
4 There was a gender difference in the ORs and the risk predictors were more powerful among women  
N/A indicates not available 
2.5.3 Stroke risk factors 
Established stroke risk factors are hypertension, hyperlipidaemia, diabetes, atrial 
fibrillation, MI, smoking, waist-hip ratio, metabolic syndrome, excess alcohol consumption 
and carotid artery disease (87). In the Framingham cohort, the RRs for stroke were 1.16 for 
10 mmHg  increase of SBP, 1.82 for atrial fibrillation, 1.41 for diabetes 1.41, and for 
smoking 1.69 (182). No gender-specific RRs were reported.  
The INTERSTROKE study, which was an extension of the global INTERHEART study, 
evaluated global associations of traditional and emerging risk factors for stroke. 
INTERSTROKE was conducted in 2007-2010 in 22 different countries, with 3000 strokes 
matched to 3000 controls. A minority of the subjects (37%) were women (183). The stroke 
types evaluated were ischemic (78% of all strokes) and haemorrhagic (22% of all strokes) 
strokes; subarachnoid haemorrhages were excluded from this study (183). The ORs for 
strokes  combined  for  both  genders  are  shown  in  Table  10,  as  well  as  genderwise,  when  
available. Hypertension was the strongest predictor of stroke, and it was more strongly 
associated with stroke among young (<45 years old) subjects with OR of 8.53 (99% CI 5.39-
13.49). The population attributable risk for all strokes, both genders combined, was 80% 
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when five risk factors were included: hypertension, smoking, abdominal obesity, diet and 
physical activity. Population attributable risk for all stroke increased to 90.3% when 
hypertension, current smoking, abdominal obesity, diet, physical activity, diabetes, excess 
alcohol intake, cardiac causes and ApoB/A1 were taken into account (183). At present no 
gender-specific population attributable risk analysis from the INTERSTROKE data has 
appeared. 
Table 10.  Risk factors for stroke according to the INTERSTROKE study (183) 
Both genders OR 
(99% CI)  
Men  
OR (99% CI)  
Women  
OR (99% CI)  
Increasing risk 
Hypertension 3.89 ( 3.33-4.54) 3.88 (3.22-4.68) 4.89 (3.79-6.32) 
Cardiac causes  2.38 (1.77-3.20)  N/A N/A 
Smoking (current vs. never) 2.09 (1.75-2.51) 2.46 (2.02-3.01) 1.56 (1.03-2.36) 
ApoB:ApoA ratio 1.89 (1.49-2.40) N/A N/A 
Abdominal Obesity 1.65 (1.36-1.99) 1.25 (0.99-1.59) 2.70 (1.95-3.74) 
Diabetes  1.36 (1.10-1.68) N/A N/A 
Psychosocial stress 1.30 (1.06-1.60) N/A N/A 
Decreasing risk 
Regular physical exercise  0.69 (0.53-0.90) N/A N/A 
Increased consumption of 
fruit 
0.61 (0.50-0.73) N/A N/A 
Increased consumption of 
fish
0.78 (0.66-0.91) N/A N/A 
Hypertension was defined as self-reported hypertension or measured blood pressure 160/90 mmHg. 
ApoB/ApoA1- ratio was based on a comparison of highest tertile to the lowest tertile. Abdominal obesity 
was based on the comparison of gender specific highest tertile to lowest tertile of waist-hip ratio. 
Individuals were considered to have psychosocial stress if at least one of the stress components was 
present (i.e. global stress, financial stress, locus of control or other stresses (separation, job loss, family 
conflict). Diabetes was self-reported. Cardiac causes included atrial fibrillation, flutter, previous 
myocardial infarction, rheumatic valve disease or prosthetic valve replacement. Subjects were considered 
as physically active if they did moderate (walking and cycling) or strenuous exercise 4 hours / week. 
N/A indicates not available.  
2.5.4 Heart failure risk factors 
Heart failure has various causes; CHD, hypertension, cardiomyopathies, valvular and 
congenital causes, infectious diseases, arrhythmias, cardiotoxic substances (for example 
alcohol, anthracyclines) but the most common cause is considered to be CHD. Data from 
NHANES in the United States showed CHD to have a 61.6% population attributable risk 
for heart  failure (184). In the Framingham heart study, 59% of men and 48% of women 
had CHD and 70% of men and 78% of women had hypertension as the underlying 
aetiology for heart failure (185). Valvular disease was found in 31% of women and 22% of 
men (185).  Diabetes and valvular disease were proposed to exert a stronger impact on 
women´s risk of heart failure in the Framingham cohort, however the gender comparison 
was not statistically evaluated (Table 11) (186). Among younger men (<65 years old), 
hypertension and diabetes were both separately associated with a 4-fold increased risk for 
heart failure, and among younger women (<65 years old) hypertension was linked with a 
3-fold, and diabetes with a 8-fold risk for heart failure. Among older subjects these risk 
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factors  remained associated with heart failure, although their impact was less dramatic 
(185).
Table 11. The impact of risk factors for developing heart failure in subjects without heart 
failure at baseline 
Both genders 1* Men * Women * 
Hypertension 1.40 (1.24-1.59) 2.1 (1.3-3.2)2 3.4 (1.7-6.7) 2
CHD  8.11 (6.95-9.46) 4.63 (3.52-6.10) 3 4.64 (3.42-6.31)3
Left ventricular hypertrophy N/A 2.2 (1.5-3.2) 3 2.9 (2.0-4.1)3
Diabetes 1.85 (1.51-2.28) 1.27 (0.90-1.79) 3 4.17 (2.91-5.97) 3
Obesity N/A 1.90 (1.30-2.79)4** 2.12 (1.51-2.97)4**
Valvular  heart disease 1.46 (1.17-1.82) 2.43 (1.73-3.41) 3 3.47 (2.46-4.92) 3
* Relative risk ** Hazard ratio  1 According to NHANES (184) 2 Mosterd et al. 2007 (187) 3 Kannel WB et al. 
1999 (186) 4 Kenchaiah et al. 2002 (188) 
2.5.5  Unique risk factors for women  
In addition to the above presented traditional risk factors, women have some unique CVD 
risk factors, some of which are related to normal physiological female aging, such as 
menopause, some related to therapeutical interventions provided only for women, such as 
OCs and hormone replacement therapy (HRT), some related to disease conditions, such as 
polycystic ovary syndrome (PCOS), monosomal X-syndrome and some are related to 
pregnancy. Normal pregnancy and the peripartum period (= 6 weeks after delivery) 
increase the stroke risk by 2.4-fold (189). Normal pregnancy does not increase the CVD 
risk later in life. However, pregnancy complications such as pre-eclampsia, gestational 
diabetes, preterm labour and third trimester bleeding have been shown to increase the risk 
of suffering future CVD events (108). Women with pre-eclampsia in combination with 
poor fetal growth or intrauterine death are considered to be at the greatest risk (190). 
These  risk  factors  should  to  be  taken  into  account  when  evaluating  the  CVD  risk  in  
women (191). 
Menopause 
Menopause is determined as the loss of ovarian function, permanent cessation of menses 
for at least 12 months, and subsequent deficiency of endogenous estrogens (192).  In 
Finland, the average age of natural menopause was 51 years in 2007, and the mean 
menopause age has increased during the last decade (193). CVD incidence is substantially 
lower among women than men during the fertile age, but CVD morbidity increases after 
menopause. Even though studies have failed to show abrupt changes in CVD morbidity 
rates at menopausal age, the hypothesis of protective effects of estrogen is generally 
accepted. The overall epidemiological evidence is controversial, as to whether the 
increased risk is caused by the age at menopause per se, or chronological aging itself 
which  affects  CVD  risk;  this  is  probably  due  to  the  alterations  of  ovarian  function  years  
before the actual menopause (=perimenopause). In the Nurses’ Health Study, which was a 
prospective cohort study, women with natural menopause who had not taken estrogens 
did not have any increased risk for CHD when compared to premenopausal women (age 
and smoking adjusted RR  1.2; 95% CI 0.8-1.8) (194). A meta-analysis of 18 studies 
confirmed this result; pooled RR after adjustments for age and smoking was 0.96 (95% 
0.77-1.12) (195). However, women with premature (<40 years old) or early menopause (<45 
years old, affecting approximately 5% of the female population) have an increased risk for 
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death (RR 1.04; 95% CI 1.00-1.08), which is mostly due to the increased risk for CVD (196). 
Premature and early menopause increased the risk for CHD death by 80% in comparison 
to women with normal menopause (197). In a meta-analysis, early menopause exhibited 
an RR of 1.25 (95% CI 1.15-1.35) (195). In the Nurses’ Health Study, surgical hysterectomy 
with bilateral oophorectomy among women under 45 years old increased the risk for fatal 
and non-fatal CHD event risk by 17% after adjustments for traditional CVD risk factors 
and the use of estrogen replacement therapy; the younger the age at the time of the 
surgery, the greater the risk was increased (198). The North American Menopause Society 
has recommended that subjects with early and premature menopause should receive 
estrogen replacement therapy until the median age of natural menopause. This 
recommendation is based on some beneficial findings, although not from randomized 
clinical trials, on estrogen’s effects in relieving menopausal symptoms, preventing 
osteoporosis, and possibly also preventing in CVD and dementia (199). 
Estrogens are known to have regulating effects on several metabolic factors, such as lipids, 
inflammatory markers, and the coagulation system. These sex hormones have a direct 
vasodilating effect through - and - adrenoceptors on blood vessel wall, and estrogen is 
also  known  to  prevent  coronary  artery  spasms  (200).  The  loss  of  estrogen  can  evoke  
several disadvantageous changes in major CVD risk factors, as detailed in Table 12. The 
lipid profile is known to change to be more atherogenic after the menopausal transition i.e. 
an increase in total and LDL cholesterol levels, and changes in HDL to a smaller particle 
size have been shown to occur within one year after the last menstruation (201). This is 
considered to some extent to be due to the loss of estrogen’s effect on hepatic 
apolipoprotein gene expression (200). Plasma cholesterol levels peak in women at the age 
of 55-65 years old (which is 10 years later than in men) (202). The changes in other CVD 
risk factors are more controversial. The prevalence of hypertension is higher in men of the 
same age when compared to premenopausal women; and after menopause, the prevalence 
of hypertension is greater among women than in men. According to the NHAHES data on 
55 to 64 years old individuals, 56% of women and 47% of men had hypertension and a 
total of 75% of postmenopausal women were hypertensive in 1999-2002 (203). In addition 
to aging itself, the increase in blood pressure is considered to be due to changes (partly via 
unknown mechanisms) in the blood vessel walls, partly due to the effects of hormonal 
changes in renin-angiotensin-aldosterone-system, sympathetic nervous activity, and  fat 
distribution (from gynoid to abdominal) (200, 203). The changes in blood pressure levels 
occur during the decade following after the menopause (203).  
In women, the body fat distribution is linked to ovarian function, and thus the 
premenopausal gynoid fat distribution (hips and gluteus) changes to a android pattern 
(abdominal) after menopause. The weight gain after menopause, 0.5 kg annually on 
average, is due to aging rather than the menopause itself (204). Loss of estrogen is known 
to   reduce glucose-induced insulin  secretion,  and to  reduce peripheral  insulin  sensitivity  
(200), which are factors increasing the risk for impaired glucose intolerance and type 2 
diabetes. It is not clear whether these changes and the elevated risk for metabolic 
syndrome and type 2 diabetes are indirectly caused by the changes in body fat 
composition, or by direct effects of menopause itself. However, changes in blood glucose 
levels have been shown to occur later, years after the menopausal transition (205).  
While postmenopausal ovaries continue to produce small amounts of estradiol and 
estrone, they produce significant amounts of androgens: testosterone, androstenedione 
and dehydroepiandrosterone, which are converted to estrogen peripherally, which may 
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explain  some  of  the  differences  seen  in  surgical  versus  natural  menopause  in  CVD  risk.  
Furthermore, testosterone levels, the estradiol-testosterone ratio and alterations in sex 
hormone-binding globulins may exert some consequences on metabolic activities and 
CVD  morbidity  (206).  Further  studies  on  menopause,  hormonal  changes  and  changes  in  
risk factors are thus needed.  
Polycystic ovary syndrome, PCOS  
PCOS is a complex reproductive endocrine disorder characterised by ovarian dysfunction; 
oligo-or amenorrhoea, oligo/anovulation, hyperandrogenism and polycystic ovaries. 
Although the precise definition is still controversial (207). PCOS is one of the most 
common hormonal disorders among women; its prevalence is estimated to be 7-10% in the 
female population (208). Women with PCOS are affected by various metabolic disorders 
and risk factors for CVD including insulin resistance, metabolic syndrome, type 2 diabetes, 
dyslipidemia, hypertension, obesity and non-alcoholic fatty liver disease (209-211). 
Metabolic  syndrome,  a  cluster  of  CHD  risk  factors,  is  common  among  PCOS  women.  A  
study by Ehrmann et al. found that 3 metabolic syndrome criteria were fulfilled in 33.4% 
of PCOS women (210).
A recent meta-analysis showed increased levels of potentially adverse vascular biomarker 
levels  (CRP,  homocystein)  in  PCOS  women  (212),  and  women  with  PCOS  have  been  
shown to exhibit more subclinical vascular disease than normal women (213). Although 
these  risk  factors  are  known  to  increase  the  risk  for  CVD  and  CHD  events,  evidence  of  
PCOS’s independent role as a CVD risk factor remains unclear. Wild et al. retrospectively 
studied women with PCOS in the United Kingdom from 1979 to 1999, and showed that 
despite their higher CHD risk factor prevalence compared to non-PCOS women, they had 
a similar CHD incidence and mortality: OR for CHD was 1.5 (95% CI 0.7-2.9). PCOS 
women had a higher rate of cerebrovascular disease (OR 2.8 with 95% CI 1.1-7.1) (214). 
Nevertheless, a recent consensus statement advised that PCOS women should be screened 
for glucose intolerance by an oral glucose tolerance test, and for dyslipidemia, and given 
advice about the benefits of weight control and a healthy lifestyle (215).  
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Pre-eclampsia   
Pre-eclampsia is a syndrome characterised by the appearance of hypertension and 
proteinuria after the 20th week of gestation, but the pathogenesis behind pre-eclampsia 
remains unknown. Pre-eclampsia is estimated to affect 3-5% of all pregnancies. However, 
eclampsia, i.e. the development of seizure(s) due to pre-eclampsia, is a rare complication 
in the western world (217). A meta-analysis by MacDonald et al. detected an increased 
CVD risk later in life among women with pre-eclampsia, 5-15 years after pregnancy; the 
RR for CHD was 2.33 (95% CI 1.95- 2.78), for cerebrovascular disease 2.03 (95% CI 1.54-
2.67) and for CVD mortality 2.29 (95% CI 1.73- 3.04) (190). The severity of  pre-eclampsia 
increased  the  risk,  such  that  those  who  had  preterm  delivery,  poor  fetal  growth  or  fetal  
death, had the highest risk (190). CVD events have also been shown to occur early in life 
among  pre-eclamptic  women.  Ray  et  al.  found  only  a  median  of  only  8  years  after  pre-
eclamptic pregnancy, and the mean age of 38.3 years old for experiencing the first CVD 
event or revascularization (218). Recently, pre-eclampsia and other placental syndromes 
have also been connected to an increased risk for developing of heart failure later in life. 
Ray et al. analysed retrospectively 1 130 764 women having delivered, and the placental 
syndrome, mainly gestational hypertension and pre-eclampsia, was considered to have 
occurred in 75 242 women (6.7% of all women). After adjusting for traditional CVD risk 
factors and excluding those women with known CHD or thyroid dysfunction, the HR for 
heart failure and dysrhythmias was 1.51 (95% CI 1.26-1.80) and even higher in those 
women with preterm delivery or poor fetal growth (HR 2.42, 95% CI 1.25- 4.67) (219). It is 
unknown whether pre-eclampsia and other placental disorders independently increase the 
risk for CVD, for example by inducing harmful effects to entire vascular endothelial 
function,  whether  pre-eclampsia  is  an  early  presentation  of  CVD  due  to  the  similar  risk  
factors shared by both pre-eclampsia and CVD, or whether it is a combination of both of 
these conditions (191, 220). 
Gestational diabetes
Gestational diabetes  is defined as any degree of glucose intolerance which is recognised 
for the first time during the pregnancy (221). Gestational diabetes is mainly caused by the 
pregnancy-related increase in insulin resistance.  Gestational diabetes  has been shown to 
affect 2-4% of pregnant women (222). In Finland, the prevalence of abnormal glucose 
values during pregnancy is increasing; in 2006, abnormal glucose levels were found in 
8.4% of pregnant women, and insulin therapy was required in 2.1% cases, whereas in 2010, 
abnormal glucose levels were found in 11.2% of pregnancies (223). Gestational diabetes  is 
diagnosed with an oral glucose tolerance test and fasting glucose 5.3 mmol/l, 1- hour 
glucose level 10 mmol/l or 2- hour glucose level  8.6 mmol/l are all  considered abnormal 
(221).  The  oral  glucose  tolerance  test  is  performed  for  all  pregnant  women  in  the  1st
trimester if there is a known increased risk for gestational diabetes (such as obesity or 
PCOS), or more commonly in the 3rd trimester. Gestational diabetes is known not only to 
increase risk for pre-eclampsia and other pregnancy- and birth-related disorders, but it 
also has long-term consequences for both mother and infant. For example, gestational 
diabetes is a risk factor for developing diabetes: 20-60% of mothers with gestational 
diabetes develop type II diabetes in the future (224). Diabetes itself is a major risk factor 
for CVD, however, gestational diabetes also increases the risk for other CVD risk factors; 
obesity, hypertension, dyslipidemia and the metabolic syndrome (225). In a case-control 
study from Canada, women with gestational diabetes were at an increased risk for 
suffering future CVD events with a HR of 1.71 (95% CI 1.08-2.69); the  increased CVD risk 
was mainly mediated by the increased risk of type 2 diabetes (226). Women with previous 
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gestational diabetes, independently of their current BMI and metabolic abnormalities, 
display more endothelial dysfunction and increased levels of inflammatory markers as 
well as subclinical atherosclerosis as assessed via the carotid intima-media thickness (227). 
Gestational hypertension 
Gestational hypertension refers to hypertension detected for the first time during the 
second half of the pregnancy without proteinuria. Blood pressure values are considered as 
high if SBP 140 or DBP 90 mmHg.  Increased blood pressure is the most common 
gestational complication affecting 4-10% of pregnant women (228). A recently published 
cohort study of 12 055 women from northern Finland with an average follow-up of 39 
years showed that gestational hypertension increased the subsequent risk for overall CVD, 
the HR being 1.45 (95% CI  1.29- 1.63), for CHD the HR is 1.44 ( 95% CI 1.24-1.68), for fatal 
CHD the HR is 3.00 (95% CI 1.98-4.00), for heart failure the HR is 1.79 (95% CI 1.43-2.21), 
for stroke the HR is 1.59 (95% CI 1.24-2.04) and for hypertension the HR is 2.53 (with 95% 
CI 2.25-2.84) even after adjustments for diabetes, smoking and socioeconomical status. The 
mean age of these events were low, 58  years for CVD events, 61 years for CHD, 67 years 
for fatal CHD events, 58 years for heart failure, 67 years for stroke and 50 years for 
hypertension (229). In this cohort, the prevalence of gestational hypertension was 17% of 
all pregnancies and of these, 30% had a CVD event before the late 6th decade, and 3% died 
of  MI.  The  authors  concluded  that  CVD  risk  assessments  are  needed  later  in  life  for  
women with hypertensive pregnancies (229).  
Hormone-replacement therapy 
Observational studies from the beginning of the 1990s suggested that estrogen hormone 
replacement therapy (HRT) might be beneficial for CHD prevention in women. A large 
meta-analysis combining these results showed that post-menopausal HRT was associated  
with a 37% risk reduction (RR 0.63, 95% CI 0.55-0.72) in fatal CHD, and estimated that this 
benefit of HRT would prevent more deaths than the increased risk of breast cancer and 
uterine cancer due to HRT might cause combined (230).  At the same time, the American 
College of Physicians published counselling guidelines for postmenopausal women about 
preventive  hormone  therapy  recommending  HRT  for  women  in  order  to  prevent  CVD  
(231). In the mid-1990s, the rationale was to recommend HRT, and the provision of 
estrogen was one of the criteria used to evaluate  the quality of medical care (232).  
The first randomised clinical trial aiming to evaluate the “benefit” of estrogen therapy was 
launched in 1993. The Heart and Oestrogen/progestin Replacement Study (HERS) aimed 
to evaluate whether conjugated equine estrogen (=CEE 0.625 mg/day) with 
medroxyprogesterone acetate (=MPA 2.5mg) therapy would reduce CHD events in 
women with prevalent CHD compared to placebo. The HERS included 2763 
postmenopausal women (mean age 67 years old) with an intact uterus and known CHD. 
The trial was terminated in 1998 after an average follow-up of 4.1 years. No overall 
difference between the study groups was seen in the primary endpoint of nonfatal MI and 
CHD death combined (HR 0.99 95% CI 0.81-1.22). However, there were significant 
reductions  in  the  LDL level  and an increase  in  that  of  HDL.  During the  first  study year,  
there was a 52% significant excess of CHD events in the HRT group (233).  In addition to 
other critical comments raised from the HERS results, it was speculated about whether the 
HRT was started too late as the HERS subjects already had established CHD. The 
Women’s Health Initiative was initiated to evaluate the effects of HRT in healthy 
postmenopausal women. In total, 16 608 women with a uterus were randomized into 
groups receiving either a CEE 0.625 mg/day plus MPA 2.5 mg or placebo. Another group 
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of 10 739 women without uterus were randomized to receive either CEE 0.625 mg without 
progesterone, or placebo. Due to safety reasons, i.e. risks exceeding the benefits, the CEE + 
MPA study arm was stopped after an average follow-up of 5.6 years. The increased risk 
for CHD was apparent almost immediately after starting the medication, as the HR for 
CHD was 1.29 (95% CI 1.02-1.63). Furthermore, only 2 years after the initiation of HRT; the 
stroke risk was elevated (HR 1.41; 95% CI 1.07- 1.85), and risks for pulmonary emboli and 
for breast cancer were also increased (7). The CEE only arm was stopped due to the 
increased risk for stroke, and with no benefits being detected for CHD after an average of 
6.8 year follow-up (234). 
Questions remained after these clinical trials, for example should the HRT regime doses 
should be lowered, whether the oral or transdermal administration route would be  more 
effective, what are the correct formulas and hormone administering timing, what is the 
optimal total duration for HRT, and whether natural menopause is equal to the surgical 
salpingo-oophoroectomy. One particularly important topic was the timing of HRT after 
menopause; in most observational studies women were starting HRT soon after 
menopause to relieve menopausal symptoms. In the Women’ s Health Initiative, the mean 
age of the women was 63 years, and it was estimated that only 10-17% of randomised 
women had started HRT within 5 years from menopause (235). Subsequent subgroup 
analyses of Women’s Health Initiative have supported the hypothesis of timing; older 
women who had started HRT 20 years after menopause had an increased CHD risk HR 
1.28 (95% CI, 1.03-1.58). Women starting HRT less than 10 years from menopause 
displayed no significant difference or excess in CHD events (235). However, the increased 
risk  of  stroke by HRT seemed to  exhibit  no difference  with respect  to  HRT timing (236).   
The controversy regarding benefits and harms of HRT still remains unsolved. Basic 
research and animal models have suggested that HRT might prevent atherosclerosis and 
reduce CHD events. However, randomised clinical trials have shown a lack of benefit, or 
even harm associated with HRT use. Thus, today clinical recommendations do not support 
the  HRT  use  as  a  means  of  CVD  prevention,  and  the  current  clinical  rationale  is  to  use  
HRT in the lowest possible dose and as a short duration as possible,  if  needed to relieve 
menopausal symptoms (237).  
Oral contraceptives  
Combined  estrogen  and  progestagen  OCs  are  associated  with  an  increase  risk  for  
thromboembolic  events:  MI,  stroke,  and  venous  thrombosis.  The  risk  for  venous  
thrombosis came apparent shortly after OCs came to market in the early 1960s. These first 
OCs contained many times higher estradiol doses (50-150ug/day) compared to modern 
OCs with an estradiol content on average of 20-30ug/day. Even with today’s lower 
hormone dosage and more careful patient selection, a recent meta-analysis revealed a 
doubling of the risk for current use of low-dose OCs for CVD, OR for MI was 1.84 (95% CI 
1.38- 2.44) and 2.12 (95% CI 1.56- 2.86) for ischemic strokes.  With third-generation OCs, 
the risk for ischemic stroke was only apparent with OR of 2.03 (95% CI 1.15-3.57) (238). 
The  Nurses’ Health study found no connection of past use OCs with the risk of a suffering 
a CHD event (239). 
Currently  it  is  believed  that  there  is  little  or  no  risk  associated  with  the  current  use  of  
newer generation OCs in healthy low-risk women. Women with increased risk  for CVD, 
i.e. having hypertension, smoking, having diabetes, and (migraine for stroke), may 
experience  a  modest  to  highly  significant  increase  in  their  CVD  risk  and  OCs  are  
contraindicated in these high risk groups, especially after the age of 35 years (240).  
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2.6 Total risk evaluation 
In  Finland  CVD  prevention  recommendations  are  based  on  the  European  Guidelines  on  
Cardiovascular Disease Prevention (166). These guideline apply similarly to both genders 
and at the time of writing the latest version of ESC Guidelines on cardiovascular disease 
prevention in clinical practise appeared in 2012 (166). The AHA has published its own 
guidelines for women since 2007 with the latest update being published in 2011 (191).  
The CVD risk evaluation is based on a total risk estimation, which is an estimated sum of 
several individual CVD risk factors acting additively together, predicting a person’s future 
risk  for  suffering  a  CVD  event  over  a  given  time  period,  e.g.  10  years.  The  current  ESC  
guidelines recommend that risk factors should be screened from all men 40 years old and 
all postmenopausal or 50 years old women. The risk estimation should also be performed 
if  a subject requests it,  has a history of premature CVD in the family, or has at least one 
major risk factor, or the subject has symptoms suggestive of CVD, or has been diagnosed 
with obstructive sleep apnoea or erectile dysfunction. The total risk estimation is not 
needed in subjects with an established atherosclerotic manifestation or other 
manifestations listed in the very high risk group below, since they already are in high risk 
group for experiencing a CVD event due to these diseases.   
 The total risk estimation is based on different risk estimation charts with the most 
commonly used ones being the SCORE (Systematic Coronary Risk Evaluation System) and 
Framingham Risk evaluation (Figure 6), which are presented in more detail below (166, 
241). The total risk can also be estimated using the FINRISK Risk function, which has been 
based on the FINRISK Survey years of 1982, 1987 and 1992 among 25 to 64 years old 
subjects. It estimates the absolute risk of having either a CHD event or stroke and the risk 
of  these  end-points  combined during the  next  10  years.  The FINRISK risk  function gives  
an estimation of person’s total risk using data on gender, smoking, blood pressure, total- 
and HDL cholesterol levels, diabetes and family history. In FINRISK function, the risk is 
considered high if the total risk is 10% over 10 years. This corresponds approximately to 
the  5%  risk  in  SCORE.  The  FINRISK  risk  calculator  is  available  online  
(http://www.thl.fi/finriski-laskuri) (242).   
The  SCORE  is  based  on  data  from  12  European  cohort  studies  with  2.7  million  years  of  
follow-up and 7934 CVD deaths among 25-64 years old subjects. Different charts are 
recommended to be used in low-, and high risk countries. Previously Finland has been 
considered as a high-risk country, but currently the low-risk SCORE chart is 
recommended (166) for use in Finland (Figure 6).  The SCORE evaluates a subject’s  total 
risk for having a fatal first event during next the 10 years using 5 different risk factors (age, 
gender, SBP, smoking and total cholesterol or total cholesterol/ HDL ratio). SCORE and 
ESC guideline recommendations subdivide the general population to four different risk 
categories (166).   
A) Very high risk if the calculated SCORE is 10%, or the subject has documented 
atherosclerotic manifestation (CHD, stroke, peripheral artery disease, abdominal 
aneurysm) or revascularisation or type I or type II diabetes with either one or more CVD 
risk factors and/ or target organ damage such as microalbuminuria, or the subject has 
severe chronic kidney disease (estimated glomerular filtration rate  <30 mL/min/1.73m2).
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B) High risk if the calculated SCORE is 5% and <10%, or the subject has any substandially 
elevated single risk factor (for example familial dyslipidemia, severe hypertension), or 
diabetes  mellitus  type I   or  type II  without  CVD risk  factors  or  target  organ damage,  or  
moderate chronic kidney disease.  
C) Moderate risk: subjects with the SCORE index 1% to <5%.  
D) Low risk: individuals who have <1% SCORE index. 
The Framingham Risk algorithm is based on age, gender, total cholesterol, HDL 
cholesterol, smoking status, SBP, hypertension treatment and diabetes. These risk factors 
are “summed up”, and the algorithm estimates the subject’s total risk for either having an 
event,  or  for  dying  from  a  CVD  event  in  the  following  10  years.  The  Framingham  risk  
chart is based on Framingham Heart Study and Framingham Offspring study of 3969 men 
and 4522 women aged 30-74 years with a follow-up of 12 years (241). The Framingham 
risk score divides subjects into 3 different risk categories for having an event in the next 10 
years: low <10% risk, intermediate 10-20% risk, and high >20% risk. The high-risk in 
SCORE (5% risk) to die in 10 years equals the 10 to 25% Framingham risk depending on 
chosen risk function version in Framingham (166). In addition to the above risk categories, 
the AHA has adopted a concept of “ideal CVD health” which includes meeting the criteria 
of no smoking, having normal weight, optimal blood pressure, total cholesterol <5.0 
mmol/l, fasting blood glucose <5.5 mmol/l and having a healthy lifestyle with  
recommended amount or more exercise  (150 min/wk of moderate exercise or 75min/week 
vigorous exercise) and use of  Dietary Approaches to Stop Hypertension (DASH) -like diet 
(fish 2 times a week, fruits and vegetables 4.5 cups a day, saturated fat <7% of total 
energy intake, alcohol 1 portion/day, sodium <1500 mg/day, no trans-fatty acids, nuts, 
legumes and seeds 4 servings/week, fiber 30g/day). Only 4% of women in the United 
States were estimated to fulfil these criteria of ideal CVD health (191).  
The Framingham and SCORE risk algorithms suffer limitations in risk prediction in young 
subjects. These risk algorithms are intended to predict the absolute risk for having an 
incident CVD event (in following 10 years for example) and this is low in young persons. 
Nonetheless,  those  young  persons  with  CVD  risk  factors  (i.e.  very  high  LDL  or  total  
cholesterol, smoking, blood pressure) may have a high RR for CVD event when compared 
to a healthy person of similar age. Since the development of the atherosclerosis behind 
CVD is a life-time continuum, different methods (RR chart, extrapolation to a higher age 
and the risk-age concept) have been developed to evaluate a younger person’s risk and to 
help  clinicians  in  advising  about  life-style  choices.  Using  the  risk  age,  a  RR  chart  or  
extrapolating the risk to a higher age are not recommended for clinical use when 
considering medical treatment since this might lead to overmedication (166). The SCORE 
chart has been criticised that it may underestimate a woman’s risk, as the absolute risk is 
substantially lower among premenopausal and early postmenopausal women when 
compared to men of similar age, and large increases in RR may not be taken into account. 
The SCORE may also underestimate the risk for subjects with abdominal obesity, 
premature CVD in the family, and for subjects with features associated with the metabolic 
syndrome (166). It has been suggested that women’s risk evaluation should be extended to 
higher ages (70 years instead of 60 years old). However, extrapolation is recommended to 
be used only in life-style intervention (243). 
Since most middle-aged individuals (especially women) falling into the low and 
intermediate risk groups, the additional risk evaluation methods (CRP, other biomarkers, 
family history, detection of subclinical atherosclerosis) have been proposed to be used for   
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re-evaluation of the person’s risk score (166). Ridker et al. published a gender-specific risk 
score which included gender, age, SBP, smoking, CRP, total cholesterol, HDL cholesterol, 
family history of premature MI, and HbA1c if the subject had diabetes (244). This 
Reynolds  Risk  Score  has  been  developed  from  two  different  gender-specific  cohort  
studies; the Physician´s Health Study (10 724 men) and Women´s Health Study (24 558 
women). The Reynolds Risk Score has been postulated to estimate a woman´s CVD risk 
better than other total risk estimation tools. However, the Reynolds Risk Score is a new 
risk estimator, and the role of CRP role in CVD prediction is not yet clear, and thus the 
Reynolds Risk Score needs to be further validated.  
2.6.1 Cardiovascular disease prevention and treatment goals  
CVD prevention has two complementary approaches. Population prevention strategies are 
intended to prevent CVD events in the whole population by affecting national health 
policies, legislation and health education. Population strategies are needed, because most 
events occur in those who have low-or moderate risk for CVD, simply because those 
groups are more numerous than the high-risk subjects. The total risk estimation is used in 
high-risk strategy to set treatment targets and to assist clinicians to target more aggressive 
treatments, including medications and more intense lifestyle support to those individuals 
with  a  high  CVD  event  risk.  Table  13  shows  the  treatment  goals  of  the  ESC  at  the  
population level, and specifically for the high and very high risk subjects (166).   
Table 13. Treatment targets according to the European Society of Cardiology (ESC) Guidelines 
on cardiovascular disease (CVD) prevention in clinical practise in 2012 (166) 
1 Very high risk: Established coronary heart disease, stroke, peripheral artery disease or 
revascularisation, SCORE (Systematic Coronary Risk Evaluation System) 10%, type I or type 2 
diabetes with either one or more risk factor, severe kidney disease and High risk: SCORE 5%, 
diabetes mellitus, elevated single risk factor or  moderate chronic kidney disease 
2 BMI indicates body-mass index
Treatment targets according to ESC Guidelines for CVD prevention (2012) 
For the general population For subjects with high or very high risk 1
No smoking No smoking 
Healthy diet Healthy diet 
Physical activity of 2- 2.5 h a week, preferably  
at least 30 minutes  a 5 times a week 
30 minutes of exercise 3 times a week  
Avoid obesity, BMI2 <25 kg/m2 Avoid obesity, BMI <25 kg/m2
Blood pressure <140/ <90 mmHg Blood pressure in a range of 130-140/80-85 
mmHg 
Total cholesterol <5.0 mmol/l Total cholesterol <4.5 mmol/l 
LDL cholesterol <3.0 mmol/l  LDL cholesterol 
high-risk  <2.5mmol/l ,  
very high-risk  <1.8 mmol/l 
Blood fasting glucose <6.0 mmol/l Blood fasting glucose <6.0 mmol/l  
HbA1c <7.0% and  
if safely possible  HbA1c <6.5% 
Avoidance of excess stress 
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2.6.2 Risk factor treatment among high-risk subjects for CVD 
Women have been under-represented in most cardiovascular clinical drug trials. 
Nonetheless, some important observations on gender differences have been emerged from 
pooled meta-analyses. The ESC and AHA are trying to promote the enrolment of more 
women into drug trials and for gender-specific results to be published.  
Blood pressure 
The recommended blood pressure in the general population is below 140/90 mmHg. If SBP 
is >160 mmHg or DBP >100mmHg, antihypertensive medication is recommended. Lower 
blood pressure levels of 140/90 mmHg for starting the treatment are applied if the subject 
has diabetes, renal disease, has had a CVD event, or has signs of organ damage due to 
elevated blood pressure; in these cases, the treatment target for blood pressure is 130/80
mmHg and even lower target values are recommended, if renal disease is combined with 
proteinuria. It is known that lowering the SBP by 10 mmHg and DBP by 5 mmHg reduces 
the risk of stroke by 30-40% and acute coronary events by 16% over 5 years (166). The 
blood pressure treatment goals and medications recommended to lower blood pressure 
are similar in both genders (166). The major antihypertensive drug classes, i.e. diuretics, 
ACE inhibitors, calcium antagonists, angiotensin (AT) II receptor antagonists and beta-
blockers,  do  not  significantly  differ  in  their  blood  pressure  lowering  efficacy  and  any  of  
these can be used in the initiation of treatment of high blood pressure (166). ACE 
inhibitors are recommended as the primary choice for subjects with diabetes. ACE 
inhibitors and AT II receptor antagonists are contraindicated in pregnancy, and should be 
used with caution in women who may become pregnant (191).   
According to the EUROASPIRE III study, carried out in 2006-2007 in 66 general practices 
in 12 European countries, 71% of patients had blood pressure above the target values 
140/90 mmHg or 130/80 mmHg if diabetic). Furthermore, of those who had medication 
for hypertension, only 26% had achieved the blood pressure treatment goal (245). 
Women with pre-eclampsia and gestational hypertension are known to have a doubled 
risk of suffering CVD events 5-15 years after pregnancy (246). The AHA guidelines for 
prevention of CVD in women recommend that a referral to primary care physician or 
cardiologist should be considered by the obstetrician in the postpartum unit in order to 
provide risk factor monitoring and control. The ESC guidelines for CVD prevention do not 
discuss gender-specific risk factors. The Finnish Current Care Guidelines for Hypertension 
in 2009 have recommendations for management of hypertension during pregnancy (247). 
However, these guidelines do not give recommendations for follow-up or total risk 
estimation for women who have had a hypertensive pregnancy.  
Lipids
The goal is that there should be a total cholesterol level <5.0 mmol/l and LDL <3.0 mmol/l 
in the general population, with even lower values for those who are at high-risk. The 
recommended levels are similar for both genders (Table 13). The benefit of cholesterol 
lowering therapy depends on the total risk, and it has no gender-related differences. 
Medication, primarily a statin if possible, should be considered if life-style intervention is 
not sufficient to achieve the targets set by the total risk estimation in the primary 
prevention. Based on Collaborative AtoRvastatin Diabetes and Heart Protection studies, 
the ESC 2012 Guidelines recommend statins for subjects with diabetes in order to decrease 
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the CVD risk regardless of the baseline cholesterol, and the same principle is applied also 
for subjects with familial hypercholesterolemia (166).  
In the EUROASPIRE III study 66% of the subjects had elevated total cholesterol (5.0
mmol/l and 4.5mmol/l in subjects with diabetes). An elevated total cholesterol level was 
found in  60% of  men and 71% of  women.  Furthermore,  only  31% of  subjects  with  lipid-
lowering medication achieved the total cholesterol treatment goals (<5.0 mmol/l or <4.5 
mmol/l if diabetes). The recommended total cholesterol values were achieved by 40% of 
men compared to 29% of women. Statins had been prescribed for 47% of subjects with 
hyperlipidemia. 2.6% were using fibrates and 2.7% were taking other lipid-lowering drugs 
(245).
Smoking
Cessation  of  smoking  decreases  the  risk  for  thrombosis  in  the  short-term,  and  CVD  risk  
approaches the risk of never-smokers in 10-15 years although without ever quite reaching 
the same level.  The guidelines advise that all smokers, regardless of gender or age should 
be encouraged to quit smoking and non–smokers should avoid passive smoking. Firm and 
explicit advice from a physician will increase the odds of success in the cessation process. 
Nicotine replacement therapy has been shown to be more effective when compared to 
abstinence (166).  
In the EUROASPIRE surveys I-III the prevalence smoking has remained at almost 20%. In 
the latest EUROASPIRE III, 17% of high-risk subjects were smokers. Smoking prevalence 
was 23% in men and 13% in women (245). The proportion of female smokers under 50 
years of age has increased from EUROASPIRE I 1995-1996 to EUROASPIRE III in 2005-
2006 (245, 248). 
Diabetes 
Glycemic  control  in  diabetes  reduces  microvascular  complications  and  it  has  a  lowering  
effect on the macrovascular complications of diabetes in both genders (166).  The 2012 ESC 
Guidelines set a general glycemia target of HbA1c <7.0% (<53 mmol/mol) to prevent CVD.  
A further reduction in HbA1c below 6.5% may be useful at the time of diagnosis. For 
patients with long-term diabetes, this target may be useful in prevention of microvascular 
complications, but strict glucose control achieved rapidly during a few months has been 
shown to be detrimental if the baseline HbA1c has been >7.0% (166). Metformin is 
recommended as the first-line therapy if tolerated and not contraindicated (166). Glucose-
lowering drugs have no gender-specific recommendations. However, women may  have a 
higher risk of fractures in long-term use of thiazolidinediones, and this effect needs to be 
further investigated (9).  
In the EUROASPIRE III the prevalence of self-reported diabetes was 30%, and the 
prevalence of previously undetected diabetes was 13%. Only 7% of self-reported diabetic 
subjects achieved the recommended fasting glucose level 6.0 mmol/l, and 40% had 
HbA1c 6.0 mmol/l (245).  
Acetylsalicylic acid  
Whether acetylsalicylic acid has a beneficial effect in patients without established CVD 
(although at high-risk for CVD events) has remained unclear. Furthermore, the effect of 
acetylsalicylic acid on CVD prevention has been shown to exhibit gender differences. In 
the Antithrombotic Trialist`s Collaboration study, acetylsalicylic acid achieved a 12% risk 
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reduction in vascular events, but no change in stroke and no effect on total CVD mortality. 
Moreover, major gastrointestinal and extracranial haemorrhages increased significantly, 
by 0.03% per year.  A meta-analysis by Berger et al. of 6 randomised controlled trials with 
>95 000 subjects detected a 12% reduction in CVD events with a 17% reduction in stroke, 
no effect on prevention of CVD death or MI events in women. In men, acetylsalicylic acid 
reduced CVD events by 14% with a 32% reduction in MI, but it exerted no effect on stroke 
or total CVD mortality (249). The reason for this gender difference in the effects of 
acetylsalicylic acid is unclear.  
The ESC 2012 Guidelines do not recommend acetylsalicylic acid for persons without 
established CVD due to the increased risk of bleeding (166). The recommendation of 
acetylsalicylic acid use has been revised from the previous guidelines and acetylsalicylic 
acid is no longer recommended in the primary prevention of subjects with diabetes due to 
the excess risk of bleeding complications (166). The AHA Guidelines for Prevention of 
CVD in Women - update 2011, still recommends acetylsalicylic acid for women with 
diabetes, unless contraindicated, and also for 65 year old women in ischemic stroke and 
MI prevention if blood pressure is under control; it is believed that the benefits of stroke 
prevention outweigh the risk of bleeding (191). Routine use of acetylsalicylic acid is not 
recommended by AHA guidelines for <65 year old women (191).   
2.6.2 Risk factor treatment among subjects with CVD 
Blood pressure  
The target level of blood pressure for subjects with established CVD is recommended to be 
near 130 /80 mmHg. Multiple drugs are often required to achieve this target. Beta-blockers 
are recommended for all patients, unless contraindicated, with established CHD during 
the hospital stay and their use should be continued thereafter. ACE inhibitors are 
recommended to be administered during the first 24 hours after the MI and their use 
should be maintained thereafter, unless contraindicated (166).   
Beta-blockers were prescribed equally to both genders according to an interview 
conducted in EUROASPIRE III in the subjects with CHD: 81% of women and 79% of men 
had been provided with beta-blocker treatment after hospitalisation. Women had a lower 
rate of ACE inhibitor use compared to men (59% vs. 60%, p=0.01), whereas more women 
had angiotensin II receptor antagonist (15% vs. 11%, p <0.0001). Women were also more 
likely to have received calcium antagonists and diuretics. Despite the greater drug use 
among women, their mean blood pressure was higher than that of the men, and the 
proportion of women above the recommended blood pressure target was higher in 
comparison to the men: 55% of women and 49% of men had blood pressure levels  140/90
mmHg (p=0.010)(250).
Smoking
Giving up stop smoking after  MI is  considered to  be  the  most  effective  of  all  preventive  
measures, similarly in both genders, with a mortality benefit of 36% (HR 0.64 with 95% CI 
0.58-0.71). Subjects with prevalent CVD should be recommended to avoid passive 
smoking. Medications and therapies follow the same principles as in high-risk subjects.  
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In the EUROASPIRE III 19% of men and 11% of women hospitalized due to CHD were 
current smokers (p=<0.0001 for gender difference). According to the data from 
EUROASPIRE III advice to stop smoking was given equally in both genders  (250).  
Lipids
A 1 mmol/l reduction in LDL cholesterol is considered to be associated with a 
corresponding reduction of 20-25% in CVD mortality and non-fatal MI events (166). The 
target level for LDL is <1.8 mmol/l or a reduction by 50% is the aim if that target cannot 
be achieved (Table 13). High-dose statin treatment is recommended to be started early in 
subjects hospitalised with ACS. Blood lipids should be controlled after 4-6 weeks and the 
medication  or  dose  should  be  changed  if  the  target  is  not  achieved.  Statin  treatment  
should also be started for subjects with a history of non-cardioembolic ischemic stroke or 
transient ischemic attack, for secondary prevention. Guidelines recommend avoiding 
statin treatment after hemorrhagic stroke unless there is evidence of atherosclerotic 
disease or of a high CVD risk (166).  
In  the  EUROASPIRE  III  study,  statins  were  prescribed  equally  in  both  genders  among  
subjects with CHD and thus almost 80% of men and 76% of women received a statin in the 
secondary prevention. Nonetheless, the management of high cholesterol was better among 
men: 61% of women and 52% of men had not achieved the  LDL cholesterol target of 2.5
mmol/l (p <0.0001), and women also had higher LDL cholesterol on average (250).  
Acetylsalicylic acid and other antithrombotic drugs  
The current ESC guidelines recommend dual antiplatelet therapy with ticagrelor or 
prasugrel to be added to acetylsalicylic acid in the acute phase of ACS and to be continued 
for the following 12-months, unless contraindicated due to a high risk of bleeding. 
Previously, clopidogel was recommended to be added with acetylsalicylic acid: however, 
prasugrel  and  ticogrelor  have  been  shown  to  be  more  advantageous  without  causing  
significantly more bleedings when compared to clopidogrel (166). Continuing the 
treatment with acetylsalicylic acid only is recommended after one year from the event.  
The Antithrombotic Trialist’s Collaboration meta-analysis showed that the total mortality 
was reduced by 10%, and furthermore the absolute risk for CHD and stroke was reduced, 
but major bleedings were increased. Nevertheless, the benefits of acetylsalicylic acid 
exceeded the bleeding hazards (166). In patients with prior non-cardioembolic ischemic 
stroke either dual therapy with dipyridamol and acetylsalicylic acid, or clopidogrel alone 
is recommended. In cases of intolerance for dipyridamol or clopidogrel, acetylsalicylic acid 
is recommended alone (166).  
In the EUROASPIRE III study among subjects with established CHD, acetylsalicylic acid 
and other antiplatelet treatments were prescribed significantly (p=0.03) less frequently to 
women than to men (88% women vs. 91%  men) (250).
2.6.3 Heart failure treatment 
Heart failure treatment goals are intended to relieve symptoms, and to reduce mortality 
and hospital admissions. The ESC 2012 Guidelines for heart failure treatment do not have 
any gender-related issues with all recommendations being the same for men and women 
(93). The recommended therapy is based on whether the person has HF-REF or HF-PEF. In 
heart failure with reduced EF, the treatment is based on beta-blockers, ACE inhibitors, 
mineralocorticoid receptor antagonists and diuretics. The pooled data on beta-blockers 
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have shown that they decrease mortality among both genders having  heart failure (251). 
There  is  believed  to  be  less  benefit  with  ACE  inhibitors  in  women  than  in  men.  In  an  
analysis of 30 clinical ACE inhibitor trials, men were shown to display a 37% decrease in 
heart failure mortality compared with the 22% (non-significant) decrease among women 
(252). The reason for the lesser benefit for women is unclear, and needs further 
investigation. Nevertheless, the recommendation for ACE inhibitor usage is similar in both 
genders and guidelines indicate that one should add an ACE inhibitor to the beta-
blockade for all subjects with reduced EF 40% (93). Mineralocorticoid receptor 
antagonists/ aldosterone receptor antagonists are recommended to be provided to subjects 
with persistent symptoms after treatment with beta-blockers and ACE inhibitors (93). 
Aldosterone-antagonists have not been shown to exert different efficacies in men or 
women; survival benefits have been similar. The effect of diuretics on mortality and 
morbidity in heart failure has not been evaluated. However, diuretics relieve heart failure 
symptoms, and are therefore recommended for heart failure patients for this reason.  
No treatment has yet been shown to reduce mortality and morbidity among subjects with 
HF-PEF. The ESC guidelines encourage the use of diuretics to reduce symptoms, and it is 
recommended that there should be adequate control of hypertension and myocardial 
ischemia (93). 
In the EUROHEART Failure Survey II no gender differences were reported in the use of 
ACE inhibitors and beta-blockers upon hospital admission due to heart failure. Women 
had a higher rate of receiving digitalis treatment compared to men (prevalence on 
admission 29.1% in women vs. 25% in men, OR 1.34 with 95% CI 1.13-1.60). At discharge 
no gender differences were seen in the drug usage between the genders:  approximately 
90% of both genders were using diuretics, 70% of both genders were on ACE inhibitors, 
and 60% of both genders received beta-blockers (96).
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3 Aims of the Study
The main aim of the study was to investigate gender differences in the occurrence, 
prognosis and risk factors of acute manifestations of CVDs. Secondary analyses were 
performed in different age groups to evaluate the differences between younger and older 
women as compared to men. The specific aims of the individual studies were:  
(I) To examine whether declines in the incidence, attack rate and mortality of ACS have 
been different among women than in men in Finland from 1994-1996 to 2000-2002 and, 
secondarily, whether the use of troponins in the diagnosis of ACS has changed the 
proportions of MI diagnoses between the genders. 
 (II) To examine gender differences in the case-fatality of ACS and changes in case-fatality 
from 1994-1996 to 2000-2002 using three time windows: pre-hospital case-fatality, 28-day 
case-fatality and 1-year case-fatality. 
 (III) To examine whether cardiovascular risk factor levels and treatment of high 
cardiovascular risk differ between the genders.   
(IV) To examine gender differences in the incidence and clinical spectrum of the first major 
adverse cardiovascular disease events, i.e., CHD, stroke and heart failure, among subjects 
with no previous CVD events.  
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4 Material and Methods 
4.1 Data sources, registers and register linkage 
4.1.1 Administrative registers and register linkage 
Hospital Discharge Register (HDR) 
In Finland, all hospitalisations have been collected in a nationwide register since 1967. The 
National Institute for Health and Welfare maintains the register (253). The register collects 
data primarily for administrative purposes. It includes data on the hospital and its ward, 
the patient’s discharge diagnoses, surgical procedures, dates of the hospital admissions 
and discharges. The hospitalisations are coded according to the International Classification 
of Diseases and Health Related Problems -codes (ICD codes). The first diagnosis listed is 
the principal cause of hospitalisation, and up to three additional codes are registered. 
Clinicians responsible for the patients’ care assign both the diagnoses and ICD codes for 
the hospitalisations. In Finland, the 8th version of the ICD was used from 1968 until 1986, 
the 9th version used from 1987-1995 and since 1.1.1996 the 10th version has been used.  
Causes of Death Register 
Causes of Death register (CDR) is maintained by Statistics Finland. Data from death 
certificates has been collected in Finland since 1936 (254). If a person has been treated in a 
hospital  or  in  an  outpatient  clinic,  the  physician  responsible  for  the  patient’s  care  at  the  
time of death defines the diagnosis for the cause of death and assigns the corresponding 
ICD codes in the death certificate, or decides whether autopsy is required for determining 
the causes of death. The death certificate has the following strict format: the main causes of 
death are categorised into a.) the immediate cause of death, b.) intermediate cause of 
death, and c.) the underlying cause of death. Thereafter, other causes which have 
contributed to the death, but have no causal connection to the main responsible causes (a-
c) are determined. Death certificates are inspected by local health authorities at the 
Regional State Administrative Agencies, and since 2010, the certificates have been sent to 
the National Institute for Health and Welfare, where they are inspected, and indefinite 
cases are further evaluated by a specialist in forensic medicine. Once accepted, the data are 
sent to Statistics Finland and are further checked for completeness from the Population 
Information System. An autopsy has to be performed, if the circumstances preceding the 
death are unclear, the death was unpredictable regarding the existing clinical condition, 
the causal relationships of the illnesses are unclear, or if the death has occurred suddenly 
or in a public place without preceding significant illnesses. 
Drug Reimbursement Register  
The National Insurance Institute (KELA) maintains a drug reimbursement register (DRR). 
Information on the persons entitled to drug reimbursement has been collected and 
registered since 1964. Special reimbursements are available on medicines for severe and 
long-term diseases, and are granted if certain disease-specific indications are fulfilled. The 
physician  responsible  for  patients  care  writes  a  medical  certificate  based  on  signs,  
symptoms and medical findings, and based on the certificate, a physician in the National 
Insurance Institute decides whether the reimbursement will be granted. The National 
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Insurance Institute also registers pharmacy data using anatomic therapeutical 
classification (ATC) codes. All prescribed drugs purchased by patients have been 
registered in the pharmacy database since 1995.  
Register linkage 
All permanent residents in Finland have a unique personal identity (ID) code. A system of 
unique personal identification numbers was launched in 1964 and by 1968 all permanent 
residents and Finnish citizens had been allocated their own numbers. The Finnish 
Population Register Centre and the Local Register Offices maintain the Population 
Information System and admit the ID codes. Computerised data from the administrative 
registers has been available since 1969 (HDR, CDR and DRR (since 1964), Pharmacy 
database (1995) and Population Information System) and can be linked based on the 
personal ID code. The ID code includes a character for internal validity check, which 
minimises the risk of registering a faulty personal ID. The HDR register has been validated 
frequently. Also the register linkage between the HDR and MI register FINAMI has been 
validated and showed to improve: in 1991 0.26% of the personal ID codes were imperfect, 
and in 2002 less than 0.08% of codes were incomplete. None of the personal ID codes in 
CDR were imperfect (255). Register linkage between the HDR and CDR showed less than 
0.5% of ID codes to be incomplete and in 0.2% (358 cases during the years 1991-2001) of 
deaths did the date of death differ between the HDR and CDR (38). The National 
Cardiovascular Disease Register (CVDR) links data from the HDR, CDR, and from 
National Insurance Institute. After linkage, the data are added to the CVDR database and 
anonymised. The CVDR summary data are available at the website of the National 
Institute of Health and Welfare (http://www.thl.fi/cvdr/). In the FINAMI register, collected 
data are cross-checked for completeness with the HDR and CDR using the personal ID 
numbers. The FINRISK database has been linked to all of the above mentioned 
administrative databases from the year 1969 onwards. Further characteristics of the CVDR, 
FINAMI and FINRISK databases are described in the following paragraphs. 
4.1.2 Cardiovascular disease registers  
FINAMI-register 
The FINAMI register is a population-based register aiming to evaluate all events 
suspected to  be  a  MI event  or  CHD death among permanent  residents  of  the  four  study 
areas. The FINAMI register follows similar procedures as the FINMONICA MI register, 
which was the Finnish contribution to the WHO MONICA Project, which operated in 
Finland in 1983-1992 (256). The FINAMI register covers the following geographical areas:  
The city of Turku in south-western Finland, the city of Kuopio in eastern Finland, the city 
of  Joensuu  and  surrounding  rural  areas  of  Ilomantsi,  Juuka  and  Lieksa  in  the  former  
province of North Karelia and the city of Oulu in north-western Finland. Oulu joined the 
register later, and has collected data for the years 1993, 1997, 1999, and 2001 – 2007. Due to 
practical reasons and workload, the Kuopio area lacks data for the year 1998 and Turku 
for the year 1999. This is not believed to have any effect on these results since the 
beginning  and  the  end  of  the  monitored  time  interval  are  included.  All  other  areas  and  
years have been covered since 1993. Data from on the persons older than 75 years have 
been registered since 1995. The average population at risk aged 35 years in FINAMI areas 
was ~ 313 000 in the study periods 1993-2002.  
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The FINAMI register’s primary sources for case finding are hospital admission diagnoses 
and death certificates of each area. Trained nurses, supervised by register physicians, 
collect the information from hospital documents, death certificates and autopsy reports 
onto a data collection form on a laptop. Local registration teams send the data to the 
coordinating centre at the National Institute for Health and Welfare in Helsinki, where 
data are checked for logical errors. Data are cross-checked annually with CDR and HDR 
for  completeness.  The  ICD  codes  used  in  FINAMI  case  finding  and  cross-checking  with  
administrative registers are shown in Table 14. Events that are not included in the register 
are sent back to the local registration teams which evaluate the event according to the 
study protocol for possible inclusion in the register. 
In  FINAMI  the  ACS  events  were  classified  into  diagnostic  categories  according  to  
symptoms,  signs,  biomarker  and  ECG  findings,  and  in  fatal  cases  also  according  to  the  
autopsy findings using the guidelines as suggested in the AHA Scientific Statement in 
2003 (257). The classification categories for non-fatal MI were 1) definite MI, 2) probable 
MI, 3) possible MI, 4) non CHD event. Fatal events in hospital circumstances are classified 
as 1) definitive fatal MI, 2) probable fatal MI and 3) possible fatal coronary event 4) non- 
CHD death and in out-of-hospital circumstances 1) definitive fatal MI, 2) definitive fatal 
CHD, 3) possible fatal CHD, 4) non-CHD-related death. The biomarkers in each case (if 
taken) were determined according to the usual practice in each register hospital. The 
concentrations of troponin T or I were classified as diagnostic, normal or missing on the 
basis of the limits set by the laboratory of the hospital in question. The local register 
physician evaluated the clinical relevance of troponin value from the clinical information. 
If  the  troponin  value  was  considered  to  be  non-relevant  (for  example  because  of  kidney  
failure, or because of false timing of sampling) it was recorded as missing. Other 
biomarkers (CK, CK-MB and CK-MBm) were classified according to the principles of the 
WHO MONICA Project using the limits set by the local laboratories (258). The time period 
for one event was considered to be 28 days, during which the most severe findings were 
recorded. 
The FINAMI register has been approved by the ethical committee of the National Institute 
for Health and Welfare.  
National Cardiovascular Diseases Register (CVDR) 
 The CVDR has been set up to cover the whole Finland and identify all Finnish residents 
with a CHD event or cerebrovascular disease event. The register has been compiled using 
data from three different nationwide administrative data sources (presented above); HDR 
maintained by the National Institute for Health and Welfare, CDR maintained by Statistics 
Finland and National Insurance Institute´s records on individuals receiving 
reimbursements for CVD medications. The National Institute for Health and Welfare in 
Helsinki maintains the register. At the time of this present study, CVDR data were 
available for the years 1991-2007. Data on hospitalisations due to CHD in the HDR were 
linked to the CDR using personal ID numbers. ICD codes used for case identification in 
the CVDR are shown in Table 14; all codes were accepted as main or side diagnosis. ICD-9 
and  ICD-10  coding  systems  were  used  in  Finland  during  the  study  periods.  The  
corresponding  codes  from  the  ICD-8  were  used  for  identification  of  prior  cases.  In  fatal  
cases,  the  CVDR  included  CHD,  if  the  codes  were  as  an  underlying  or  as  an  immediate  
cause  of  death,  or  if  MI  (ICD-9th version code 410 or ICD-10th version I21-I22) was 
identified as a contributing cause of death.  
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Similarly  to  FINAMI,  the  time  period  for  one  event  was  28  days.  The  CVDR  and  the  
underlying administrative databases have been validated repeatedly (255, 259). CVDR has 
shown to have 83% sensitivity and 90% of positive predictive value against the FINAMI 
register with the AHA 2003 definition (255).  
The CVDR has been approved by the ethical committee of the Institute for Health and 
Welfare. 
FINRISK
The National FINRISK Survey aims to monitor the levels of cardiovascular risk factors in 
Finland (12). FINRISK is a population-based health examination survey, which has been 
conducted at five year intervals since 1972. The first two surveys were carried out in North 
Karelia and Kuopio provinces as the basis for evaluation of the North Karelia Project (260). 
Between the years 1982 and 1992, the surveys were conducted as a part of the WHO 
MONICA project (18). During the years 1992-2007, the study has been carried out in four 
geographical areas in Finland: North Karelia and Kuopio provinces in eastern Finland, 
Turku and Loimaa areas in South-western Finland and the metropolitan area of Helsinki 
and Vantaa in Southern Finland. The fifth area, Oulu province in North-western Finland, 
has been included since 1997. In 2002, the province of Lapland was also included. 
The FINRISK survey is a cross-sectional study: In each study-year, a sex and 10-year age 
group stratified random sample of inhabitants have been drawn from the Finnish 
Population Information System. In 1992, subjects aged 25-64 years were invited to the 
survey. In 1997, similarly, 25-64 years old persons were invited, although not in two areas: 
North Karelia and the metropolitan area of Helsinki-Vantaa, where the age-range was 25-
74 years and the number of 65-74 year old men was twice the number of participants in the 
other strata. Since 2002, subjects aged 25-74 years have been included in the survey in all 
areas. Sampling has been stratified according to sex, 10-year age group and study area. 
Between the years 1992 and 2002, 250 subjects in each sex and 10-year age group have 
been sampled from each study area. In 2007, the corresponding number was 200. Table 15 
shows sample size separately in men and women, and participation rates percent to health 
examination. 
Table 15. Samples and health examination participation rate (%) of men and women aged 25-
64 years old  in 1992-2012*.
Year Men 
(n) 
Participation rate
(%) 
Women
 (n) 
Participation rate
(%) 
1992 3965 72 3962 81
1997 5000 68 5000 75
2002 4972 59 4980 70
2007 3983 56 3979 66
2012 3960 52 3961 60
* Including North Karelia, Kuopio provinces, Turku/Loimaa, Helsinki/Vantaa and Oulu province.    
The methodology has been kept as similar as possible over the study years. The WHO 
MONICA protocol has been used since 1982, although in 2002 the methodology was 
revised to comply with some detailed recommendations from the European Health 
Monitoring Project (258, 261). Risk factor information was collected from a self-
administered questionnaire, and from a clinical examination including physical 
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measurements and laboratory tests. The questionnaire and invitation to the health 
examination were sent by mail to the subjects. Specially trained nurses carried out the 
blood sampling and physical  measurements  in  local  health  centres  or  other  survey sites.  
Blood pressure was measured from the right arm after a 5 minutes’ rest using a mercury 
sphygmomanometer. The first phase of Korotkoff sounds was recorded as the SBP and the 
fifth phase as the DBP.  
Blood sampling has been done in a comparable manner over the study years. Venous 
blood samples have been drawn with the subject in a sitting position after at least 4 hours 
of fasting between 11 am and 6 pm. Samples were centrifuged in the survey site and 
mailed daily for total cholesterol, HDL cholesterol and triglyceride measurements to the 
laboratory of the National Public Health Institute. In 2007, the sera was frozen and sent 
packed in dry ice to the laboratory once a week. The total cholesterol concentration has 
been measured using an enzymatic method since 1982. In 2007, serum total cholesterol 
was measured using an enzymatic assay (Abbott Diagnostics Europe, Wiesbaden, 
Germany). LDL cholesterol has been obtained indirectly, using the Friedewald equation: 
LDL cholestrol (mmol/l) = Total cholesterol (mmol/l) - HDL cholesterol (mmol/l) – 0.4545 x 
(Triglyceride  (mmol/l).  The  equation  is  considered  to  be  valid  if  the  triglyceride  level  is      
<4.52 mmol/l. The laboratory methods, reagents and instruments have been described in 
detail elsewhere (262).   
Smoking was assessed by a questionnaire based on the subjects’ answers. Current smokers 
were defined as those who had smoked regularly 1 year. Ex-smokers were those who had 
smoked regularly, but had stopped 6 months or more before the survey and never 
smokers were those who had never smoked regularly. Physical activity was assessed by a 
self-administered questionnaire. Low physical activity was defined as no leisure-time 
physical activity, or less than 4 hours of light physical activity (e.g walking) per week.   
The FINRISK surveys were each approved separately by the local ethics committee at 
National Institute for Health and Welfare, Helsinki, Finland and/or the coordinating ethics 
committee of the Helsinki and Uusimaa Hospital District.   
FINRISK cohort follow-up 
 Participants of the FINRISK surveys are followed up (since FINRISK 2002 only if the 
participant  has  given  written  informed  consent)  by  annual  record  linkage  by  the  
participants’  personal  ID  code  to  the  HDR,  CDR  and  DRR  of  the  National  Insurance  
Institute.  New CVD events during the follow-up are identified using the case definitions 
explained in detail below with the ICD codes being followed shown in Table 14.  
4.1.3 Definitions of events and covariates in the registers
Diagnoses in the HDR, CDR and CVDR are recorded using the ICD codes. In FINAMI the 
completeness of data are checked using the ICD codes for case finding from HDR and 
CDR. 
MI event classifications in FINAMI  
 ACS diagnosis is based on symptoms, ECG findings, and elevation of biomarkers, and in 
the fatal cases on autopsy findings using adapted AHA case definitions (257).  
Non-fatal events 
A. Definitive MI. Evolving ischemic changes in ECG or diagnostic biomarkers  
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B. Probable MI. Positive ECG findings + cardiac symptoms or signs+ missing troponin 
or positive ECG findings and equivocal enzymatic markers 
C. Possible MI. Equivocal enzymatic markers + nonspecific ECG findings or equivocal 
enzymatic markers + cardiac symptoms or signs or missing troponin or enzymatic 
markers + positive ECG 
D. Non-CHD event. 
Fatal events (hospitalised patients) 
A. Definitive fatal MI.  Death within 28 days of hospital admission and defined as 
definitive before death or post-mortem finding consistent with MI in 28 days 
B. Probable fatal MI. Death within 28 days of hospital admission and defined as 
probable before death or death within 6 hours of hospital admission with cardiac 
symptoms and/or signs. Other confirmatory data (biomarkers, ECG) are absent or 
not diagnostic.  
C. Possible fatal coronary event. Death within 28 days of hospital admission in cases 
defined as possible before death or defined as UAP when alive (new cardiac 
symptoms with positive ECG findings with normal biomarkers, changing symptom 
pattern and positive ECG findings  with normal biomarkers or stable angina when 
alive (cardiac symptoms in a pattern that remains constant in presentation, 
frequency, character and duration over time) or post-mortem findings show old 
infarct and / or 50% atherosclerotic narrowing of coronary arteries. 
D. Non-CHD event. 
Fatal events (out of hospital)
A. Definitive fatal MI. Documented definitive, probable or possible MI within the 
previous  28  days  and  no  evidence  of  non-coronary  cause  of  death,  or  autopsy  
evidence of coronary occlusion or MI <28 day old. 
B. Definitive fatal CHD. Either: A) History of CHD and /or documented cardiac pain 
within 72 hours before death and no evidence of non-coronary cause of death in 
autopsy;  B)  Autopsy evidence of  chronic  CHD, including coronary atherosclerosis  
and myocardial scarring.    
C. Possible fatal CHD. ICD codes classified in Table 14 and no evidence of non-
coronary cause of death. 
D. No CHD-related death or insufficient information. Evidence of non-coronary 
cause of death or insufficient information to determine whether the death was a 
CHD death or a non-cardiac death. 
Incident event 
Incident event means the first event for the patient in question. In the FINAMI register, an 
event was considered as incident, if hospital records or other documents did not show any 
previous clinically recognised CHD events in the patient’s history. In CVDR, an event was 
considered  as  incident  if  that  person  had  no  record  of  ACS  in  the  HDR  during  the  
preceding seven years.  The most severe diagnosis during the 28-day period was used.   
All events
The time frame for one event was 28 days. If a patient had recurrent symptoms and signs 
within this time frame, they were considered to belong to the same event. New symptoms 
and signs >28 days after the onset of the previous event were considered as a recurrent 
event. The same ICD codes as for the incident events, listed in Table 14, were used for 
recurrent events. The attack rate was calculated as the sum of incident and recurrent 
events i.e. all events during a specified time period and in a specified population.   
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Fatal events 
An event was considered as fatal if  the patient died within 28 days after the onset of the 
event and the cause of death (immediate, underlying or contributing cause of death) was 
any of the ones listed above (Table 14).   
Case-fatality  
Case-fatality  is  defined  as  the  proportion  of  fatal  events  from  all  events  within  a  given  
time period. The 28-day period for one event was defined according to the WHO 
MONICA Project (33). The day of symptoms’ onset was defined as day 0, and the last day 
was the day 27 after the onset of symptoms. The pre-hospital case-fatality was defined as 
the proportion of cases which did not reach a coronary care unit or hospital ward alive. 
These subjects died either in out-of-hospital circumstances or in the emergency room. In 
calendar time, their survival was less than one day. In-hospital deaths were considered to 
occur after the incoming phase to a hospital, in calendar time during the days 2-27 after 
symptom onset. In practice, deaths occurring after the discharge from a hospital but 
within the 28-day time frame were also included in the in-hospital case-fatality. The 1-year 
case-fatality was the proportion of events that ended fatally at any time from the 
beginning of symptoms to the end of the 364 th day.   
High-risk subject 
In study III, a person was considered to have a high risk of CVD if he/she had had either a 
prior diagnosed CVD event (see diagnoses detailed in Table 14), had a revascularisation, 
i.e. percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG) 
in the HDR, had prevalent diabetes, or had a calculated CVD risk >20% based on the 
Framingham risk function (241). The Framingham risk function adopted from (241) was 
used in this study. Beta-coefficients used in the Framingham equation were estimated 
from FINRISK data using Cox proportional hazards regression.     
Hypertension 
The diagnosis of hypertension was defined in study III as the use of antihypertensive 
medication according to the self-administered questionnaire, or blood pressure 140/90
mm Hg or 130/80 mmHg if the subject had diabetes.  
Diabetes 
The diagnosis of prevalent diabetes was defined in study III as either self-reported or 
confirmed from the HDR (Table 14), pharmacy database for purchase of hypoglycaemic 
drugs and from the DRR if the subject had the right to special reimbursement for diabetes.  
High cholesterol  
In study III, among high-risk subjects (Framingham 10-year risk 20%, prevalent CVD or 
diabetes) cholesterol was considered high if the total cholesterol concentration was >4.5 
mmol /l and/or LDL cholesterol >2.5 mmol/l (263). 
Smoking
Smoking was assessed by a questionnaire based on the subjects’ answers. Persons who 
had smoked regularly 1 year and during the past 6 months were considered as current 
smokers. Ex-smokers were those who had smoked regularly and had quit >6 months 
before the survey, and never smokers were those who had never smoked regularly. 
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Heart failure 
Heart  failure  was  identified  in  study  IV  from  the  HDR  and  CDR  using  the  ICD  codes  
shown in  Table  14.  Heart  failure  cases  were  also  identified from the DRR of  the  Finnish 
National Insurance Institute. If a participant was entitled to special reimbursements for 
heart failure medications, he/she was considered to have heart failure or if a participant 
had at least 3 times purchased furosemide since 1995 to the end of follow-up in study IV 
he/she was considered to have heart failure. This definition of heart failure has been 
recently validated and found to have  high specificity, but only modest sensitivity (264).  
4.2 Study population in different studies (I-IV) 
Study I
ACS events were collected from the FINAMI and CVDR for two time periods, in 1994-1996 
(prior troponins) and 2000-2002 (post-troponins). A total of 4586 (2370 among men and 
2216 among women) CHD events were found from the FINAMI register among persons 
aged 35 years  for the time period  1994-1996 and 5564 (2882 in men and 2682 in women)  
for the time period 2000-2002. Correspondingly, a total of 72 699 CHD events (38 849 in 
men and 33 850 in women) were found from CVDR in the first period, and 76474 (39 860 
in  men  and  36  614  in  women)  in  the  later  time  period.  The  total  numbers  of  events  are  
shown by event type, study period and gender in Table 1, Publication I.  
Study II 
A total of 6342 incident ACS events were found from the FINAMI register for two time 
periods, 1994-1996 and 2000-2002, combined and 117 632  from the CVDR. The numbers of 
incident events and fatal events are shown in Table 1 of Publication II.  
Study III and IV 
The participation rates in FINRISK survey are shown in Table 15. Some baseline 
characteristics of the participants in the FINRISK surveys are shown in Table 16. 
Study  III  were  included  those  FINRISK  participants  for  whom  the  relevant  risk  factor  
measurements were available, i.e. clinical evaluation done and total cholesterol 
measurements. A total of 13 991 men and 15 281 women aged 25-74 were included.  Of 
these, 3057 high-risk men and 1365 high-risk women were identified when the FINRISK 
survey years of 1992, 1997, 2002 and 2007 were pooled together. The numbers and the 
mean ages of groups are shown in Table 1 of Publication III.  
In study IV, a total of 13 999 men and 15 286 women who had given permission for record 
linkage of their examination data to the national health care registers were included. 
Subjects with a prior major adverse CVD event (MI, stroke or heart failure) found from the 
HDR (n=1388, 936 men and 452 women) were excluded from the follow-up. Thus, 13 063 
men and 14 834 women who were healthy at the time of baseline investigation were 
followed- up until the end of 2010.  
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Table 16.  Characteristics of participants in the FINRISK surveys  
Men Women 
Total 1992 1997 2002 2007 Total 1992 1997 2002 2007
All subjects with relevant 
risk factors available 
(Study III1)
25-54 years old 8820 2137 2490 2560 1633 10348 2399 2827 3142 1980
55-74 years old 5171 707 1735 1439 1290 4933 781 1336 1483 1333
All subjects participated 
and allowed register 
linking (Study IV) 
25-54 years old 8825 2137 2490 2557 1641 10353 2399 2827 3138 1989
55-74 years old 5174 707 1735 1439 1293 4933 781 1336 1481 1335
All high-risk subjects2
25-54 years old 451 102 125 136 88 384 73 99 127 85 
55-74 years old 2606 297 968 680 661 981 95 279 281 326 
10-year risk >20% 
according to Framingham 
score 
25-54 years old 107 31 30 37 9 3 0 1 1 1
55-74 years old 1900 215 746 472 467 553 43 152 150 208 
Subjects with prevalent 
CVD3
25-54 years old 163 38 43 51 31 82 10 29 30 13
55-74 years old 773 95 272 209 197 370 38 110 121 101 
Subjects with diabetes4
25-54 years old 273 52 81 78 62 361 70 89 118 84 
55-74 years old 636 64 199 148 225 511 59 142 144 166 
1 Equal to the total participant number in study III  
2 Framingham 10-year risk >20%, history of any of the following: CHD, stroke, diabetes  
3In study III. History of any of the following: myocardial infarction, revascularisation, stroke or heart 
failure.  
 4 Prevalent CVD not excluded  
4.3 Statistical methods
Data analyses were performed with SAS software, version 8 (study I) and version 9 
(studies II-IV) (SAS Institute Inc, Cary, NC, USA) or R version 2.5.1 (study I), version 2.9.2 
(studies II, III) or version 2.14 (study IV) (R Foundation for Statistical Computing, Vienna 
Austria). Statistical significance was based on the level of p <0.05 and two-tailed tests. Age-
group specific analyses were performed for two different age groups: younger, 25-54 years 
old, and older, 55 years old.  
In study I, all FINAMI areas were pooled together. The Oulu area had data for the years 
1993 and 1997 in the first period and 2001-2002 in the later study period. All other study 
areas had full three year time periods of 1994-1996 and 2000-2002. The incidence rate was 
defined as the number of first events per 100 000 persons per year. The attack rate was 
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defined as the sum of incident and recurrent events per 100 000 persons per year. Age-
standardisation for event rates was conducted according to the direct method using 5-year 
age groups and the European standard population (http://seer.cancer.gov/stdpopulations/). 
The population counts  used for  the  denominators  of  the  event  rates  were  obtained from 
the Finnish National Population Information System. The 95% CIs for the event rates were 
calculated assuming a Poisson distribution for the annual number of events. In FINAMI, 
the significance of changes of age-adjusted rates for both genders separately were done 
using 100 000 simulated Poisson-draws from each age group and using direct age 
standardisation to obtain representative samples for both time periods and both genders. 
In CVDR, this was not needed as the differences between study periods were self-evident.  
In the FINAMI and CVDR the comparisons of the gender differences in the event rate 
changes were done using negative binomial regression models, as Poisson regression 
models showed overdispersion. The models  for incidence, mortality and attack rate were 
adjusted for age in 5-year groups with gender interaction and the comparisons of trends 
being conducted using interaction terms with the effect of the year in two age groups <55 
years and 55 years separately. The relative differences in event trends between the 
genders in two time periods were normalised by their respective rates during the first 
study period.  
In study II, all FINAMI areas were pooled and the same time periods were used as in 
study I. Age-standardisation for incident ACS case-fatality was done using weights based 
on the combined age distribution of cases in the MI and stroke registers of the WHO 
MONICA Project. Weights (beginning from the age group 35-39 years old and ending with 
the age group of 85+ years old) were for each 5-year age groups: 5, 9, 16, 26, 42, 56, 75, 93, 
100, 100, 100. The case-fatalities were expressed as percents: the number of deceased cases 
were  divided  by  the  number  of  all  incident  cases  and  multiplied  by  100.  Logistic  
regression analyses were used to evaluate gender differences in the pre-hospital, 28-day 
and 1-year case-fatality and Cox proportional hazards regression analyses in the 28-364 
day time interval. In all regression models the study period (later vs. earlier), sex (as 
baseline  difference  women  vs.  men),  history  of  diabetes  and  its  interaction  with  sex  
(men=0, women=1) were used as explanatory variables. In the Cox regression analyses, the 
entry was day 28 after the onset of the event and non-fatal events were censored at the day 
364. Deaths due to causes other than CHD were censored at day of death.  
In study III data from all FINRISK study regions and survey years 1992, 1997, 2002 and 
2007 were pooled. Logistic regression analyses were used to test the significance of gender 
differences for discrete risk factors and linear regression for continuous risk factors. 
Models were adjusted for baseline age and study area (East: North-Karelia, Kuopio, Oulu 
vs. West: Helsinki-Vantaa and Turku-Loimaa). 
In study IV, data were similarly pooled as in study III and the same survey cohorts were 
analysed. The age-standardisation for event rates was done similarly as described above in 
study I. Event rates were compared using male/ female ratios. They were obtained by 
dividing  age  standardised  incident  event  rates  in  men  by  event  rates  in  women.  To  
investigate the effect of age, all male/female comparisons were repeated separately for the 
younger (25-54 years) and the older (>55) age group. The 95% CIs of age-adjusted rates 
and rate ratios were calculated using methods described in (265). 
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5 Results
The gender-specific age effect was linear with 5-year age groups with a significant 
(p<0.001) change point (interaction) in women at the age of 55-59 years old (Figure 7).  
Figure 7. Fatal  coronary  heart  disease  (CHD)  events  in  5-year  age  groups  per  100  000  
inhabitants per year in men and women in 1994-1996 and 2000-2002 in the Cardiovascular  
Disease Register (CVDR). In the logarithmic scale a straight line corresponds to a multiplicative 
effect on the relative risk (RR). Unpublished data from study I.
5.1 Gender differences in the incidence-, mortality-, and attack rates of   
ACS from 1994-1996 to 2000-2002 (Study I) 
The gender differences in average age-standardised ACS incidence, mortality and 
recurrent event rates per 100 000 inhabitants per year in the two time periods with 95% CIs 
are shown in Figure 8.   
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Figure  8.   Average age-standardised acute coronary event incidence, mortality and attack 
rates per 100 000 in the FINAMI and CVDR registers in 1994-1996 and 2000-2002. The error 
bars denote 95% CIs of the event rates. * Male-female difference in gender-specific relative 
(to the 1st time period) changes of  age-adjusted event rates.  Adapted from Lehto H-R et  al.  
BMC Cardiovasc Disord 12;7:35, 2007.
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Table 2 in Publication I reveals the male-female differences in gender-specific relative (to 
1st time period) changes of age-adjusted event rates. Significant differences between the 
genders  were  seen  in  the  relative  decline  in  incident  and  recurrent  events  and  also  in  
mortality in CVDR. In the FINAMI register, the relative changes differed significantly 
between the genders in incident and recurrent events (Figure 8).    
Further analyses with a negative binomial regression model in CVDR confirmed that the 
incidence, attack rate and mortality had generally declined between the study periods 
(Table 3 in Publication I).  However, when evaluating the decline rate differences between 
the genders in two different age groups (subjects of 35-54 years old and subjects 55 years 
old),  the  relative  changes  seen  in  younger  (<55  years  old)  women  were  smaller  than  in  
similarly aged men and older women. No differences were seen between older (55 years 
old) women and men. The gender by year interaction expressed as RR in the younger age 
group was 1.04 for incidence (p=0.01), 1.04 (p=0.01) for attack rate and 1.04 (p=0.03) for 
mortality rate. The results from negative binomial regression models are shown in 
Publication I Table 3.  
In the FINAMI register,  negative binomial regression models produced results that were 
generally consistent with the findings in the CVDR, but the year by gender interaction 
among age group <55 years old failed to reach statistical significance, probably due to the 
small numbers of ACS events in women aged <55 years old in the FINAMI data.  
The proportion of definitive MIs increased after adoption of troponins in both genders. In 
women, the proportion of definitive MIs changed from 40% in the first period to 60% in 
the second period. Among men, the proportion of definite MIs was higher than the 
corresponding value in women in the first study period 54% (vs. 40% in women) but 
increased to 75% in the second period. The changes in different MI subtypes are shown in 
Table 4 in Publication I.  
5.2 Gender differences in the prognosis of ACS from 1994-1996 to 
2000-2002 (Study II) 
Generally the short- and long-term prognosis improved among both genders between the 
study periods. Age-standardised case-fatality percents for the three main indicators in two 
different time periods are shown in Table 17.    
Figure 1 in Publication II shows the age-standardised case-fatality (%) with 95% CIs for 
both age groups in 1994-1996 and 2000-2002 in both FINAMI and CVD Registers.
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Table 17. Age-standardised case-fatality (%) for incident acute coronary syndrome according 
to gender, age group and three case-fatality time windows in both study periods  
Pre-hospital 28-day 365-day 
1994-1996 2000-2002 1994-1996 2000-2002 1994-1996 2000-2002
FINAMI 
Men1 29.7 26.7 46.5 41.0 49.5 45.1
<55 years old 27.4 27.0 34.1 29.2 35.9 30.2
55 years old 30.1 26.6 48.8 43.5 52.0 48.5
Women1 24.1 25.6 53.5 48.6 59.4 54.4
<55 years old 9.4 29.6 15.6 31.5 18.8 31.5
55 years old 24.4 25.5 54.4 49.1 60.3 55.1
CVDR 
Men1 33.6 29.5 54.7 50.1 59.2 55.1
<55 years old 30.8 29.2 36.1 33.7 37.5 34.8
55 years old 34.0 29.6 57.6 52.6 62.7 58.1
Women1 27.0 24.4 58.9 54.6 65.7 61.8
<55 years old 25.7 25.2 32.7 31.2 33.8 32.2
55 years old 27.1 24.3 59.6 55.2 66.6 62.6
1 Subjects aged 35 years old
Short-term case-fatality  
Generally, short-term case-fatality improved between the time periods. However, when 
comparing the case-fatality declines between the genders using logistic regression 
analyses, the results showed smaller declines in pre-hospital and 28-day case-fatality 
between the study periods among young (<55 years old) women when compared to men 
and older women. In FINAMI, the OR for pre-hospital case-fatality was 2.03 (sex by study 
period interaction in the age group of <55 years old) with 95% CI of 1.08-3.82, and 
correspondingly in CVDR, the OR was 1.35 with 95% CI 1.11-1.63. Similarly, for 28-day 
case-fatality, the OR was 2.04 (95% CI 1.14-3.64) in FINAMI and 1.80 (95% CI 1.50-2.16) in 
CVDR. All results from the logistic regression analyses are shown in Tables 2, 3 in the 
Publication II.  
Interestingly, the decline in 0-27-day case-fatality was slower among women aged <55 
years due to a slower decline  in the pre-hospital case-fatality in this age group, whereas 
the in-hospital (2-27 day) case-fatality revealed no gender differences (Table 18). With 
respect to in-hospital case-fatality, the gender by study period interactions in FINAMI and 
CVDR, separately in the age group <55 years old, and in the age group 55 years were all 
statistically non-significant (Table 18).  
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Table 18. Odds  ratios  (95%  confidence  intervals)  for  in-hospital  (2-27  day)  case-fatality  of  
incident coronary events in the FINAMI and CVD registers  
OR 95% CI p
FINAMIa
Study period (latter vs. former) 0.99 0.77 – 1.27 0.940
Age, per 5 years in men 1.13 0.85 – 1.51 0.384
Age, per 5 years in men 55 years  1.24 0.90 – 1.70 0.190
Age, per 5 years in women 1.30 0.59 – 2.85 0.517
Age, per 5 years in women 55 years 1.06 0.48 – 2.37 0.879
Gender by study period interaction in  
age group <55 years  
0.73 0.20 – 2.72 0.639
Gender by study period interaction in  
age group 55 years 
0.82 0.60 – 1.14 0.241
History of diabetes mellitus  1.49 1.11 – 2.01 0.008
History of diabetes mellitus in women 0.67 0.46 – 0.98 0.038
CVDR 
Study period (former vs. latter) 0.83 0.79 – 0.88 <0.0001
Age, per 5 years in men 1.25 1.11 – 1.41 0.0001
Age, per 5 years in men 55 years  1.01 0.90 – 1.15 0.851
Age, per 5 years in women 1.33 0.97 – 1.81 0.076
Age, per 5 years in women 55 years 0.92 0.67 – 1.26 0.590
Gender by study period interaction in  
age group <55 years  
0.84 0.54 – 1.30 0.434
Gender by study period interaction in  
age group 55 years 
0.98 0.90 – 1.06 0.557
History of diabetes mellitus  1.38 1.29 – 1.48 <0.0001
History of diabetes mellitus in women 0.95 0.87– 1.04 0.236
Long-term prognosis 
Generally, the 1-year case-fatality improved between the time periods. The logistic 
regression analyses for 0-364 day case-fatality are shown in Table 19. The results differed 
between the registers. In FINAMI, no gender difference was seen in 1-year case-fatality for 
either of the age groups. In the CVDR, the 1-year case-fatality improved more among 
older women than among men and younger women, whereas in younger women the 1-
year case-fatality seemed to decline more slowly compared to men and older women 
(Table 19). The 28-364 day case-fatality interval showed no differences between the 
genders in the CVDR in either age group. These results are shown in Publication II, Table 
4. In FINAMI, the gender difference could not be tested in the younger age group because 
there  were  no  deaths  in  that  group  of  young  women  in  the  later  study  period.  Gender  
differences were also tested during the time interval from the second day after the event to 
364 days. No gender differences were seen in either of the studied age groups in both 
registers. The gender by study period interaction for the younger age group was 
statistically non-significant (OR 0.39, 95% CI 0.11-1.40) in FINAMI and OR 0.75, 95% CI 
0.51-1.10 in the CVDR as well as for the older age group (OR 0.78, 95% CI 0.58-1.04) in 
FINAMI and OR 0.99, 95% CI 0.93-1.06 in CVDR. This indicates that a slower pre-hospital 
case-fatality decline was behind the slower 1-year case-fatality decline detected in younger 
women in the CVDR. 
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Table 19. Odds ratios (95% confidence intervals) for 1-year case-fatality of incident coronary 
events in the FINAMI and CVD registers  
OR 95% CI p
FINAMI 
Study period (latter vs. former) 0.83 0.72 – 0.96 0.014
Age, per 5 years in men 1.06 0.95 – 1.19 0.314
Age, per 5 years in men 55 years  1.21 1.05 – 1.38 0.007
Age, per 5 years in women 0.95 0.71 – 1.28 0.727
Age, per 5 years in women 55 years 1.57 1.16 – 2.14 0.004
Gender by study period interaction in 
age group <55 years  
1.68 0.95 – 3.00 0.078
Gender by study period interaction in 
age group 55 years 
0.94 0.77 – 1.16 0.575
History of diabetes mellitus  1.26 1.05 – 1.52 0.016
History of diabetes mellitus in women 0.82 0.64 – 1.06 0.134
CVDR 
Study period (latter vs. former) 0.78 0.75 – 0.80 <0.0001
Age, per 5 years in men 1.00 0.96 – 1.04 0.952
Age, per 5 years in men 55 years  1.29 1.23 – 1.35 <0.0001
Age, per 5 years in women 0.68 0.61 – 0.75 <0.0001
Age, per 5 years in women 55 years 2.22 2.00 – 2.47 <0.0001
Gender by study period interaction in 
age group <55 years  
1.87 1.56 – 2.24 <0.0001
Gender by study period interaction in 
age group 55 years 
0.93 0.88 – 0.97 0.002
History of diabetes mellitus  1.23 1.18 – 1.29 <0.0001
History of diabetes mellitus in women 1.02 0.96 – 1.09 0.473
5.3 Gender differences in the prevalence, causes and treatment of high 
CVD risk (Study III) 
The prevalence of high-risk subjects in FINRISK Surveys 1992-2007, defined here as the 
Framingham risk score 20% in 10 years, or prevalent CVD or diabetes, was almost equal 
in men and women in the age group of 25-54 years: 5.1% (n=451) in men and 3.7% (n=384) 
in women, whereas in the group aged 55-74 years, the high risk status was more common 
in men (50.4%, n=2606) than in women (19.9%, n=981). The difference was similar also in 
the FINRISK 2007 separately (Publication III, Web Supplement Table 1).  
Among high-risk subjects, women had a significantly higher prevalence of diabetes than 
men in both age groups (94% vs. 60.5%, p <0.001 in younger age group) and 51.2% vs. 
24.4%, p <0.001 in the older age group). More men had a history of a prior CVD event 
(29.3% vs. 7.8% in younger age group, p<0.001 and 23.5% vs. 18.9% in older age group, 
p=0.002). Smoking and former smoking were more prevalent among men than women in 
both age groups. The prevalence of selected risk factors is shown in Publication III, Table 
3.
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Generally,  high-risk  women in  both age-groups had better  lipid values  and lower  blood 
pressure levels, but higher BMI values than men. The average levels of measured risk 
factors in all high-risk patients are shown in Publication III Table 2. In the FINRISK 2007, 
mean cholesterol levels were lower as compared to the cholesterol levels in the pooled 
years and mean blood pressure values were lower in 2007 when compared to the blood 
pressure values in the pooled years whereas the mean BMI level and waist-hip ratio were 
higher in 2007 when compared to the results in pooled study years (Table 20 for results of 
the study in 2007 and for pooled years Table 3 of the Publication III). The proportion of 
high-risk subjects achieving blood pressure target values and recommended cholesterol 
level <4.5 mmol/l was higher in 2007 when comparing the results in the pooled years 
(Publication III Table 3). The prevalence of LDL level >2.5mmol/l had declined in 2007 
when compared to the results in the pooled years, and the prevalence of high LDL (>2.5 
mmol/l) was similar in both genders and in both age groups in 2007 (Table 20).  
The use of medications to control the risk factor levels is presented in Publication III Table 
4. If one considers the high-risk subjects, then it seemed that young women generally used 
preventive medications less than their age-matched male counterparts. In the older age 
group, this situation tended to be reversed. 
Subjects with diabetes  
Among diabetic subjects, the mean total cholesterol levels were equal in the younger age 
group  (5.4  in  men  and  5.5  mmol/l  in  women),  whereas  in  the  older  women  the  mean  
cholesterol level was higher in women than in men (5.7 mmol/l vs. 5.3 mmol/l, p 0.001). 
Men achieved the recommended level of total cholesterol <4.5mmol/l more often than 
women: in the younger age group 21% of men but only 14% of women achieved the 
recommended levels (p=0.01). Similarly in the older age group, 28% of men but 13% of 
women had total cholesterol less than 4.5mmol/l (p <0.001). Among young diabetic 
women, the prevalence of lipid treatment was 9% being much less than in men where the 
prevalence of lipid treatment was significantly higher (18%, p=0.001). This difference was 
no longer present in the older age group: 31% in men and 32% in women had lipid 
lowering treatment (p=NS). The mean blood pressure values were in men 137/85 mmHg 
and in women 134/80 mmHg in the younger age group (p=NS for SBP and p <0.001 for 
DBP, and 149/82 mmHg in men and 147/79 mmHg in women in the older age group 
(p=NS for SBP and p <0.001 for DBP). Among the older age group, the prevalence of blood 
pressure treatment was equally common: 51% of men and 52% of women were being 
treated for high blood pressure (p=NS). In the younger age group, women less often were 
receiving antihypertensive treatment than men (22% vs. 34%, p=0.01). Acetylsalicylic acid 
was more commonly used by men: 19% in young men vs. 7% young women (p  0.001) 
and among the older age group (44% in men vs. 36% in women, p=0.005). Beta-blockers 
were equally commonly used in both age groups: 21% in men and 13% in women in the 
younger age group, and 43% vs. 38% in the older age group, respectively (p= NS for both 
age groups). 
Subjects with prevalent CVD 
Subjects with prevalent CVD had similar mean total cholesterol levels in both genders.  
Mean total cholesterol was 5.5 mmol/l in men and 5.7 mmol/l in women in the younger 
age group, and 5.1 mmol/l and 5.2 mmol/l in the older age group; in both age groups there 
was no significant gender difference.  
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Among subjects with prevalent CVD, the target cholesterol level of <4.5 mmol/l was 
reached by 22% of the younger men vs. 20% of younger women (p=NS). In the older age 
group, the corresponding numbers were: 29% vs. 25% (p=NS). No gender differences were 
seen in provision of lipid treatment: 42% of younger men received lipid lowering 
treatment vs. 27% of women (p=NS), and in the older age group: 51% of men and 54% of 
women (p=NS). Mean blood pressure levels and the prevalence of blood pressure 
treatment were similar between the genders (data not shown). A lower proportion of 
women were taking acetylsalicylic acid in the younger age group: 40% in women vs. 62% 
in  men  (p=0.03)  and  in  the  older  group  59%  in  women  and  68%  in  men  were  receiving  
acetylsalicylic acid (p=0.02). In contrast, beta-blockers were equally commonly used in the 
younger age group: 48% in men vs. 40% in women (p=NS) and 70% of men vs. 65% of 
women (p=NS).  
5.4 Gender differences in the incidence and clinical spectrum of major 
adverse CVD events (Study IV) 
A total of 27 897 subjects (13 063 men and 14 834 women) without prevalent CVD were 
identified at baseline when the FINRISK 1992-2007 surveys were pooled together. During 
a total of 292 316 person years of follow-up, 1599 incident major adverse CVD events were 
identified in men and 974 in women. The incident event numbers by clinical subcategory 
were: 173 fatal CHD events in men and 48 in women, 645 non-fatal CHD events in men 
and 222 in women, 318 stroke events in men and 219 in women, 463 cases of heart failure 
in men and 485 in women. The median follow-up time was 8.9 years (interquartile range 
8.8 years).  The mean age at the time of an incident major adverse CVD event was 65 years 
(standard deviation (SD) ±9.5) in men and 66 years (SD ±9.9) in women. The mean ages 
and detailed numbers of events and co-morbidities are shown in Publication IV Table 1. 
The incidence of major adverse CVD event per 100 000 persons per year and the rate ratios 
according to the age group, gender and major adverse CVD event subgroup are shown in 
Figure 9. The incidence in men was almost double that encountered in women (rate ratio 
of 1.8 95%CI 1.6-2.0). Men had significantly higher incident CHD event rates, especially 
fatal  CHD events  and stroke compared to  women.  Men had four  times  more fatal  CHD 
events,  three  times  more non-fatal  events  and almost  two times  more stroke events  than 
women. Both genders had an equal amount of heart failures. The rate ratios for younger 
and older age groups separately are shown in Figure 9.  
The relative proportions of major adverse CVD event categories differed between the 
genders, but were similar in different age groups (Table 21).  
The potential aetiological factors for heart failure were analysed further. In this analysis 
only prevalent heart failure cases were excluded. A total of 1195 incident heart failure 
cases (633 in men and 562 in women) were found during the follow-up period. 
Hypertension was the main factor preceding heart failure, in 83% of men and 76% of 
women. Prior CHD was found in 42% of men and in 24% of women. Diabetes had been 
diagnosed in 28% of men and in 24% of women.  In addition in the younger age group, 
hypertension was a common preceding factor for heart failure; 83% in men and 62% in 
women, whereas CHD was found in 28% of men and in 12% of women, and diabetes in 
27% of men and 21% of women.  
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Figure 9. The incidence of major adverse cardiovascular disease events per 100 000 persons per year and 
the rate ratios according to the age group (A= 25-74 years old, B= 25-54 years old, C=55-74 years old), 
gender and major adverse cardiovascular disease subgroup. Adapted from Lehto H-R et al. Eur J  Prev  
Cardiol, 2013. Published online. 
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In the older age group, hypertension preceded heart failure in 83% of men and in 82% of 
women. CHD had been diagnosed in 46% of men and in 29% of women. Diabetes 
preceded the heart failure diagnosis in 28% of men and 26% of women.
Table 21. Relative proportions of major adverse cardiovascular disease categories in the 
different age groups 
All 
25-74 years old1
Young 
25-54 years old1
Old 
55-74 years old1
Men Women Men Women Men Women 
1. Non-fatal  
CHD 
(38.8%)
1. Heart Failure 
(49.5%)
1. Non-fatal 
CHD 
(46.9%)
1. Heart 
Failure 
(51.8%)
1. Non-fatal 
CHD 
(35.6%)
1. Heart Failure 
(48.6%)
2. Hear Failure 
(29.6%)
2. Stroke 
(22.9%)
2. Heart 
Failure 
(25.6%)
2. Stroke 
(25.1%)
2. Heart 
Failure 
(31.2%)
2. Non-fatal 
CHD 
(23.0%)
3. Stroke 
(20.3% ) 
3. Non-fatal  
CHD 
(22.3%)
3. Stroke 
(18.0% ) 
3. Non-fatal 
CHD 
(20.3%)
3. Stroke 
(21.3%)
3. Stroke 
(22.1%)
4. Fatal CHD 
(11.3%)
4. Fatal CHD 
(5.3%)
4. Fatal CHD 
(9.5%)
4. Fatal CHD 
(2.8%)
4. Fatal CHD 
(12.0 %) 
4. Fatal CHD 
(6.3%)
The sum of each column is 100% 
1 Baseline age 
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6 Discussion 
6.1 Summary of the main findings 
The  FINAMI  and  CVDR  studies  showed  that  the  incidence,  mortality  and  attack  rate  of  
coronary events have generally declined from 1992-1994 to 2000-2002 in Finland, and 
furthermore  that  the  prognosis  of  ACS  has  improved  between  these  time  periods.  
However,  the  incidence  and  decline  in  mortality  and  the  improvement  in  prognosis  
revealed a gender difference during this time interval. This was due to the slower decline 
in the incidence of ACS, mortality and attack rate among young (<55 years old) women 
compared with men and older women. Although the short- and long-term case-fatality of 
ACS has declined, the decline was slower among younger (<55 years old) women. This 
was mainly due to the slower decline in pre-hospital case-fatality in the younger women.  
In population-based FINRISK studies, it was found that the treatment of risk factors was 
less intensive in these young female high-risk patients when compared to men and older 
women. In the follow-up of initially healthy FINRISK participants, gender differences 
were seen in the incidence of CVD events. Men had a higher rate of non-fatal and fatal 
coronary events and stroke than women, whereas incident heart failure event rates were 
similar  in  both  genders.  Men  and  women  also  differed  in  the  clinical  spectrum  of  CVD  
events;  in  men the  most  common incident  CVD event  was a  non-fatal  ACS,  whereas  for  
women heart failure was the most common CVD. These differences were similar in all age 
groups. 
6.2 Study population and methods 
The subjects examined in studies I and II were obtained from two large population-based 
registers. CVDR is a nationwide register and it includes data mainly from the HDR and 
CDR registers which have been validated against the AHA 2003 definition. Together these 
registers showed a sensitivity of 80% and a positive predictive value of 90% for MI (255). 
Sensitivity improved from 1988 to 2002 in both genders, which was most likely due to the 
adoption of troponin into the diagnostic protocols. The diagnostic sensitivity and accuracy 
of MI seemed to be lower in women than in men. The accuracy of MI diagnosis between 
1998 and 2002 (as acquired from the HDR and CDR registers) was tested against the AHA 
2003 definition; the sensitivity was 81% and the positive predictive value 90% for men 
aged 35-74 years, the corresponding percents for women were 78% and 86%. When UAP 
was taken into account, sensitivity increased and positive predictive value decreased. In 
those subjects over 75 years old, the percentages were similar as those found in the 
younger groups. In fatal cases, sensitivity and positive predictive value were similar 
among both genders; sensitivity was 92% and positive predictive value 91-92% (255). In 
Finland, the frequency of autopsies in out-of-hospital deaths is high; more than 70% (50). 
The diagnosis of stroke, based on the HDR and CDR registers, was found to have a good 
positive predictive value (86%) for the first stroke event, and no gender differences  were 
seen (266). The diagnosis of heart failure, according to the HDR, CDR, DRR and pharmacy 
prescription data had poor sensitivity (48.5%) but good positive predictive value (85.9%) 
against register-based clinical classification (264). No gender specific data quality analysis 
was reported (264).   
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The  FINAMI  register  collects  data  mainly  from  urban  areas  (Kuopio,  Oulu,  Turku,  
Joensuu),  and  also  from  a  few  rural  areas  around  Joensuu.  FINAMI  has  a  strict  case  
definition coding, and the quality of ACS diagnosis is likely to be higher than in the CVDR 
register. However, FINAMI contains a smaller amount of coronary events, and due to this 
some gender differences, which were apparent in the CVDR, may not have been apparent 
in the FINAMI data.  FINRISK is a unique survey of CVD risk factor trends in Finland, and 
has comparable data for over 30 years collected at 5 year intervals. The participation rate 
has been fairly good, ranging from 58% to 81% depending on the survey year and gender. 
Women had slightly higher participation rates than men in all survey years (19). The non-
participants usually have higher risk factor levels, and their overall health may be poorer 
compared to the participants (267). The characteristics of non-participants have not been 
studied  during  the  2000s,  but  it  is  unlikely  that  gender  would  influence  the  non-
participants differently.  
Pre-hospital mortality in this study was defined as death in the same day as the symptoms 
had begun, which corresponds to a survival time of less than one day. In the FINAMI, 
register autopsies were performed on 64.9% of men in the first time period, and on 73.4% 
in the second period, and in women 33.9% and 43.3%, correspondingly. Due to the Finnish 
legislation concerning determination of the cause of death, it can be assumed that these 
percents are similar, or even higher among young subjects. In this study, the 28-day time 
period was considered to depict in-hospital mortality, and to consist of one single event in 
the  registers.  This  definition  has  been  adopted  from  the  WHO  MONICA  criterion.  The  
average hospitalisation period for ACS in Finland according to the CVDR database was 7.4 
days among men aged 35-84 years old in 2010 and 8.1 days among similar aged women.  
Unrecognised  MIs  could  not  have  been  registered  as  MI  cases  in  CVDR  or  FINAMI  
registers. The amount of unrecognised MIs is known to be higher among women than in 
men (34% of all MIs in women vs. 27% in men) (23, 268). This may underestimate the 
incidence of ACSs among women, and this in turn would widen the gender differences. 
However, it is not likely that unrecognised MIs would change ACS mortality rates, as the 
cause of death still needs to be identified.    
Aging is known to affect CVD rates exponentially. Women are known to have low rates of 
CVD events before the menopause, and after menopause the male-to-female ratio starts to 
decrease.  In  women,  the  increasing  effect  of  age  on  CHD  mortality  is  more  pronounced  
than in men. CHD mortality increases up to 2.3 -2.7 fold  per every decade of life  among 
men compared to the greater, 2.9- 3.7 fold, increase in women (269). The epidemiological 
evidence is controversial i.e. is it the menopause per se rather than age that carries an 
association with CHD. In a meta-analysis, the pooled RR of CVD in postmenopausal 
women was 1.36 (95% CI 1.15-1.60), however when this was adjusted for age and smoking, 
the difference between pre-and postmenopausal women became non-significant (RR 0.96 
95% CI 0.77-1.21) (195). However, in this meta-analysis of 18 studies, early menopause was 
identified as a risk factor (RR 1.38, with 95% CI 1.21-1.58) after adjusting for age and 
smoking (195). A study from the Netherlands which included 824 CVD deaths revealed a 
reduced RR of 0.98 for a CVD event per each year of delay of menopause, and the inverse 
relation was greater at younger ages (270). Surgical menopause had a pooled RR of 4.55 
(95%CI 2.56-8.01) (195).  
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The relationship between menopause and age has also studied in mathematical analysis of 
modelling longitudinal mortality data from three birth cohorts from England and Wales, 
and the United States; in these no acceleration of CVD mortality was seen at the 
menopause age group (45-55 years old), whereas the increase in breast cancer mortality 
was shown to significantly decelerate after the age of 45 years. In men, a rapid increase in 
CVD mortality has been shown to occur as they reach young adulthood this being 
followed by a slower increase after the age of 45 years (271). The authors concluded that 
deceleration of the increase in CVD mortality in men explained the gender differences 
better than the postmenopausal estrogen deficiency in women (271). Menopausal changes 
occur transitionally during perimenopause, and the changes in lipid metabolism as well as 
some effects on blood pressure occur during one to ten years after the menopause. Aging 
itself has also effects on CVD risk factors and the changes caused by menopause are 
difficult to differentiate from those attributable to aging. It has even been suggested that 
the increased levels of CVD risk factors might have an effect on menopause age rather 
than the other way around (272). In the CVDR, fatal CHD events had a significant 
changing point at the age group of 55-59 years in women, and therefore 55 years was 
selected as the cut point between the two age groups. No significant change was seen in 
the average menopause age in the 50-51 years old. Our data from FINAMI and CVD 
registers do not include information of menopause status per se, nor the time point of loss 
of menstruation. It is possible that this change among age group of 55-59 years old, is due 
to the aging, and possibly to some extent this could have influenced effect of menopausal 
changes on risk factors. It also might be that these early menopausal women are not 
considered to be at risk for CHD, and thus remain underdiagnosed and treated, leading to 
a change in mortality. The cutpoint of 55 or 60 years have been used in other population-
based studies also (23, 37, 273).  
CHD has different clinical presentations, and women are known to suffer more from 
angina, and men more from clinical events as the clinical presentation of CHD (23). In this 
study, the FINAMI register collects all acute coronary events and deaths in the register 
areas. Thus stable angina is not included in the registration in either FINAMI or in CVD 
register. Non-fatal events and stable angina are problematic, since they invariably depend 
on the classification, methods and diagnostic tools used in determining the diagnoses. In 
the SCORE project, the outcome was a fatal CVD event, because data on fatal events are 
more robust and better comparable over different time periods than data on non-fatal 
events in different European countries (166). Stable angina is also a problematic clinical 
presentation  of  CHD:  especially  among  women  in  whom,  despite  the  poor  prognosis  
related to stable angina, CHD with occluding atherosclerosis is more rarely identified in 
coronary angiography (274). In a large cohort study of 375 886 patients from the United 
States, the risk-adjusted OR for significant coronary stenosis was only 0.34 in women with 
stable angina compared to men with stable angina, but at the same time, the in-hospital 
mortality was significantly higher in the women (274). The present method of collecting 
data on acute coronary events, can be assumed to have good specificity and, due to gender 
differences in the clinical spectrum of CHD (women having lower rate of events compared 
to men), it is possible that the results on acute events alone might  actually underestimate 
the  overall  occurrence  of  CHD  in  women.  Due  to  the  lower  rate  of  diagnostic  testing  in  
women, it is also likely that only the most severe cases of CHD were detected.  
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6.3 Gender differences in the incidence-, mortality - and attack rate 
trends of ACS (Study I) 
In general, the incidence, attack rate and mortality of CHD declined between the time 
periods 1994-1996 and 2000-2002. This decline is consistent with other reports of CHD 
trends in western countries and Finland during the past decade (13, 28, 29). The rate of the 
decline differed between genders; a slower decline among women was seen in the 
incidence and the attack rate in both registers, and a slower decline in mortality among 
women was seen in the CVDR register. A slower decline in mortality from total CVD 
events was also seen in the Olmsted County, Minnesota, cohort (29). A slower mortality 
decline  in  women,  without  age-grouping,  was  also  shown in  two other  studies  from the  
United States; however, both of these studies evaluated time periods before the mid-1990s 
(30, 31).  In the present study the slower decline in mortality was age-dependent in women 
since  it  was  only  seen  in  young  women.  Similarly,  more  recent  studies  from  the  United  
States, France, Australia, England and Wales, have pointed to a slower decline in CHD 
mortality among younger, middle-aged subjects (4, 35-37). In France, Wagner et al. 
reported a slower decline in the mortality of CHD among young women during 2000-2007 
(37). Ford et al. reported a levelling off in the CHD mortality decline in both genders, even 
an increase in mortality seemed to occur among young (aged 35-54) women from 2000 to 
2002 (4). Contrary to this report and these present results, Vaartjes et al. described an 
attenuation in the decline of CHD mortality decline among young 35-54 years old subjects 
and there were no gender differences in this respect in the Netherlands between 1972- 
2007 (273).  
The slower decline in CHD mortality among young women - who have the lowest 
absolute risk - is difficult to explain. In general, changes in mortality are due to changes in 
incidence and case-fatality and, moreover, incidence changes are associated with changes 
in diagnostics or risk factor levels. In the present study, the decline in CHD incidence was 
slower among young women compared to men and older women according to both the 
FINAMI and the CVDR registers. This gender difference could either be attributed to the 
adoption of troponins in Finnish hospitals during the study periods, or to changes in the 
development of risk factors in Finland. The effects of troponins on the incidence of CHD 
have been previously studied using data from the FINAMI register. Salomaa et al. 
described a declining trend in incidence (-2.0% per year) between 1993 and 2002 in men 
aged 35-74 years in Finland, whereas a non-significant 1.0% decline was seen among 
women  of  the  same  age.  However,  when  the  effect  of  troponin  measurements  in  the  
diagnostics were taken into account, the decline among women in the age group of 35-74 
years was changed to being statistically significant, i.e. - 2.7% per year (13). Furthermore, 
the adoption of troponin measurements was shown to have the greatest effect on the 
number of events among the elderly, 75 year old women (13). In the present study, the 
slower  decline  in  incidence  was  seen  among  young,  <55  year  old,  women.  Thus  it  is  
unlikely  that  the  adoption  of  troponin  measurements  would  entirely  explain  those  
changes in the incidence. The gender difference seen in the decline of CHD mortality is not 
explained by troponins, since most of the CHD deaths occur suddenly in out-of-hospital 
circumstances, i.e., before any laboratory measurements can be taken or before the blood 
concentration of troponin has become elevated (18).   
Since many of the first CHD events are fatal, it maybe that it is changes in risk factor levels 
in Finland that account for the gender difference seen in the declines of incidence and 
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mortality. Traditional risk factor levels have been monitored in Finland at five-year 
intervals since 1972. Jousilahti et al. showed that differences in risk factor levels, especially 
in the HDL cholesterol levels and smoking, explained nearly half of the difference in CHD 
risk  between  the  genders  (10).  It  is  likely  that  detrimental  movements  in  risk  factors  
explain these gender differences. Mean cholesterol levels have declined among both 
genders. However, during the time period 1992-1997 cholesterol levels remained the same 
among women, but after that cholesterol levels have started to decline again. In 2002 the 
mean total blood cholesterol was 5.7 mmol/l in men and 5.5 mmol/l in women (12). 
Similarly, the SBP among women stayed at the same level between the years 1997 and 
2002, whereas DBP was declining in both genders until 2002 (12).  
The most adverse changes were, however, seen in smoking, and the increasing prevalence 
of obesity and diabetes. In Finland, women have traditionally smoked much less than 
men, but smoking increased in women until 2002 and has stayed at the 2002 level until 
2007. After that, smoking has declined among women. In men, the prevalence of smoking 
decreased from the 1970s to 1997, when smoking prevalence seemed to increase until 2002,  
but it has been declining since that time (12).  
The most prominent risk factor change from the 1970s is the increasing obesity in Finland, 
as in other western countries, among both genders. Globally 33.6% of men and 35% of 
women are overweight, and 9.8% of men and 13.8% of women are obese based on the 
definition of BMI 30kg/m2(14). From 1978 to 2001 in Finland, the prevalence of obesity 
has increased more in men; from 11% to 21% compared to a change from 18% to 24% in 
women. The mean BMI increased more in men during this time period. However, changes 
in the fat distribution may well have been more disadvantageous in women, since the 
waist circumference has increased by 4.3 cm in women but only by 2.7 cm in men in the 
past decades (275, 276). The prevalence of obesity has increased even further since 2001, 
and the latest FINRISK 2012 findings have suggested that 66.3% of men and 46.4% of 
women are overweight in Finland (1, 161). Abdominal obesity was shown to have a small, 
but significantly greater effect on CHD events in women than in men in the INTERHEART 
study (11).  
The prevalence of diabetes has increased, and in 2008 it was estimated that diabetes 
prevalence was 10% globally (1). According to FIN DM II data currently there are 300 000 
diabetic persons in Finland, and an additional 200 000 persons are believed to have 
unrecognised diabetes (277). From the mid-1990s to 2007, the prevalence of type 2 diabetes 
increased by 5.5% annually. The encouraging news for women was that the proportion of 
women has declined among subjects with type 2 diabetes; from 55.9% in 1997 to  50.1% in 
2007 (277). The population attributable risk of CHD event due to diabetes is, however, 
significantly greater in women (19.1 women vs. 10.1% men, p <0.0001). Overall, risk factors 
related to metabolic syndrome explained 73% of women´s CHD events and 68% of men´s 
events in the INTERHEART study (11).   
The potential changes in case-fatality in explaining the slower mortality decline will be 
discussed in detail below.  
The declines in CHD event rates between the study periods in men and women showed 
some inconsistency between the registers: the incidence and attack rate did not decline in 
women according to the FINAMI register. In CVDR, declines were seen among both 
genders in incidence, attack rate and mortality. This discrepancy is partly due to the 
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differences in registers; in FINAMI, the register areas are mainly cities, and the hospitals 
are large university hospitals (Kuopio, Turku, Oulu), with one large central hospital 
(Joensuu). As the CVDR covers the whole country, including a large proportion of smaller 
hospitals, it is likely that the adoption of troponins occurred gradually in different 
hospitals, at first in larger hospitals in the late 1990s and then later in the smaller hospitals. 
The effect of troponins has been shown to have a greater impact on women’s MI diagnosis 
than men’s (13). Moreover, in the FINAMI register, the event numbers were low with 
respect to young women in both time periods, and therefore the FINAMI register was 
underpowered to reveal changes in this group between these time periods.  
6.4 Gender differences in the prognosis of ACS (Study II) 
Short-term and 1-year case-fatality improved among both genders from the mid-1990s up 
to 2002. Pre-hospital case-fatality declined more slowly in young (<55 years old) women 
when compared to men and older women. The slower decline in pre-hospital case-fatality 
was also reflected in a slower decline in 28-day case-fatality in young women. The 
reduction in-hospital (2-27 day) case-fatality was similar in both genders and age groups 
(<55 years and 55 years), as was the decline in 28-364 day case-fatality.  
This slower decline in early case-fatality may explain the slower mortality decline seen in 
study I. Almost 50% of total CHD mortality change has been shown to be due to the 
changes in case-fatality (42). The present results are similar as those reported in 
population-based studies from the United States, New Zealand and Scotland, including 
both pre-hospital and in-hospital deaths (29, 53, 54, 278). Those study settings which 
examine only hospitalised subjects may distort the results of gender differences as pre-
hospital case-fatality is higher in men than in women (26).  
There  may  be  several  explanations  for  the  slower  decline  of  pre-hospital  case-fatality  in  
young women.  First, pre-hospital deaths due to incident events are considered to depict 
the efficacy of primary prevention in the population, and as revealed in Study III, the 
high-risk situation is not always recognised and appropriately treated in women 
(discussed in detail below) even though most of the women who will die of CHD have at 
least a one elevated CVD risk factor (279). The high-risk situation needs to be recognised, 
since 64% of women who die suddenly, do not display any prior symptoms (2). The 
prevalence of smoking was increasing in women in the 1990s and this trend continued at 
the beginning of the 2000s, and smoking is known to be one of the most important risk 
factors for sudden death in women (135). Population-based preventive actions and 
campaigns to increase knowledge on heart disease among women are important if one 
wishes to reduce CHD mortality in women (191). 
Secondly, the clinical presentation and symptoms are more complex among women, and 
non-invasive diagnostic tests are known to have lower reliability and this may lead to 
poorer  CHD  recognition  among  women,  especially  among  pre-menopausal  women.  
Women report more unusual prodromal symptoms before an acute coronary event such 
as: fatigue, sleep disturbances and shortness of breath (62). It is not clear whether women 
experience less or a similar rate of chest pain during an acute event as men. However, 
women are more likely than men to report fatigue and shortness of breath  and other heart 
failure symptoms as one of the symptoms during the acute coronary event (280). Women 
also report more angina evoked from emotional stress, men more often display exertional 
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angina (62). The symptoms poorly predict obstructive CHD, especially among 
premenopausal women. In the Women’s Ischemia Syndrome Evaluation i.e. WISE study, 
signs of obstructive CHD were found in 21% of women having typical symptoms, in 17% 
of women with atypical symptoms and in 21% with non-angina symptoms among the 45-
55 years age group. In post-menopausal women, symptom prediction for obstructive CHD 
was better, but still less than for men of same age (62). Diagnostic testing, such as exercise 
ECG evaluation, shows poorer reliability in women, especially among premenopausal 
women, among whom angina and ischemia symptoms may vary depending on the phase 
of the menstrual cycle. In the luteal phase, when estrogen levels are low, ischemia and 
angina symptoms may be provoked more easily. Overall, exercise ECG, taking 1mm ST-
depression as a marker of ischemia, has ~ 60% sensitivity and  ~ 70% specificity for 
significant obstruction in a coronary artery in women, compared to the ~ 80% diagnostic 
sensitivity  and specificity  reported in  men (62).  Single-photon emission tomography and 
pharmacologic stress testing have been proposed to have higher sensitivities and 
specificities for prediction  of obstructive CHD (62).  
Women with stable angina are admitted to diagnostic tests and to coronary angiography 
less often than men in stable angina (281). Daly et al. estimated that there was 2-times 
higher risk of death in 1-year follow-up in those women with stable angina compared to 
men, even after adjustments  for clinical characteristics, severity of CHD, revascularisation 
and usage of drugs  (281). Theoretically, some restrictions are associated in the search for 
obstructive CHD, as 15% of subjects with diagnosed non-ST-elevation MI exhibit non-
obstructive CHD in angiogram (280). In women diagnosed with STEMI, 10.2% have 
normal or no obstruction in coronary arteries, compared to 6.8% of men (p=0.02 for gender 
difference) (282). Women account for the majority of subjects with angina symptoms, 
suspected ischemia and non-obstructive CHD in coronary angiography, also named as 
cardiac syndrome X (274).  This status has commonly been considered as a benign state. 
However, data from the Women’s Ischemia Syndrome Evaluation study has shown that 
women with persistent angina symptoms without obstructive CHD or normal coronary 
arteries are twice as likely to suffer CVD events, including non-fatal MIs, strokes, heart 
failure and CVD deaths when compared to those women without angina symptoms in 5-
year follow-up (283). This non-obstructive CHD has been further investigated recently; 
most  of  these  women have been shown to  have an abnormal  coronary flow reserve and 
endothelial dysfunction (62, 283).  
A  recently  published  study  from  Japan  reported  that  in  women  with  angina  and  non-
obstructive CHD, an intracoronary acetylcholine provocation test revealed epicardial 
coronary artery vasospasm to be the cause of ischemia in 49.3% of cases and microvascular 
coronary artery vasospasm in 21.3% of the cases, whereas a non- ischemic cause was 
found in 18.5%, and 10.9% of cases could not be classified. In the same study, 
microvascular coronary artery spasm was found significantly more frequently in women 
than men (21.3% vs. 3.1%, p<0.0001) (284). Vasospasms evoke stress on the endothelial 
cells and erosions leading to thrombus formation, and this may trigger an acute coronary 
event. Women are known to have more superficial erosions, and men to have more deep 
plaque ulcerations in the lipid core (285). Endothelial dysfunction has been proposed to be 
the  cause  of  symptoms  encountered  in  non-obstructive  CHD,  and  to  be  a  cause  of  
microvascular disease (62, 274, 284). However, knowledge of these disease states is scarce; 
more information on prognosis, risk factors and benefit of medications would be clearly 
desirable. However, the Red Alert project has recommended to evaluate and treat risk 
factors in these women (286).  
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Thirdly, women have anatomical and physiological differences which may be responsible 
for  the  poorer  short-term  prognosis.  Women  have  a  high  risk  for  spontaneous  coronary  
dissection due to their thinner coronary artery walls, and more women suffer heart muscle 
ruptures due to MI than men (287, 288). Women also have been postulated to react 
differently to ischemia via autonomic nervous system: in premenopausal women the 
stronger vagal reflexes protect them from ventricular fibrillation, but on the other hand, 
extreme vagal activation can evoke asystole and hemodynamic instability (289).  
Fourthly, women have higher rate of co-morbidities, especially diabetes, which may 
interfere with symptom recognition, or may even mean that the acute coronary event 
remains undiagnosed (268).  
There were no gender differences detected in in-hospital (2-27 day) case-fatality changes 
between the time periods of 1994-1996 and 2000-2002. Several prior studies from other 
countries have shown poorer in-hospital prognosis in women, especially young women, 
compared to  men and older  women (6).  However,  more  recent  data  has  shown that  this  
difference has narrowed from the 1990s to 2006, although it still is apparent (57). The 
lower rate of revascularisation procedures (PCI or CABG), and higher mortality related to 
these procedures have been considered to explain this gender difference in the in-hospital 
case-fatality (290). However, the gender gap related to PCI and CABG outcomes has now 
narrowed between the genders (291). Current ESC non-ST-elevation MI Guidelines of 2011 
do note that women with non-ST-elevation MI are less likely to receive evidence-based 
medicine and diagnostic procedures including revascularisation (280). The long-term 
benefit of invasive vs. conservative strategy in women has been highlighted in a Cochrane 
meta-analysis, although with an early increased hazard. The guidelines now recommend 
to consideration of early invasive strategy for women according to the same principles as  
for  men (280).  
There were no gender differences in the changes in long-term prognosis (28-364 days) in 
this study. Commonly, women have been perceived to enjoy a better long-tem prognosis 
(280). Nonetheless, register studies on long-term prognosis have shown controversial 
results. Vaccarino et al. described an age-dependent difference in long-term prognosis; 
poorer 2- year prognosis was seen in young women compared to men and older women 
(61).  A  recurrent  MI  event,  non-fatal  or  fatal,  has  been  reported  to  occur  during  the  
subsequent 5 years in 22% of women and in 15% of men <50 years old, but in 22% of both 
genders in subjects 65 years old (2). 
In this present study diabetes was associated with a lower risk of pre-hospital case-fatality, 
although the long-term prognosis was not advantageous. Women with diabetes are 
probably recognised by themselves and their physicians to be a high risk group for a CHD 
event, and thus may have a shorter delay in contacting the health care system.  
The adoption of troponins does not explain the difference seen in case-fatality changes 
between the genders. In the pre-hospital deaths, troponins do not play any role in 
diagnosis, since samples for troponins have been taken yet, or the time to troponin 
elevation (at least 4 hours in old troponins) is too short that it has not occurred before 
death. In addition, troponins have been shown to have no effect on 1-month case-fatality 
trends in either of the genders (13, 56).  
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6.5 Gender differences in the prevalence, causes and treatment of high 
CVD risk (Study III) 
Prevalence of high CVD risk was almost the same in men and women in the age group of 
25 to 54 years, but in the older (55-74 years) age group, the high-risk situation was more 
common among men than in  women.  Diabetes  was the  main cause  for  a  high-risk  to  be  
present in young persons. In young women, diabetes was the most common cause, 
whereas in men a high Framingham risk score and prevalent CVD also seemed to have an 
important role. In older age-groups, diabetes was the main cause among women, whereas 
in  men  the  proportions  of  diabetes,  prior  CVD  event  and  high  Framingham  risk  score  
were more evenly distributed. The use of preventive medication differed between the 
genders. In the younger age group, women received less preventive medications, whereas 
in the older age group women received more preventive medications than similarly aged 
men.  
In publication II, it was concluded that the pre-hospital case-fatality had declined more 
slowly among <55 year old women from the mid-1990s to the 2000s. As stated earlier, pre-
hospital mortality is considered to be an indicator of prevention, especially of primary 
prevention.  In  addition  to  the  population  prevention  approach  affecting  the  whole  
population through health education, legislation and tax policies, also a high-risk 
approach is needed to identify those individuals at high-risk for suffering a CVD event 
since it is the best way to target intensive therapy as effectively as possible. In the present 
study  the  prevalence  of  high-risk  was  almost  the  same  in  young  women  as  in  similarly  
aged men, and this was mostly due to diabetes. Here, the prevalence of high-risk was close 
to the diabetes prevalence reported among the working-aged subjects (1). As could have 
been expected in the younger age group, only a few (0.03% of young women and 1.2% of 
young men) high-risk subjects could be identified using the Framingham risk score (>20% 
absolute risk to either die or to have CHD or stroke event within the next 10 years). It is 
well known that absolute risk charts may seem to indicate a low risk even though young 
subjects may have a high relative risk. Clearly, prevention would be efficient in these 
younger subjects. However, it has been also suggested that risk scores have a lower 
sensitivity of high-risk identification in females. Ketola et al. studied risk prediction 
models among >25 000 subjects aged 40 years and without prior CVD in the FINRISK 
Survey years 1972-1992. The subjects were followed for 10 years, and CVD events were 
identified from administrative registers. The Framingham risk score >20% to predict CVD 
events had 47% sensitivity and 79% specificity among men, whereas the sensitivity was 
only  7% in  women with specificity  of  98%.  The same study also  showed 88% sensitivity  
and 40% specificity for CVD mortality among <55 years old men with Framingham score 
>10%, and the corresponding numbers for women <55 years were 41% and 84% (292). This 
indicates that the Framingham score has good or even high specificity among women, but 
at the same time low sensitivity to identify those women with an increased risk to 
experience a CVD event or to die of a CVD event.  
High-risk status identified from chart algorithms often is used as a guide for the initiation 
of preventive medications. However, it has been reported that physicians assign a lower 
risk  category  to  women  than  men  with  similar  Framingham  risk  scores,  and  these  risk  
classifications also are known to influence their treatment decisions (293). It has been 
claimed that physicians use these risk classification charts insufficiently in primary care, 
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mostly since they are concerned of exaggerating the need for medical therapy and perhaps 
partly  due  to  the  lack  of  time.  The  ESC  guidelines  working  group  reported  that  85%  of  
cardiologists and physicians knew they should base CVD risk assessment on the 
evaluation of overall CVD risk. But nonetheless, only 62% of them used those scores (166). 
One in every four men aged  40 years have been estimated to belong to the high-risk 
group when the Framingham risk score >20% equation is used, compared to a mere 2% of 
women (292). When estimated at the age of 40 years the actual remaining lifetime risk for 
CHD is one in three for women, and one in two for men (2).  
In order to improve high-risk prevention and identification in young individuals, the ESC 
has launched relative risk charts, and AHA has introduced the concept of vascular age 
(166, 191, 241). The use of relative risk chart and extrapolation to higher ages are advised 
to be used only in targeting lifestyle intervention, but not to be considered as a basis for 
initiating medication (166). The use of these tools may help to identify women with 
unhealthy lifestyle, and to guide in lifestyle management before the absolute risk score is 
fulfilled at high-or intermediate risk level. 
CVDs  are  mostly  due  to  an  unhealthy  lifestyle,  and  the  pathogenesis  of  CVDs  is  a  
continuum of decades or a lifetime, and therefore, the prevention should also be equally 
long-sighted. Women are considered to be protected during their fertile years, and only to 
be at risk after that period. This concept is based on event numbers, and does not take into 
account the fact that atherosclerosis develops over decades. In women, the risk factor 
levels present at a young age, i.e. prior menopause, have been suggested to predict the 
vascular risk 20-30 years later, and subclinical atherosclerosis has been shown to be as 
prevalent  among  women  with  an  early  menopause  as  it  is  in  men  matched  for  age  and  
traditional risk factors (294, 295). The optimal timing of the lifestyle guidance for women 
should be further refined. Lifestyle guidance would probably be more beneficial when 
given to women prior to, or early in the menopausal transition, since physiological 
changes  increase  the  risk  factor  levels  during  the  menopausal  transition  and  in  the  
following decade. In addition, atherosclerosis rapidly progresses in women after the 
menopause. Now the ESC guidelines of 2012 consider that in women aged 50 years or 
who are postmenopausal, the CVD risk should be evaluated to determine whether or not 
the person has a high-risk (166). 
Currently, none of the risk estimating tools includes risk factors specific for women, 
namely, early menopause, pre-eclampsia or gestational hypertension or gestational 
diabetes in the total risk estimation. The AHA guidelines for women include pre-
eclampsia, gestational hypertension and gestational diabetes as risk factors and for these 
women the overall risk estimation is recommended (191). With increasing knowledge of 
the gender difference in CVD prevention, gender-specific guidelines may become 
available in the future.  
In this study, the overall risk factor target levels were poorly achieved. High-risk young 
men were more often achieved lipid targets, but the levels of other risk factors were poorer 
compared to similarly aged women. Women received less preventive medications 
compared to men. This overall excess of risk factors has been shown to explain almost 
completely the overall higher CVD morbidity in men when compared to women (10, 11). 
Among the older age group, the target values were achieved equally in both genders, and 
more women used preventive medications than men. The overall risk factor treatment has 
been shown to be poor among high-risk subjects throughout Europe (245). In this study, 
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acetylsalicylic acid was less often used by young women who were at a high-risk for CVD 
compared to men of a similar age, but more equally between men and women in the older 
age group. Current ESC guidelines do not recommend the use of acetylsalicylic acid in 
subjects without established CVD due to  the increased risk of bleeding (166). In the meta-
analysis  by  Berger  et  al.  acetylsalicylic  acid  prevented  CVD  events,  with  the  risk  of  
bleeding being similar in both genders. The clinical end-point that was prevented differed 
between  the  genders.  In  men  acetylsalicylic  acid  prevented  MI  events,  and  in  women  it  
inhibited stroke events, but had no effect on MI prevention (249).  
Here those subjects with prevalent CVD, i.e. subjects in secondary prevention, risk factor 
treatment  was  applied  equally  insufficiently  in  both  genders.  Current  ESC  guidelines  
recommend that initial treatment should be with beta-blocker, statin, ACE inhibitor/ 
angiotensin receptor II blockers and acetylsalicylic acid, unless contraindicated, in subjects 
with ACS (166). In subjects with ischemic stroke, acetylsalicylic acid plus dipyridamol or 
clopidogrel are recommended. There was no information available on the use of 
dipyridamol  or  clopidogrel  in  this  study.  EUROASPIRE III  and REACH register  studies,  
with larger cohorts than here, confirmed the lower use of antithrombotic agents in women 
(250, 296). Acetylsalicylic acid use has been confirmed to be beneficial in both genders in 
subjects who already suffered had a CVD event (166). Lipid lowering drugs were used in 
our  study equally  in  women and men.  However,  the  numbers  of  women were  small.  In  
larger  register  studies,  the  results  are  conflicting:  in  EUROASPIRE  III,  statins  were  
reported to be prescribed equally commonly but in the REACH register study, women had 
a lower chance receiving lipid-lowering medication (250). A German register study 
pointed out a 74% reduction in total mortality among subjects who used optimal medical 
therapy (listed above) over 1-year after ACS. This reduction was similar in both genders 
and in subjects with diabetics (297). Interestingly, the REACH register study reported 
similar  rates  of  the  combined  endpoints  of  CVD  death,  MI  and  stroke  in  both  genders  
despite the lower use of preventive medication and overall poorer risk factor management 
in  women.  The  REACH  study  authors  concluded  that  if  secondary  prevention  could  be  
improved in women, this might well reduce event rates (296).  
Diabetic subjects were divided into two-groups in the ESC 2012 guidelines, i.e. subjects 
with very -high or high -risk. A very high-risk was considered to be present if in addition 
to  diabetes  there  were  one  or  several  other  CVD  risk  factors  (hypertension,  smoking,  
hyperlipidaemia) or a target organ failure.  The other diabetic subjects were considered to 
be at a high risk. The AHA Guidelines for CVD prevention in women consider diabetes as 
a high-risk feature without any other requirements (166, 191).  In this study, diabetes was 
considered as a high-risk feature, in line with those recommendations used in 2010-2011 
and we did not further classify diabetic persons as high and very high risk. Nevertheless, 
young women with diabetes were being treated with significantly less preventive 
medications compared to men, a fact which was not apparent in the older age group. The 
current guidelines recommend statin therapy regardless of gender and baseline LDL, 
targeting LDL cholesterol levels to <1.8mmol/l in individuals in this very-high risk group. 
With respect to the diabetics in the present study, LDL was >2.5 mmol/l in 80% of young 
women (vs. 66% of young men) and in 68% of older women vs. 48% in men according to 
FINRISK survey of 2007. Acetylsalicylic acid is no longer recommended for diabetic 
persons without established CVD or other high-risk features (166). Under-treatment of 
blood pressure and blood cholesterol levels, especially among diabetic women has been 
also detected in other studies (298).  
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6.6 Gender differences in the incidence and clinical spectrum of major 
adverse CVD events (Study IV) 
As  was  expected,  men  experienced  two  times  more  incident  major  adverse  CVD  events  
compared to women. Men suffered four times more fatal CHD events, and three times 
more non-fatal CHD events. The male/ female ratio was larger in the younger age group 
(seven times more fatal and four times more non-fatal events in men). In the older age 
group, the differences were evident, but smaller (three times more fatal and non-fatal 
events in men). In the Framingham study, gender differences in CHD were examined in 
detail, and in the 26-year follow-up the male-to-female ratio was ~ 6.5 in the age group of 
35-44 years old, ~ 3.2 among 45-54 years old, ~2.2 among 55-64 years old, but after that the 
ratio was equal (23). In fact the ratio became reversed among subjects >75 years old (23). 
Wagner et al. recently reported male to female ratio of  3.4 for fatal CHD among 35-54 year 
old subjects and 2.4 for subjects aged 55-74 years in France, evidence for smaller gender 
differences in fatal CHD between the genders than in Finland (37). As already mentioned, 
the risk factors explain most of the observed gender differences (10, 11). In France, the 
average blood cholesterol levels in population are comparable to those in Finland. The 
mean blood pressure is slightly lower, but the prevalence of obese subjects is slightly 
higher than in Finland. Furthermore, the prevalence of smoking is higher among women 
in France, and it increased from 16.6% from the end of 1980s to 21.5% in 2007 among 45-54 
year old women (1, 37).  
Non-fatal CHD events were the most common CVD presentation in the men in both age 
groups, as was expected. Fatal CHD events occupied the 4th place in the clinical spectrum 
in all groups. Twelve percent of first CVD events were fatal in 55-74 years old men and the 
value was 10% in younger men. The high-risk situation is probably identified more readily 
in  men  than  in  women,  but  the  general  risk  factor  levels  are  poorly  treated,  and  
improvement  is  needed  in  both  genders.  Even  though  in  women  the  proportion  of  fatal  
events were substantially lower than in men, 2.8%  of women´s first CVD events were fatal 
CHD events in the young age group and 6.3% in the older age group. Due to the 
possibility of the lack of symptoms prior to the first clinical event, which may be fatal, total 
risk estimation and risk factor identification are important if one wishes to change this 
situation. This is even more so in women, in whom a larger proportion than men do not 
have  any  symptoms  suggestive  of  CHD  before  death  (2).  Nevertheless,  if  one  wishes  to  
avoid fatal events then both the high-risk approach and the population level approach are 
needed in prevention. These male-female ratios do not depict the overall CHD burden, 
since stable angina was not included; if it had been, the ratios might have been closer to 
each other.  
The incidence of heart failure did not differ between the genders in this study, and it was 
the most common first CVD presentation in women in both age groups. The heart failure 
incidence numbers differ between the sources: the present incidence numbers were 
consistent with those reported by Roger et al. from the Olmsted County cohort, Minnesota 
(95). In that study both Framingham criteria and clinical criteria were used in the heart 
failure diagnosis, and men were found to have higher heart failure incidence than women 
(95). In a study from the United Kingdom, the rate-ratio was 1.4 for men in heart failure 
diagnoses made by GPs (99). However, it is likely that women are diagnosed with heart 
failure less often than men, since women have more HF-PEF, the diagnostic criteria of 
which have only recently been established. Mosterd et al. reported an equal prevalence of 
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heart  failure  in  both  genders  in  the  general  population  of  the  Netherlands  when  the  
clinical definition for HF was used  (106).  
Hypertension was the most common predisposing factor preceding heart failure in the 
present study, but in men CHD preceded heart failure more commonly than in women. In 
general, a total of 75% of all heart failure cases have been estimated to have preceding 
hypertension (2). The Rotterdam study suggested that hypertension had a stronger role as 
a contributing factor in women than in men (106). Dunlay et al. evaluated population 
attributable fractions of heart failure using Olmsted County, Minnesota and Rochester 
Epidemiology  Project  resources,  and  concluded  similarly  that  hypertension  had  a  larger  
role in heart failure in women. Population attributable fraction of heart failure due to 
hypertension was 28% in women and 20% in men (299). The gender differences in blood 
pressure levels are multifactorial and poorly understood. Women have lower rate of 
hypertension until the age of 45. At the age of 45 to 64 years men and women have similar 
rates of hypertension, whereas after the age of 65 years more women (69 %) than men 
(64%) have hypertension (2). In the United States, the prevalence of hypertension is 
estimated to be 34% among adult males and 33% among adult women (2). The prevalence 
of hypertension in Europe has been reported to be higher. Wolf-Maier et al. studied blood 
pressure  values  in  several  European  countries,  and  found  that  the  overall  prevalence  of  
hypertension was 44% in adult population in Europe (300). Finland was also included in 
that  study,  and  had  one  of  the  highest  blood  pressure  levels  and  prevalence  among  
subjects aged <60 years old (300). The prevalence of hypertension in Finland among the 
working-aged population was 49%, (55.7% in men and 42% in women). The study of 
Kastarinen et al. revealed, that working-aged women had better awareness of high blood 
pressure, they were more likely to be using antihypertensive medications and a higher 
proportion of them reached target levels than men (awareness 73%, treatment 55%, control 
40% in women vs. 63%, 49%, 34% in men) (301). Respectively, in the United States, where 
among adults a lower prevalence of hypertension than in Finland has been reported, the 
proportion of subjects aware of hypertension is higher (79.6%), and 70.9% hypertensive 
subjects are being treated and almost one in every two (47.8%) have their hypertension 
under  control  (2).  This  indicates  that  more  efficient  measures  are  needed  in  this  field  in  
Finland. In addition, the increasing prevalence of obesity, which is a risk factor for heart 
failure,  also  after  adjustment  for  hypertension,  may  have  an  impact  on  the  similar  heart  
failure incidence in women and men, since obesity may be a stronger risk factor in women 
than in men (188). Dunlay et al. studied temporal trends in heart failure risk factors, and 
when comparing  the 1970s to the 2000’s they emphasized the increasing significance of 
obesity and hypertension as predisposing factors (299). 
The unique risk factors for heart failure in women are the pregnancy-related disorders. 
Ray et al. retrospectively combined women with different placental syndromes during 
pregnancy and compared the risk for being hospitalised due to heart failure or 
dysrhythmias to women with a normal pregnancy, and found that there was a 1.5 times 
higher risk in women with the history of placental syndrome to be hospitalised during a 
median follow-up time of 7.8 years (219). The mean age at the time hospitalisation was <40 
years (219). In this respect, prospective studies of maternal complications and the risk for 
subsequent heart failure are needed. However, a recent systematic review revealed that 
women with pre-eclampsia had double the risk for early cardiac, cerebrovascular and 
cardiovascular mortality, including fatal heart failure, when they were compared to 
women without pre-eclampsia (190). Chronic hypertension is a risk factor for pre-
eclampsia and certain blood pressure medications are contraindicated during pregnancy. 
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However, pre-eclampsia had a separate independent role beyond hypertension in the later 
risk for CVD (190, 219, 302, 303). One of the potential mechanisms for this could be the 
endothelial dysfunction associated with pre-eclampsia but there has also been speculation 
on the role of possible damage to the kidneys caused by pre-eclampsia (190, 304, 305). 
When considering all age groups in the whole population, CHD plays the largest causal 
role in heart failure development, and explains 60% of heart failure cases in general 
population and 23% of heart failure cases in men (299). It is also possible, that due to the 
high prevalence of heart failure during the acute presentation of ACS among women, and 
due to more atypical symptoms in women compared to men, underlying CHD might 
remain undiagnosed (62). During an acute CHD event, women have been reported to have 
a higher rate of heart failure and prior heart failure diagnoses (6, 57, 62).  
The incidence and prevalence of heart failure has not changed; it may even have increased 
due to the aging of western populations, and increasing prevalence of known 
predisposing factors such as: diabetes, obesity and excess alcohol consumption  (1, 95, 98). 
In addition, better survival due to improved management of MI may be reflected in two 
ways; better survival increases the number of those who are at risk of subsequent heart 
failure and, on the other hand, due to better treatments MI events may not be so severe to 
evoke heart failure as frequently as earlier (306). The prevalences of obesity, diabetes and 
alcohol consumption have also increased in Finnish women (1). The finding that heart 
failure was the first incident CVD event among young women is alarming because of the 
high mortality related to heart failure. Unfortunately, clinical data on EF was not available 
in  the  present  study  population.  Heart  failure  with  preserved  EF  has  been  shown  to  be  
more common in women, and despite the better prognosis of this type of heart failure, the 
mortality is still high, and since there is no proven therapy for this type of heart failure the 
survival rates have not changed (93).  
In this study, men had a 30-70% excess in the incidence of strokes, depending of age 
group,  when  compared  to  women.   Stroke  was  the  second  most  common  adverse  CVD  
event among young women, and the third most common in older women. Appelros et al. 
calculated the age-adjusted pooled incident male/ female rate ratio from 44 different 
population-based studies, and found a male excess of 33% (75). In this study, the male/ 
female rate ratio was higher, 1.6, in 25-74 year old subjects. However, this is explained by 
the age groups. The incidence peak of stroke is known to occur in the age group of over 
75–years, and even higher incidence rates have been reported among women over 85 years 
old than in men (76). In Appleros’s study, the pooled rate ratios among younger age 
groups (<55 years) were in a range of 1.42-1.49, which are in the same order of magnitude 
of  the  value  of  1.3  found  here  in  the  younger  age  group  (75).  Hypertension  is  the  most  
important  risk  factor  for  stroke,  and  the  prevalence  of  hypertension  in  the  general  
population is closely associated to stroke mortality (87, 300). In the study by Wolf-Maier et 
al., Finland had the highest stroke mortality out of eight countries studied in its working-
aged population (300).  
In summary, men suffer a higher incidence of major adverse CVD events, except for heart 
failure. Further studies are needed to clarify the gender differences in the relative burdens 
of  different  CVDs  and  their  risk  factors.  If  it  were  possible  to  understand  the  gender  
differences and the unique risk factors for women this could have important implications 
since it could lead to more focused CVD prevention, eventually achieving a reduction in 
the overall CVD burden.  
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7 Conclusions 
I) ACS mortality, incidence and attack rate have declined more slowly among younger 
(<55 years old) women in Finland from 1994-1996 to 2000-2002 than older women and 
men. This slower decline in incidence may have partially been caused by technical 
advances, i.e. the adoption of troponin measurements. The slower mortality decline, 
however, cannot be explained by troponins since troponin evaluation does not play a 
major role in fatal cases.  
II) The ACS case-fatality has declined among both genders between 1994-1996 and 2000-
2002. The decline in ACS case-fatality was slower among <55 years old women than older 
women and in men. The slower pre-hospital and first day case-fatality declines among 
young  women  explained  the  gender  differences  detected  in  the  28-day  and  1-year  case-
fatalities. The slower pre-hospital case-fatality decline may have been caused by risk factor 
changes in Finland, or by poorer detection and inadequate treatment of these high-risk 
younger women.  
III) The prevalence of high CVD risk was almost the same in both genders in the FINRISK 
cohorts pooled for the years 1992-2007. The most common cause of high risk was diabetes 
among young subjects, whereas among older persons the proportions were more equally 
distributed between Framingham score >20%, prior CVD and diabetes. However, older 
men had more prior CVD events. The overall risk factor target levels were poorly 
achieved. Young women received fewer preventive medications than other groups. The 
high-risk status seemed to be poorly recognised among young women.  
IV)  As  expected,  men  had  a  higher  rate  of  all  incident  major  adverse  CVD  events  (non-
fatal and fatal CHD events and stroke) than women. The incidence of heart failure was 
equal in both genders. Women and men differed in the clinical spectrum of the first CVD 
event: the most common incident event was a non-fatal CHD event in men and heart 
failure in women. This difference in the clinical spectrum was similar in both age groups 
(<55 years old and 55-74 years old).  
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8 Summary  
This study was carried out to compare trends in incident fatal, and non-fatal acute 
coronary events, and to determine if there were differences in the prognosis of acute 
coronary events between the genders from the mid-1990s to the beginning of the 2000s.  It 
was also decided to investigate gender differences in the prevalence of high CVD risk at 
the population level, attainment of the guideline- recommended treatment targets in major 
risk factors, and the use of preventive medications. In addition, male-female incidence 
ratios in major adverse CVD events (fatal and non-fatal CHD, stroke and heart failure) 
were estimated, and it was examined whether there were differences in the clinical 
spectrum of the first CVD event between the genders. The age groups were <55 years and 
55 years.  
In studies I and II the acute coronary events were identified from the FINAMI and 
CVD registers, and two time periods 1994-1996 (prior to troponins) and 2000-2002 (after 
the adoption of troponins) were compared. A total of 10 150 subjects 35 years old were 
included  from  the  FINAMI  register  and  149  173  from  CVDR.  In  study  II  when  the  two  
time periods were combined, a total of 6324 incident fatal acute coronary events were 
identified from the FINAMI register and 117 632 from the CVDR. In study III, the FINRISK 
years 1992-2007 were pooled, and a total of 29 272 subjects aged 25-74 years were 
included. We identified 3057 high-risk men and 1365 high-risk women. The high-risk 
status was considered to be present, if a subject either had a Framingham Score > 20% for 
10 years, or had diabetes or a history of a prior CVD event. In study IV a total of 27 870 
persons, who were healthy at the time of their participation in the FINRISK survey were 
followed to the end of 2010. The incident adverse CVD events were recorded from the 
Hospital Discharge Register and the Causes of Death Register. Heart failure diagnoses 
were also gathered from the National Insurance Institute’s Pharmacy database and the 
Drug Reimbursement Register.   
Study I:  Generally, acute coronary event rates have declined in Finland between the study 
time periods. Incident events and all events declined more slowly among <55 years old 
women compared to men and older women according to both registers. Mortality 
declined more slowly in young women than other groups. Negative binominal regression 
models using CVDR data revealed significant gender by year interactions. When 
expressed as RR for the younger age group, then the RR was 1.04 for incidence (p=0.01), 
1.04 (p=0.01) for attack rate and 1.04 (p=0.03) for mortality rate. 
Study II:  The prognosis of acute coronary events has improved during the study periods. 
The 0-27 day and 0-364 day case-fatalities declined more slowly among young (<55 years 
old) women than in men and older women. However, 2-27 day case-fatality changes were 
equal in both genders, as were the 2-364 day case-fatalities. This indicates that the slower 
pre-hospital  mortality  decline  was  responsible  for  the  poorer  improvement  in  the  short-
and long-term prognosis among young women. The OR of pre-hospital death was 
significantly elevated in young women: In FINAMI the sex-by-study-period interaction in 
the age group of <55 years old was 2.03 with 95% CI of 1.08-3.82, and correspondingly in 
CVDR, the OR was 1.35 with 95% CI 1.11-1.63. 
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Study III:   A high CVD risk was almost as common in women as in men in the younger 
age group (5.3% in men vs. 4.3% in women). In the older age group, high-risk was more 
common in men (51.2%) than women (24.5%). In general, risk factor management was 
poor. Younger high CVD risk women used fewer preventive medications, whereas in the 
older age group women tended to use more medications than similarly aged men.  
Study  IV:   Men  had  almost  two  times  more  incident  major  adverse  CVD  events  than  
women. Men had almost four times more fatal CHD events, three times more non-fatal 
CHD events, and almost two times more strokes than women. The incidence of heart 
failure was similar in both genders (male/ female-rate ratio of 1.1 with 95% CI 0.9-1.2).  The 
most  common  incident  event  was  a  non-fatal  CHD  in  men  and  heart  failure  in  women.  
This gender difference was similar in both age groups of 25-54 years and 55 -74 years.  
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Cardiovascular diseases (CVDs) have 
remained the main cause of death in 
Finland. CVDs, especially coronary 
heart disease, have traditionally 
been considered to be diseases 
predominantly affecting men. 
However, each year more women 
than men die from CVDs both in 
Finland and globally. The aim of 
this study was to examine gender 
differences in CVD occurrence, 
prognosis and preventive treatments 
in Finland. 
